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Abstract 
Malaria continues to pose a significant global health and socio-economic burden on those 
regions where it is endemic. Despite substantial investment in the delivery of artemisinin-based 
combination therapies, causing a fall in malaria mortality, recent data suggest that this parasitic 
disease still imposes a significant impact. A major problem is the narrow drug discovery 
pipeline, made worse by reports of artemisinin resistance. 
In recent years, high-throughput screening of natural products derived from plants and marine 
organisms has led to the discovery of potent anti-malarial indole alkaloids (such as 
dihydrousambarensine (A)), many of which contain an indoloisoquinoline core.  
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Building on previously discovered methodology in our group, we have developed a series of 
novel, enantiomerically pure, synthetic indoloisoquinoline and their potential as anti-malarial 
leads was assessed. The structure-activity relationship of these compounds was investigated in 
several areas and a lead compound (B) was generated with an activity close to that of a known 
anti-malarial natural product dihydrousambarensine (A). 
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We have also developed a synthetic route to these indoloisoquinolines in racemic form, derived 
from compound (E), that give anti-malarial activity comparable to their enantiomerically pure 
analogues. This provides quicker and cheaper access to these anti-malarial compounds. 
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Chapter 1 
Introduction 
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1.1 Introduction to Malaria, Causes and Treatments. 
1.1.1. Malaria 
Malaria is a parasitic disease, endemic in 105 countries throughout the tropical and 
temperate regions. In 2010 alone malaria caused an estimated 655,000 deaths and a 
further 216 million clinical cases. 1 Although everyone is susceptible, the majority of fatal 
cases occur among African children, where malaria accounts for approximately 22% of 
childhood deaths. Malaria can also cause high rates of miscarriage or low birth weight. An 
estimated 200,000 infants die per year as a result of the disease during pregnancy, 
making young children and pregnant women the most vulnerable against malaria. 
Malaria is caused by a protozoan parasite of the genus Plasmodium. There are four main 
species that can cause infection in humans; P. vivax, P. ovale, P. malariae and 
P. falciparum. P. vivax and P. falciparum are the most common, with the latter being the 
most deadly. 1 Recently, there have been reported cases of P. knowlesi in humans, 2, 3 
creating a 5th species that is a danger. Until now, P. knowlesi had only been found in 
monkeys in South-East Asia. The Plasmodium parasites are transmitted by the female 
Anopheles mosquito of which 50-60 species can spread the infection. 
The clinical symptoms of malaria vary between species. It most commonly presents with 
flu-like symptoms of a periodic fever, joint pains, vomiting and headaches. If left untreated 
the disease can cause more serious symptoms of renal failure, hypoglycaemia, and 
anaemia. In severe cases the parasite enters the brain, a condition known as cerebral 
malaria, and can cause a coma, leading to death. 1 Due to the non-specificity of the early, 
less severe symptoms, malaria is often over-diagnosed in endemic areas, and therefore 
treatment is over-prescribed, which can lead to resistance against anti-malarials. 
The life cycle of the parasite also varies between species. Figure 1 shows the life cycle of 
P. falciparum. 
13 
 
 
Figure 1: Life cycle of P. falciparum. 4 
 
The parasite undergoes sexual reproduction in the mosquito’s digestive tract and asexual 
reproduction in the body cavity. Reproduction in the mosquito’s digestive tract produces 
sporozites which migrate into the salivary glands and are then passed into the human host 
when the mosquito feeds. The sporozites travel to the liver and undergo asexual 
reproduction. This forms a schizont, which contains approximately 40,000 merozoites. 
When the schizont matures, it erupts, releasing the merozoites which invade the host’s 
red blood cells. Here, the merozoites mature through a ring stage to form a new schizont 
containing approximately 24 merozoites. When this is mature the merozoites are released 
to infect further red blood cells. The schizonts mature and erupt every 36-48 hours 
depending on the species of parasite. This accounts for the periodic fever. Not all 
merozoites invade red blood cells, however; some form gametocytes which are then taken 
up by another mosquito host when it feeds
. 
5
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1.1.2. Brief history of treatment 
The first anti-malarial drug to be used was quinine (1), an alkaloid discovered in the bark 
of the Cinchona tree (Peruvian fever tree) traditionally used to treat fevers. Resistance to 
quinine has been reported, but it is rare and the drug is still one of the most effective anti-
malarials used today. 6  
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Since the first use of quinine in the 17th century, no other drugs were used until the 
20th century, when pharmacological research allowed the discovery of new compounds. 
Chloroquine (2), the second breakthrough in malaria treatment, was first discovered in 
1934; however it was not until 1946 that it was established as a safe and effective 
anti-malarial. 7 It works by inhibiting the development of asexual erythrocytic forms of the 
parasite, thus reducing parasitaemia. 8 Resistance to chloroquine by P. falciparum was 
first documented in the 1950’s in South East Asia and South Africa, and has become 
widespread since then. 9 
(1) 
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Many other drugs have been used as treatments and prophylaxis for malaria. These 
include mefloquine, proguanil, mepacrine, primaquine and pyrimethamine. Resistance to 
all these drugs has been reported. 10 
 
1.1.3. Current treatments 
The current front-line treatments for malaria are a class of compounds known as the 
artemisinins. Artemisinin (3) resides in the leaves of the Chinese plant Artemisia annua 
which has been used in traditional Chinese medicine for over a thousand years. In 1967 
the leaves were screened and found to have potent anti-malarial activity. In 1972, the 
active ingredient was isolated, purified and named Artemisinin. 11  
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Derivatives of this compound have been synthesised; the most of important of these 
include artesunate (4), artemether (5), artemotil (6) and dihydroartemisinin (7).  The 
artemisinins have been widely used as anti-malarials in combination therapies since 
wide-spread resistance to other anti-malarials occurred. 12 
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They act quickly, and are eliminated quickly, with a half-life of roughly one hour. The exact 
mechanism of action is not known, however studies have proven that the endo peroxide 
bridge is essential for activity. 13 This suggests that free radicals are involved in the 
mechanism and there is evidence to support this. There is also evidence to support that 
binding to the haem group in the host’s blood also contributes to activity. The endo 
peroxide bridge although essential, causes problems in manufacturing and co-formulation, 
due to it’s instability, an instability that is accelerated under tropical conditions. 
(4) (5) 
(6) (7) 
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Resistance to the artemisinins was slow to emerge and was not reported until 2009. 13 The 
reasons for this are believed to be due to: 
1) The short half-life and quick elimination from the body of the drug, therefore the 
parasite is not exposed to it for long. 
2) Activity against gametes: this is the stage at which the parasite is taken from the 
blood into the mosquito and transmitted to a new host. Killing the gametes reduces 
transmission; therefore gametes exposed to artemisinins are less likely to infect a 
new host.  
3) Use in combination therapy, which tends to delay the onset of resistance. 
The most recent anti-malarial, named Synriam, was launched by Indian drug company 
Ranbaxy on world malaria day, 2012. It is the first drug in recent years not to be based on 
artemisinin; however it still contains a peroxide bridge in its structure, thought to be 
causing its activity. It is given as a fixed-dose prescription as a combination of arterolane 
maleate (8) and piperaquine phosphate (9). Ranbaxy report a cure rate of 95% when 
three doses are taken over three days, providing a very simple and effective regime. 14 
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Another drug in the pipeline comes from the Medicine for Malaria Venture and is code 
named MMV390048 (10). 15 It was identified during a high throughput screening campaign 
in which several millions of chemical samples were screened to identify new compounds 
with anti-malarial activity. It was synthesised in 2010, displaying potent activity and high 
stability. Animal testing in 2011 discovered that a low oral dosage could completely cure 
the test subject. It has been found to be active against a wide variety of drug-resistant 
strains and against multiple points in the parasites’ life cycle. This is a very promising drug 
candidate which is hoped to enter clinical trials in 2013.  
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1.1.4 Vaccine 
A lot of research today focuses on creating a vaccine for malaria. Vaccines display an 
advantage over drugs as they prevent people from contracting and spreading the disease 
and have led to the complete eradication of certain illnesses in the past (e.g. smallpox). 
RTS,S is the most clinically-advanced current vaccine candidate and the first to ever enter 
large-scale phase 3 clinical trials. Created in 1987 by GlaxoSmithKline, and developed 
since with funding from the Bill and Melinda Gates foundation, it has been shown to 
protect young children against P. falciparum. The vaccine induces the production of 
(10) 
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antibodies and T cells that are believed to affect the parasites ability to infect, develop and 
survive in the human liver. 16 Studies have shown that it remains effective for at least 18 
months after administration in reducing clinical malaria by 35% and severe malaria by 
49%. 17, 18 
 
1.1.5. Other methods to combat malaria 
Other methods to try to combat malaria include environmental control, biological control 
and vector control. The latter is concerned with the eradication of the Anopheles mosquito 
which carries the parasite. This can be done by spraying areas where the vector may rest 
with an insecticide or impregnating materials with one, which can then be made into 
mosquito nets. This method was highly successful until resistance to the insecticides used 
(pyrethroids and DDT) was reported. 19, 20 
Biological control involves releasing species that consume mosquito larvae, introducing 
bacteria that produce toxins into breeding sites and sterilisation of male mosquitoes. 
Environmental control is the reduction of breeding sites by draining areas of stagnant 
water. These methods although effective, are on their own not enough.  
As mentioned above, resistance has been documented against the artemisinins. The 
discovery of new lead compounds with high anti-malarial activity that can be developed 
into effective drug candidates is highly desirable, but resistance to these is likely to appear 
after a few years. The development of a promising vaccine is also helpful, but it is not 
100% effective. All established treatments for malaria have been met with resistance from 
the parasite, and all species of the parasite are showing resistance, therefore there is still 
an urgent need for new anti-malarial compounds. 21 
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1.2 Natural Compounds with Anti-Malarial Properties 
1.2.1 Traditional medicines 
Plants have been used as medicines for thousands of years and indeed, some of the 
major breakthroughs in modern medicine have been derived from natural sources. The 
discovery of penicillin from a fungus; aspirin derived from willow bark, and the previously 
mentioned quinine and artemisinin are just a few examples. In 1996, it was reported that 
30% of the current top prescribed drugs were derived from natural compounds and 
according to the World Health Organisation only 4 out of the current 15 anti-malarial drugs 
are totally synthetic. 22 
Traditional medicines for malaria have often come from locally sourced plants or trees in 
areas where the disease is endemic.  The bark of the Cinchona tree, native to South 
America, was used long before quinine was isolated and identified. Also from this region, 
the bark of Geissospermum vellosii 23 is used by the native population. In traditional 
Congolese medicine Anisopappus chinensis, Entandrophragma palustre, Melia 
azedarach, Physalis angulata and Strychnos icaja are all used to treat malaria. 24 
Strychnos icaja is also native to central Africa and is used as a medicine along with the 
related species Strychnos spinosa and Stychnos henningsii. 25  
 
1.2.2 Indole alkaloids  
Many of plants mentioned in 1.2.1 have been screened for activity and the active 
compounds have been isolated, purified and individually tested against P. falciparum. 
These compounds, in general, are indole alkaloids. The most notable of these are 
ochrolifuanine A (11) and isotrychnopentamine A (12) which both have an IC50 <500 nM 
(0.5 µM) against all Plasmodium lines tested, Another notable compound is 
dihydrousambarensine (13) which has an IC50 value of < 2 µM against all strains tested 
21 
 
and has a reported IC50 of 39 nM (0.039 µM) against a particular chloroquine-resistant 
strain. 26 
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These structures are fairly similar, and the screening of numerous compounds has shown 
some patterns that could be the cause of high anti-malarial activity. It has been reported 
that the indole moiety is important for activity, 27, 28 and many report that bis-indole 
compounds are far more active than mono-indoles. 23, 25, 26, 27, 29 Frederich et al. reported 
that of all structures screened, the highest activity for a mono-indole compound was an 
IC50 of 10 µM, whereas all the bis-indoles showed values of less than 2 µM. 26 This is 
supported by Giradot et al., who found bis-indoles from Muntafara sessilifolia (a plant 
(11) (12) 
(13) 
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native to Madagascar whose bark is traditionally used to treat fevers) to be more active 
than the mono-indoles. 27 
Stereochemistry also plays a key role. This is shown clearly with ochrolifuanine A (11) and 
its enantiomer ochrolifuanine E (14), which has an IC50 value of <2 µM compared to 
ochrolifuanine A’s activity of <500 nM (<0.5 µM). Many of the naturally occurring 
compounds with high potency, including dihydrousambarensine, share the same 
stereochemistry at position 12b as ochrolifuanine A.  
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An ethyl or ethylidene side chain (as shown on compounds (11)-(13)) on the D-ring and a 
fully or partially aromatised second ring system have also been found to increase 
activity. 26, 30 
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1.2.3 Mechanism of action 
It is known that the basicity of chloroquine contributes to its activity, as this causes it to 
accumulate in the acidic food vacuole of the parasite. 31, 32 However, it has been shown by 
Schalkwyk et al. 33 that the acidity of a compound can be also be a cause of activity. The 
Plasmodium parasite is known to regulate the pH of its cytosol by pumping protons out 
across the parasite’s plasma membrane. This generates a pH gradient which is critical to 
the transport of Vitamin B5, an essential nutrient. Disruption of this pH gradient would 
result in inhibiting parasitic growth. Schalkwyk et al. showed that there was a strong, 
positive correlation between anti-malarial activity and the ability of the compounds tested 
to disrupt the cytosolic pH of the parasite.  
Another possible mechanism is the interference of heat shock protein 90 (HSP 90). Heat 
shock proteins (named for their increase in production after periods of heat or stress) are 
a class of compounds that are involved with the folding and unfolding of other proteins. 
HSP 90 has been found to be essential for the growth of P. falciparum during the 
erythrocytic stage. 34 This mechanism was proposed by Shahinas et al. during their 
research into harmine (15), an indole alkaloid from the shrub Guiera senegalensis, found 
in the savannah regions of Central and West Africa that is used as a traditional remedy for 
malaria. 35 Harmine has a very potent activity of 0.0501 µM against the P. falciparum strain 
3D7. Shahinas et al. found that harmine inhibits P. falciparum HSP 90 by competing for 
the ATP binding site and that it also synergises with known anti-malarials chloroquine and 
artemisinin. 35, 36   
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The structure of harmine is similar to the tetracyclic indolizino[2,3-a]quinolizidine ring 
system (16). It is possible that other indole alkaloids with this basic structure inhibit 
P. falciparum the same way as harmine does. 
Although the exact mechanism is unknown, it appears that the indole moiety is highly 
important for anti-malarial activity. All the most active compounds have a free indole NH 
and compounds with two indole moieties are more active still. 33, 37 
The aim of this project is to investigate the structure-activity relationships of the 
indolizino[2,3-a]quinolizidine ring system (16) and to build upon the findings to synthesise 
a compound with high anti-malarial activity. 
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1.2.4 Synthesis of the indolizino[2,3-a]quinolizidine core 
Many different methods have been employed for the synthesis of this synthetically 
important ring system. Jana et al. 38 utilised the condensation of various amines with 
haloaldehydes followed by a cyclisation and subsequent Pictet-Spengler reaction to give a 
one-step synthesis of many derivatives of the core (Scheme 1). They used this method to 
generate the Kopsia griffithii alkaloid harmicine (21) in racemic form, found to exhibit 
activity against the parasite that causes leishmaniasis. 
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Martin et al. 39 utilised another method to access this template en route to a synthesis of 
geissoschizine (a pivotal intermediate in the biosynthesis of biologically-active alkaloids) 
(Scheme 2). It began with the conversion of D-tryptophan (23) into the dihydrocarboline 
(24) in a single step. This was followed by a reaction with vinyl ketene acetal (25) to give 
compound (26) which was then treated with isobutylene in acidic conditions to give (27). 
N-Acylation of (27) with diketene, followed by a Michael reaction gave compound (28) as 
a precursor to geissoschizine (29). 
Scheme 1 
(17) (18) 
(19) 
(20) (21) 
(22) 
26 
 
N
H
COOH
NH2
N
H
NH
COOH
OTBDMS
OMe
N
H
NH
COOH
CO2Me
N
H
NH
CO2But
CO2Me
N
H
N
CO2But
O
HH
H
O
MeO2C
HCO2H, Ac2O
HCO2H, HCl
Me2C=CH2
H2SO4
Diketene, DMAP
t-BuOK
6 Steps NH
N
H
H
MeO2C
OH
 
 
 
Chang et al. 40 synthesised the template en route to the natural product deplancheine (35), 
a compound isolated from the New Caledonian plant Alstonia deplanchei, that has a 
simple structure containing the indolizino[2,3-a]quinolizidine template. Tryptamine (17) 
forms an amide with chloroacetyl chloride in the presence of triethylamine, which is then 
treated with p-toluenesulfinic acid sodium salt to give compound (30). This was then 
reacted with various α,β-unsaturated esters (31) in the presence of sodium hydride, 
followed by a reduction with sodium borohydride and a cyclisation reaction to give the 
(23) (24) 
(25) 
(26) (27) 
(28) (29) 
Scheme 2 
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tetracyclic template (34). This was then functionalised further to give the natural product 
deplancheine (35) (Scheme 3).  
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Scheme 3 
(17) 
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(32) 
(33) 
(34) 
(35) 
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1.2.5 Synthesis of bis-indole compounds 
Although the synthesis of the indolizino[2,3-a]quinolizidine core and its derivatisation to 
natural compounds has been well investigated and reported, synthesis of bis-indole 
compounds have not. One that has been investigated is ochrolifuanine A (11), and it’s full 
synthesis was reported by Malhorta et al. in 1999. 41  
The bottom ring system was introduced by a condensation reaction between tryptamine 
hydrochloride and aldehyde (37) to give imine (38) which was then cyclised to give a 
β-carboline unit, forming ochrolifuanine A (11). The reaction was carried out at 37-40 °C in 
the presence of a 0.2 M phosphate buffer at pH 4.5 (Scheme 4). 
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1.2.6 Biosynthesis of indole alkaloids 
L-Tryptophan is the most common precursor in the biosynthesis of indole alkaloids. It is 
formed from the shikimate pathway (Scheme 5), via the intermediate anthranilic acid (39) 
which is converted into indole (47), and subsequent reaction with L-serine (48) and the 
enzyme tryptophan synthase, gives L-tryptophan (49). 42 
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L-Tryptophan (49) is then converted into tryptamine (17) by a decarboxylation reaction 
assisted by the enzyme tryptophan decarboxylase (Scheme 6).  
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The C2 carbon of the indole ring is nucleophilic due to the adjacent nitrogen atom, and 
can therefore participate in Mannich and Pictet-Spengler type reactions, forming a 
β-carboline (52) (Scheme 7). 
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Extra carbon atoms and rings are supplied by reacting tryptamine (17) with various 
aldehydes and ketones, depending on the complexity of the desired target. More complex 
compounds use an aldehyde such as secologanin (55), shown below (Scheme 8) in the 
synthesis of strictosidine (56), a precursor to complex indole alkaloids such as ajmalicine 
(57), an antihypertensive drug used in the treatment of high blood pressure. 43 
Scheme 7 
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More simple compounds like harmine (15) described above, use ketoacids as precursors 
(Scheme 9). 
Scheme 8 
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(17) 
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1.3 Allin Group Synthesis of the Indolizino[2,3-a]quinolizidine ring system 
1.3.1 N-Acyliminium ions 
Previous work in the Allin group has focused on the application of N-acyliminium ions in 
the asymmetric synthesis of indole alkaloids. This has led to the synthesis of the 
indolizino[2,3-a]quinolizidine ring system 44 and some natural product targets  derived 
from it, such as both enantiomers of deplancheine (35a, 35b) 45 and (+)-12b-
epidevinylantirhine (62). 46 
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Cyclisation reactions proceeding via N-acyliminium ions (64) is a relatively new area 
compared to those that proceed via iminium ions (63) such as the Mannich 47 reaction, the 
Bischler-Napieralski 48 reaction, and the Pictet-Spengler 49 reaction.   
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Both iminium and N-acyliminium ions are used extensively as electrophiles in the 
synthesis of alkaloidal and related systems; however, it seems possible that 
N-acyliminium ions are more reactive. A study on 13C NMR spectra by Wurthwein et al. 50 
showed that substitution of an N-methyl (65) by an N-acetyl group (66) led to a downfield 
shift of the imino carbon absorption of approximately 5 ppm. This could suggest that N-
acyliminium ions are more electrophilic and therefore more reactive, than iminium ions.45  
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Due to their limited stability and high reactivity, N-acyliminium ions are generated in situ. 
There are five principal mechanisms for this: 45 
1) N-Acylation of imines: Condensation of aldehydes or ketones with amines can 
produce imines in high yields. These can then be acylated with reactive carboxylic 
acid derivatives such as anhydrides or acid chlorides. 
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2) N-Protonation of N-acylimines: This method is not synthetically useful due to the 
requirement of forceful conditions and the instability of N-acylimines, as they 
tautomerise to the corresponding enamide. 
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3) N-Protonation of enamides: N-acyliminium ions can be formed by the 
protonation of enamides. 
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4) Oxidation of amides: This method involves initial removal of an electron from the 
lone pair on the nitrogen atom of compound (75), followed by loss of a proton and 
another electron from compound (76). This gives the corresponding N-acyliminium 
ion (77). These oxidations are generally carried out in the presence of a 
nucleophile, usually methanol, in order to trap the ion as soon as it is formed 
(Scheme 13).  
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5) Heterolysis of amides with a leaving group on the α-carbon: This is the most 
common method, and the one employed in Allin group’s work. The leaving group is 
usually an oxygen substituent but could also be a halogen, nitrogen, sulfur or 
phosphorus substituent. Generally, an acid (Brönsted or Lewis) is used to 
generate the ion.      
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Tamelen et al. 54 described a synthesis of yohimbine (81), a naturally occurring alkaloid 
from the plant Pausinystalia yohimbe which has stimulant and aphrodisiac effects. The 
essential step in this synthesis is the acid-catalysed ring closure of an N-acyliminium ion 
(82). The reaction proceeds extremely quickly due to the high reactivity of the electron-rich 
aromatic ring as a nucleophile, in this case an indole ring. 
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Reactions involving iminium ions or N-acyliminium ions are reversible, the reverse 
process being examples of the Grob fragmentation. 55 The product of a reaction involving 
an iminium ion is an amine, however with an N-acyliminium ion the product is an amide.  
Amides are far less susceptible to fragmentation than amines and therefore reactions 
involving N-acyliminium ions can be viewed as less reversible. 56 
 
1.3.2 Synthesis of the (+)- indolizino[2,3-a]quinolizidine ring system (86) 
Cyclisation reactions using an N-acyliminium ion and an indole ring have played an 
important role in the Allin group’s previous work and have been utilised in the 
(81) (82) 
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stereoselective synthesis of the indoloizino[2,3-α]quinolizidine template, which, as noted 
above, comprises a tetracyclic core present in a plethora of bioactive indole alkaloids. 
The synthesis of this ring system was achieved by reacting the β-amino alcohol derivative 
of L-tryptophan (83) with an appropriate keto acid (84) under Dean-Stark conditions for 
48 hours, to give the expected bicyclic lactam product (85) as a 5:1 mixture of 
diasteroisomers, with (85a) being the major isomer (Scheme 15). 57 
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Originally both diastereoisomers of (85) were treated with titanium tetrachloride to give the 
desired cyclised product (86) as a 5:2 mixture of diasteroisomers. 57 
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In an attempt to improve the selectivity, the bicyclic lactam diastereoisomers (85a, b) were 
treated with 2M hydrochloric acid in absolute ethanol. This gave the desired product (86) 
as a single diastereoisomer (Scheme 16). 44 
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1.3.3 Cyclisation reactions of indole (46) 
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When undergoing electrophilic substitution, despite the C2 carbon being more strongly 
nucleophilic, reaction generally occurs at the C3 carbon. This is most likely due to the 
unwillingness of the benzene ring to lose aromaticity. Reaction at the C3 carbon does not 
require the benzene ring to be involved (Scheme 17). 
(86) 
Scheme 16 
(85b) 
(85a) 
(46) 
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Reaction at the C2 carbon does involve the benzene ring (Scheme 18). 
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If the C3 position is blocked, one would assume the reaction would be forced to occur at 
the C2 position, and benzene would be forced to take part. However a study has shown 
that this is not the case. The compound shown below (89) was labelled with tritium (3H) on 
the carbon attached in the C3 position (89). When the cyclisation reaction had occurred it 
was found that not all the radio-labelled hydrogen was where it was expected to be: 50% 
resided adjacent to the C3 of indole as expected and 50% had migrated as shown 
(Scheme 19). 
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For this to occur, the reaction intermediate must be symmetrical, which results from attack 
at the 3-position. This forms a spiro compound, a 5 remembered ring at right angles to the 
indole moiety. Bond migration then occurs to give the observed product (90); each CH2 
group has an equal chance of migrating (Scheme 20). 58 
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In cyclisations such as the one shown in Scheme 20, depending on the substituents of the 
compound, a new chiral centre can be introduced. A mixture of stereoisomers is possible, 
the composition of which is determined by the locations of substituents on the addition 
product. 56 When treating both bicyclic lactams (85a, b) with 2M hydrochloric acid only one 
diastereoisomer is observed (86a) (Scheme 16). 
 
1.3.4 Rationalisation of the Stereochemical Outcome 
Conformational models (Figure 2) were used by the Allin group to rationalise the 
stereochemical outcome of this cyclisation reaction. 45 Both diastereoisomers of the 
bicyclic lactam form the same N-acyliminium species as an intermediate. In the first 
conformation (A), the carbonyl moiety is eclipsed in a 1,3-fashion by the hydrogen atom at 
the β-amino alcohol chiral centre. This gives the observed diastereoisomer. This is 
possible as the hydrogen atom at the iminium carbon is small and therefore provides no 
significant steric bulk to interfere with the positioning of the hydroxymethyl or indole 
groups. Bond rotation around the C-N+ bond leads to conformation (B) which would give 
the unobserved diastereoisomer. This conformation has the hydroxymethyl group 
positioned closer to the carbonyl which appears to bring an unfavourable 1, 3-interaction 
between the two groups. 
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Figure 2 
 
It is thought by the Allin group that conformation (B) leading to the minor diastereoisomer 
observed upon treatment with titanium tetrachloride is stabilised by chelation between the 
Lewis acid-complexed oxymethyl group and the carbonyl moiety. 45 
 
1.3.5 Synthesis of the (-)- indolizino[2,3-a]quinolizidine ring system (96) 
Access to both enantiomers of the indoloizino[2,3-α]quinolizidine template was highly 
desirable as both stereochemistries appear in natural compounds. This was achieved 
using the same method as shown in Scheme 15, but using the β-amino alcohol derivative 
of D-tryptophan (94) as the starting material (Scheme 21). 
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1.4 Functionalisations of the Indolizino[2,3-a]quinolizidine Ring System  
With both enantiomers accessible, work then focused on functionalisations of the 
template. Due to the cost of unnatural D-tryptophan compared to its inexpensive 
enantiomer, the template formed from L-tryptophan was more commonly used. Figure 3 
below shows possible functionalisations of the template. 
 
 
 
Figure 3: Functionalisations of the indolizino[2,3-a]quinolizidine ring system 
 
1.4.1 Alkylations 
The simplest of these functionalisations is an alkylation at the indole NH and the free 
hydroxyl group. These were carried out initially to prevent unwanted side reactions during 
further experiments (i.e. N-protection). A benzyl moiety was added to both N and O atoms 
as a protecting group using 2 equivalents of sodium hydride and benzyl bromide in 
anhydrous dimethylformamide (Scheme 22). Other groups could potentially be added 
using the same methodology. 
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1.4.2 α,β-Unsaturation and conjugate additions 
With protecting groups in place, the compound could be further functionalised 
(Scheme 24). α,β-Unsaturation was achieved using a method employed by Reich et al. 59 
that showed selenoxides undergo clean syn elimination to form olefins at or below room 
temperature.  
Syn elimination is where the substituents a removed from the same face of the bond as 
shown in Scheme 23. 
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Lithium diisopropylamide was used to generate the enolate of the bis-protected template 
(97) which was then reacted with phenyl selenyl bromide at -78 °C to give selenide (100). 
The crude selenide was dissolved in methanol and water, and treated with sodium 
(86) (97) 
Scheme 22 
Scheme 23 
(98) (99) 
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metaperiodate to give the desired α,β-unsaturated compound (101), which could now be 
used to explore conjugate addition reactions.  
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Various nucleophiles were investigated as reagents for conjugate addition reactions, with 
vinyl magnesium bromide being the most successful (Scheme 25), giving a 65% yield of 
compound (102). It is important to note that the relative stereochemistry of the nucleophile 
at the newly created chiral centre remains the same regardless of what nucleophile is 
used and is cis to the H atom adjacent to the nitrogen on carbon 12b. This was also found 
to be true when conjugate additions were performed on the opposite enantiomer of the 
template. 60 This cis chemistry can also be produced when there is no hydroxymethyl 
moiety on the compound and the indole NH remains unprotected.  
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The opposite stereochemistry can be introduced as shown in Scheme 26. 60 
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In this case the relative stereochemistry of the nucleophile is always trans to the H atom.  
This stereocontrol could prove useful in the synthesis of natural compounds as both 
relative stereochemistries are found in natural products. 
 
1.4.3 Rationalisation of the Stereochemical Outcome 
The stereochemical induction in compound (102) that gives rise to the protons at position 
12b and position 2 having trans relative stereochemistry appears to result from the 
nucleophile approaching the face of the amide that carries the bulky benzyloxymethyl-
(103) (104) 
Scheme 26 
(101) (102) 
Scheme 25 
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substituent, which is unexpected. However, the conformation of (102) is bowl-like and the 
nucleophile is actually approaching from the outer (possibly less hindered) face of the 
bowl. 60 
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With no hydroxymethyl group, and a Boc-protected indole nitrogen, conjugate addition 
reactions yielded compounds with the protons at 12b and 2 having cis relative 
stereochemistry, as in compound (104). Without the bulky benzyloxymethyl-substituent, 
the opposite face is most likely the less hindered. 
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1.4.4 Removal of hydroxymethyl moiety  
A rhodium-induced decarbonylation method for the removal of the hydroxyl methyl group 
(Scheme 27) was investigated to demonstrate the potential of synthetic utility of the 
indolizino[2,3-α]quinolizidine template as a precursor to natural compounds, none of which 
contain this moiety. 45  
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Compound (86) is oxidised to the corresponding aldehyde which is then subjected to the 
rhodinium decarbonylation protocol using mesitylene as a solvent. Unfortunately, possibly 
due to long reaction times and high temperatures, this method caused racemisation of the 
hydrogen on carbon 12b and was therefore abandoned. An alternative procedure was 
adopted using the radical decarbonylation of phenylseleno esters (Scheme 28). 60 
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Compound (86) is converted to the corresponding aldehyde as in Scheme 27. The indole 
nitrogen is then Boc-protected (107), and the aldehyde is further oxidised to the carboxylic 
acid (108). Compound (108) is converted into a phenylseleno ester (109) which is then 
eliminated using a tin-mediated radical de-carbonylation reaction to give the desired 
compound (110). 
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1.4.5 Synthesis of both enantiomers of deplancheine 
Enolate addition to the indolizino[2,3-α]quinolizidine has been used to introduce an 
ethylidene group. This was achieved using acetaldehyde and lithium diisopropylamide, 
followed by activation of the hydroxyl group and a DBN-induced elimination procedure 
(Scheme 29). This was done as part of the synthesis 45 of the natural compound 
deplancheine (35), isolated from the plant Alstonia deplanchei. As one of the simplest 
indole alkaloids that shares the indoloisoquinoline tetracyclic core, numerous syntheses 
have been reported that test out different methodologies, with many giving racemic 
mixtures. The Allin group utilised their new methodology and control over stereochemistry 
to synthesise both enantiomers of deplancheine individually (Scheme 29) starting from the 
respective enantiomer of compound (107). 45 This introduction of the ethylidene group is 
important as it is found in natural compounds such as dihydrousambarensine (13). 26   
 
 
N
H
N
N
HN
H
H
 
 
 
 
(13) 
55 
 
N
N O
Boc
N
N O
Boc
N
H
N O
N
H
N
1. LDA, CH3CHO
THF -78 C to RT, 24 h
2. TEA, MsCl
DCM, -40 C to RT 3 h
3. DBN, THF, RT, 16 h
TBAF, THF
Reflux, 9 h
1. Me3OBF4, 2,6-t-Bu2Py,
DCM, RT, 21 h
2. NaBH4, MeOH
0 C, 0.5 h
H H
H H
N
H
N
H
+
 
 
 
The enolate of compound (110) is generated using lithium diisopropylamide which then 
reacts with acetaldehyde. The OH group formed as a result of this reaction is activated 
using mesyl chloride and subsequently eliminated to give the ethylidene moiety, forming 
compound (111). The Boc protecting group is removed by heating under reflux with 
tetrabutylammoniunm fluoride to give compound (112). The removal of the carbonyl group 
is carried out using an adaption of the Borch protocol, 61 in which trimethyloxonium 
tetrafluoroborate is used as a methylating agent to add a methyl group to the carbonyl 
oxygen, forming a methoxy group, which is then eliminated. 
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1.4.6 Synthesis of (+)-12b-epidevinylantirhine 
Another indole alkaloid synthesised by the Allin group is (+)-12b-epidevinylantirhine 
(62). 46 This compound was first isolated by Wenkert 62 during studies towards a synthesis 
of geissoschizol. The production of this compound (Scheme 30) is significant as it 
introduces a free OH that can be used for extra functionality, with the potential to try to 
build a bis-indole compound such as dihydrousambarensine (13) or ochrolifuanine A (11).  
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The dithiolane ring is removed using sodium borohydride with a nickel chloride catalyst in 
a similar way as using Raney nickel. Formic acid is used to remove the Boc protecting 
group and the amide and ester are both reduce by heating under reflux with lithium 
aluminium hydride in anhydrous tetrahydrofuran. 
It should be noted that addition of an ethylidene group to (+)-12b-epidevinylantirhine (62) 
would give access to the compound (+)-geissoschizol 63 (115a), the opposite enantiomer 
of a naturally occurring indole alkaloid. Utilising the Allin group’s stereocontrol and the 
incorporation of the ethylidene group, this could provide a new, asymmetric synthesis of 
(-)-geissoschizol (115b), the naturally occurring enantiomer. 
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An attempt to incorporate this moiety was made en route to (+)-12b-epidevinylantirhine as 
shown (Scheme 31), but was unsuccessful, 64 possibly due to the steric hindrance of the 
bulky dithiolane ring.  
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The methodologies previously employed in the Allin group give an indication of; 
 How to control stereochemistry 
 Conjugate additions, how to build towards bis-indole compounds 
 Enolate additions, introduction of ethylidene group 
 How to remove the hydroxymethyl group 
All of the above are important for building a structure-activity relationship picture of the 
indoloizino[2,3-α]quinolizidine template and for the synthesis of a bis-indole compound. 
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1.5 Determination of Anti-Malarial Activity 
1.5.1 Introduction 
The half maximal inhibitory concentration (IC50) is a measure of biological activity that 
shows the required concentration of a compound needed for 50% inhibition of parasite 
growth. The compounds described below in this thesis need to be tested for anti-malarial 
activity to help guide us in understanding what aspects of their structure influence their 
activity (structure-activity relationship). 
Several methods can be employed to measure anti-malarial activity. These all 
fundamentally rely on the determination of parasite growth. Intraerythrocytic development 
takes 48 hours to complete one growth cycle. Therefore, by exposing intraerythrocytic 
cultures for 48 hours to a range of drug concentrations, the concentration of drug that 
inhibits growth by 50% (IC50) can be determined. The methods to monitor parasite growth 
are varied: 
 Microscopic examination. 65 
 Colorimetric assays of enzyme production e.g. lactase dehydrogenase assay. 66 
 Radiometric monitoring of DNA replication by incorporation of triated hypoxanthine 
(a nucleotide precursor). This method is the most widely publicised and 
accepted.67 
 Fluorescence assay of DNA replication using intercalating agents such as Syber 
Green I. 68 
All the above methods are accurate and have a variety of advantages (low cost, 
sensitivity, ease of use, no need for specialist equipment) and disadvantages (expensive, 
time consuming, high cost, lack of sensitivity, storage and disposal of radioactive 
materials).  
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Keele University Institute for Science and Technology in Medicine (ISTM) have developed 
a transgenic P. falciparum line that expresses a bioluminescent reporter gene, luciferase, 
during replication. 69 They have also reported improvements in the bioluminescence assay 
format to improve reproductivity of the assay data developed. 70 Similar developments in 
luciferase expressing parasites have been reported by other groups. 71 Bioluminescence 
assays provide data comparable to the other assay formats, but the absence of 
background signals and a high signal/noise ratio offers significant advantages in 
determination of the IC50 data. 
In collaboration with Dr Paul Horrocks’ group in the ISTM the IC50 data for all the 
compounds described in Chapter 2 of this thesis were determined following the method 
outlined in section 1.5.2. 
 
1.5.2 Determining the IC50 
Stock culture [4% haematocrit, 2% trophozite stage parasitaemia of Dd2luc (transgenic 
luciferase parasite)] 69 was provided by a collaborating laboratory. 6 ml was required per 
plate. 
A 96 well plate was set up as shown in Figure 4. Columns 10 and 11 served as controls; a 
positive (+) control, containing parasites only with no drug, and a negative (-) control 
which contained no parasites or drugs, just culture medium. 
100 µl of stock culture was added to each well apart from column 2. To this, 150 µL of 
medium was added followed by 12 µL of the chosen drug at 10 mM concentration in 
dimethyl sulfoxide. These were mixed together using an auto-pipette and 50 µL was 
transferred from column 2 to column 3. The process was repeated with 50 µL being 
transferred across to each column. When column 9 was reached 50 µL was taken and 
discarded. This created a series of 3 fold dilutions of drug concentration ranging from 400 
61 
µM to 0.1 µM. The outside wells were filled with 200 µl of incomplete medium to minimise 
edge effects from evaporation during the following incubation period in a gassed chamber 
(1% O2, 3%, CO2, 96% N2) at 37 °C for 48 hours (Figure 5). 
 
              
    
 
After the incubation period, 40 µL from each well was added to 10 µL of passive lysis 
buffer (Promega UK) on a white, 96 well plate. 50 µL of standard luciferase substrate 
(Promega UK) was added and the bioluminescence was measured (in relative light units) 
for 2 seconds using a MultiGloMax luminometer by Promega.  
Each drug is done in triplicate on one plate and three biological replicas were conducted 
to provide data for analysis. 
The relative light units calculated were converted into % growth and plotted against log10-
transformed drug concentration. The IC50 values were determined from a sigmoidal dose-
response curve (Figure 6) in GraphPad Prism v5. (GraphPad Software, Inc., San Diego, 
CA). This methodology has been submitted for publication to The Malarial Journal. 73 
Figure 6 shows the sigmoidal dose-response curve for a compound that will be described 
further in Chapter 2. The graph can be used to determine to the concentration of this 
compound needed to inhibit parasitic growth by 50% and hence, the IC50 value (1.7 µM). 
Figure 5: Drug inhibition plate after 
48 hours 72 
Figure 4: 96 well plate                                                       
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Figure 6: Graph to determine the anti-malarial activity of (114) (1.7 µM). 
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Chapter 2 
Results and Discussion 
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2.1 Synthesis of the Indolizino[2,3-α]quinolizidine Ring System 
2.1.1 Synthesis of (+)-indolizino[2,3-α]quinolizidine  
A full investigation into the structure-activity relationship of the indolizino[2,3-
α]quinolizidine ring system as a starting point for the development of a novel series of 
anti-malarials required both enantiomers of the template (1) to be synthesised.  
  
N
H
N O
 
 
The requisite β-amino alcohol derivative of L-tryptophan was prepared by reducing 
L-tryptophan (2) with an excess of lithium borohydride and trimethylchlorosilane in 
anhydrous tetrahydrofuran (Scheme 1). 1 
 
NH2
N
H
O
OH
NH2
N
H
OHLiBH4, TMSCl
Dry THF, RT, 24 h
 
 
 
Metal borohydrides alone cannot reduce α-amino acid substrates; however in the 
presence of trimethylchlorosilane reduction becomes possible. The exact mechanism for 
this reaction has yet to be determined, but it is thought that a borane – tetrahydrofuran 
Scheme 1 
(1) 
(2) (3) 
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complex is formed (Equation 1) and it is this species, along with excess 
trimethylchlorosilane, that acts as the reducing agent. 2 
 
LiBH4 + Me3SiCl + THF LiCl + Me3SiH +BH3.THF
 
 
 
The desired keto acid (6) was formed by an acid-catalysed transesterification of 
δ-valerolactone, followed by oxidation to the corresponding aldehyde using a suspension 
of pyridinium chlorochromate and celite in dichloromethane (Scheme 2). No purification 
was carried out as re-lactonisation occurs on aqueous work up. 3   
 
O
O
OMe
O
OH
OMe
O
O
H2SO4, MeOH
80 °C, 5 h
PCC, Celite
DCM, RT, 2 h
 
 
 
 
The products of the reactions shown in Schemes 1 and 2 were then combined for 48 
hours under Dean-Stark conditions, to give the expected bicyclic lactams (7a, b) in 20% 
yield as a mixture of diastereoisomers, with (7a) being the major isomer (Scheme 3). 
 
Equation 1 
Scheme 2 
(4) (6) (5) 
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NH
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+
Dean-Stark
48 h
 
 
 
The diasteroisomers were purified, but not separated. Instead, they were treated with 2M 
hydrochloric acid in absolute ethanol at room temperature to give the desired cyclised 
product (8) as a single diastereoisomer in 95% yield (Scheme 4). The rationalisation for 
this stereochemical outcome is described in Chapter 1. 
 
N
H
N O
H
OH
NH
N
O
O
H
NH
N
O
O
H
+
2M HCl, EtOH
RT, 24 h
 
 
 
The proposed mechanisms for the reactions described above are shown in Schemes 5 
and 6. 
Scheme 3 
Scheme 4 
(3) 
(6) 
(7b) 
(7a) 
(8) 
(7a) 
(7b) 
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A mixture of diastereoisomers is formed from this reaction as the iminium ion intermediate 
(10) is planar and can be attacked from either side by the hydroxyl nucleophile. 
 
Scheme 5 
(3) 
(6) 
(9) 
(10) (11) 
(7a, b) (12) 
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As mentioned in section 1.3, attack is occurring at the 3 position of the indole moiety, 
followed by a subsequent rearrangement reaction, due to the unwillingness of the 
benzene ring in the indole moiety to lose aromaticity. 4  
 
2.1.2 Synthesis of (-)-indolizino[2,3-α]quinolizidine  
To obtain the opposite enantiomer of (+)-indolizino[2,3-α]quinolizidine, the synthesis 
outlined in the above section (2.1.1) was repeated using D-tryptophan as the starting 
material. The expected bicyclic lactams (19a, b) were obtained in 32% yield and were 
cyclised to give the (-)-enantiomer (20) in 95% yield (Schemes 7 and 8).  
Scheme 6 
(7) (13) 
(14) (15) 
(8) (16) 
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With both enantiomers in hand, the effects of ring stereochemistry on biological activity 
could now be investigated, along with a range of structural modifications of the 
indolizino[2,3-α]quinolizidine ring system. 
Scheme 7 
Scheme 8 
(17) (18) 
(18) (6) 
(19a) 
(19b) 
(20) 
75 
 
2.2 Alkylations 
2.2.1 Mono-alkylations of (+)-indolizino[2,3-α]quinolizidine  
Protecting groups positioned on the indole NH and the OH of the template are a necessity 
to stop unwanted side reactions during further functionalisations, however a variety of 
different groups could be added and this prompted an investigation into whether or not the 
addition of groups may increase or decrease anti-malarial activity and subsequently which 
groups give the best improvement. The first groups to be tested were methyl, allyl and 
benzyl.  
Due to the weakly acidic nature of the indole NH, a strong base was needed to 
deprotonate it. Sodium hydride (1.5 eq) in anhydrous dimethylformamide was used, 
followed by addition of benzyl bromide (1.5 eq) to give the mono-benzylated compound 
(21), in 63% yield (Scheme 9). 
 
N
H
N O
H
OH
N
N O
H
OH
NaH, BnBr
Dry DMF, 
0 °C to RT, 24 h
 
 
 
2.2.2 Bis-alkylations of (+)-indolizino[2,3-α]quinolizidine   
Groups were then added to the oxygen atom of compound (21). In the first instance, a 
methyl group (Scheme 10), and secondly an allyl group (Scheme 11). 2 Equivalents of 
sodium hydride were used followed by 2 equivalents of the appropriate alkylating agent. 
 
Scheme 9 
(8) (21) 
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N
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OH
NaH, AllylBr
Dry DMF, 
0 °C to RT, 24 h
N
N O
H
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Compounds (22) and (23) were produced in 14% and 37% yields respectively. 
Other compounds in this series were previously synthesised by our group. These were 
prepared using similar methods to those described above and gave access to compounds 
(24) to (26). 3  
 
N N O
H
O
                                       
N N O
H
O
 
Scheme 10 
Scheme 11 
(21) (22) 
(21) (23) 
(24) (25) 
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2.2.3 Mono-alkylations of (-)-indolizino[2,3-α]quinolizidine   
It was important to synthesise analogous compounds to those in section 2.2.1 starting 
from the template derived from D-tryptophan (20) so that their respective activities could 
be compared to determine if absolute stereochemistry is important for anti-malarial activity 
in this series of compounds. 
A benzyl group and an allyl group were added to the indole NH of template (20) as 
described in Schemes 12 and 13. Compound (27) was formed in 41% yield and (28) in 
74%. 
 
N
H
N O
H
OH
N
N O
H
OH
NaH, BnBr
Dry DMF, 
0 °C to RT, 24 h
 
 
 
 
Scheme 12 
(26) 
(20) (27) 
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Dry DMF, 
0 °C to RT, 24 h
 
 
 
2.2.4 Bis-alkylations of (-)-indolizino[2,3-α]quinolizidine   
The following compounds shown in Schemes 14 and 15 were synthesised as described in 
section 2.2.2, starting from compound (27).  By these routes compound (29) was formed 
in 51% yield and compound (30) in 93% yield.  
 
 
N
N O
H
OH
NaH, MeI
Dry DMF, 
0 °C to RT, 24 h
N
N O
H
O
 
 
 
 
Scheme 13 
Scheme 14 
(20) (28) 
(27) (29) 
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Dry DMF, 
0 °C to RT, 24 h
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When the same group was required on both the nitrogen and oxygen atoms, an excess of 
sodium hydride (4.4 eq) and the corresponding alkylating agent (3 eq) was used. This 
gave rise to the targets shown below in Schemes 16, 17 and 18. 
 
N
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N O
H
OH
N
N O
H
ONaH, BnBr
Dry DMF, 
0 °C to RT, 24 h
 
 
 
 
Scheme 15 
Scheme 16 
(27) (30) 
(20) (31) 
58% 
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Dry DMF, 
0 °C to RT, 24 h
 
 
 
 
N
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H
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N
N O
H
ONaH, MeI
Dry DMF, 
0 °C to RT, 24 h
 
 
 
 
2.2.5 Biological activities  
The IC50 values (against P. falciparum strain Dd2luc) for the range of compounds 
previously described are shown below in Table 1. Compounds in the L-series are those 
derived from L-tryptophan and compounds in the D-series are those derived from 
D-tryptophan. 
 
 
 
Scheme 17 
Scheme 18 
(20) 
(20) (32) 
(33) 
31% 
77% 
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Table 1: 
N
R
N O
H
OR1
                                           
N
R
N O
H
OR1
 
 
L-Series R R1 IC50 (µM) Dd2luc D-Series  R R1 IC50 (µM) Dd2luc 
(8) H H 71 (20) H H 56 
(25) Methyl Methyl 30 (33) Methyl Methyl 29 
(24) Allyl Allyl 16 (32) Allyl Allyl 13 
(26) Benzyl Benzyl 12 (31) Benzyl Benzyl 3.5 
(22) Benzyl Methyl 32 (29) Benzyl Methyl 1.3 
(23) Benzyl Allyl 35 (30) Benzyl Allyl 1.3 
 
      (27) Benzyl H 5 
      (28) Allyl H 41 
 
The first conclusion that can be drawn from these results is that the addition of a group 
has led to an increase in activity. In both the L and the D-series, the substituted 
compounds have lower IC50 values (and therefore higher anti-malarial activity) than the 
parent compounds (8) and (20). The results of the D-series compounds also show that the 
addition of a second group is desirable. Compound (27) is mono-benzylated at the indole 
nitrogen and has an IC50 value of 5 µM. Addition of an allyl, methyl or benzyl group to the 
oxygen atom on compound (27) gave compounds (31), (29) and (30), all of which have 
higher anti-malarial activity than (27). Comparison of compounds (28) and (32) also show 
this trend. Compound (28) has an allyl group on the indole nitrogen and an IC50 value of 
41 µM. Addition of a second allyl group gives compound (32), which has a lower IC50 
value of 13 µM and therefore has a higher anti-malarial activity.  
This shows two things: (1) that the hydrogen bonding properties of the NH and OH groups 
are not important for the binding of the compound to its target and (2) that a reduction in 
the polarity of templates (8) and (20) is desirable. They are polar compounds and 
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reducing this will allow them to pass through cell membranes more freely. 5, 6 It is also 
possible that there are hydrophobic regions in the target binding site that the compounds 
could not bind to without substitutions at the N and O atoms. In section 1.2.3 it is 
proposed that a free indole NH is needed for high anti-malarial activity; however, this does 
not appear to be the case in this series of compounds. 
The second conclusion is that compounds in the D-series (those derived from 
D-tryptophan) have better activity than their L-series analogues. This trend is apparent for 
all the compounds tested. In some cases the difference is marginal (compounds (25) and 
(33), and compounds (24) and (32)), but in others, the increase in activity is highly 
significant. Compounds (29), (30) and (31) all show a marked increase in activity 
compared to their L-series analogues, giving IC50 values as low as 1.3 µM. 
This increase in activity as we move from the L-series to the D-series highlights the 
importance of absolute stereochemistry of compounds derived from this indoloisoquinoline 
template. The more active D-series shares the same absolute stereochemistry at the ring 
junction within the heterocyclic core as the natural anti-malarial compound 
dihydrousambarensine (34).  
 
N
H
N
N
HN
H
H
 
 (34) 
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This relationship between stereochemistry and anti-malarial activity has also been 
reported by Frederich et al. 7 and is discussed in section 1.2. 
These results also show a preference for a benzyl moiety at the indole nitrogen and either 
a methyl or allyl substituent at the oxygen atom (compounds (29) and (30)). Both of these 
have IC50 values of 1.3 µM, the highest level of activity in this set of compounds. An 
increase in steric bulk at R1 (compound (31) which has a benzyl group) is not favourable. 
Free rotation round the single bond of the benzyl moiety could be causing it to mimic the 
presence of a second ring system (35) such as that found in the naturally occurring 
anti-malarial dihydrousambarensine (34). 
 
N
N O
H
OR1
                                    
 
 
2.2.6 Investigations into ring size, electronic and steric properties 
Due to the results gathered in section 2.2.5, we decided to continue synthesising only 
compounds in the D-series, as it has been shown that these have higher anti-malarial 
activity. 
To try to understand which properties of the substituents added to the template were 
responsible for giving rise to better biological activity, and to try to improve on these 
findings, a further set of analogues was prepared.  
(35) 
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A propyl group was added to the free hydroxyl group of compound (27) as shown 
(Scheme 19) in 50% yield.   
 
N
N O
H
OH
NaH, PropylBr
Dry DMF, 
0 °C to RT, 24 h
N
N O
H
O
 
 
 
Bromomethyl cyclohexane and bromomethyl cylcobutane were both used as alkylating 
agents, along with benzyl bromide and allyl bromide to produce compounds (37), (39) and 
(41). Addition of these new groups was not as straightforward as the previous examples. 
Under our usual alkylation conditions no reaction occurred, so sodium iodide was added 
and the reaction heated at 60 °C for 24 hours. Addition of sodium iodide causes a 
displacement reaction in situ (Scheme 20) giving a more reactive alkylating agent. This is 
desirable as the iodide ion is a much better leaving group due to the weak C-I bond which 
requires less energy to break than the C-Br bond and therefore the desired reaction can 
proceed. 4 
 
Br NaI+ I + NaBr
 
 
Scheme 19 
Scheme 20 
(27) (36) 
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45% 
N
N O
H
OH NaH, Bromomethyl - 
cyclohexane, NaI
Dry DMF, 
0 °C to 60°C, 24 h N
N O
H
O
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OH NaH, Bromomethyl - 
cyclohexane, NaI
Dry DMF, 
0 °C to 60°C, 24 h N
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H
OH
N
N O
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O
NaH, AllylBr
Dry DMF, 0 °C 
24 h
 
 
 
Scheme 21 
Scheme 22 
(37) (27) 
(20) (38) 
(39) 
31 % 
41% 
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46% 
N
H
N O
H
OH NaH, Bromomethyl - 
cyclobutane, NaI
Dry DMF, 
0 °C to 60°C, 24 h N
N O
H
OH
N
N O
H
O
NaH, AllylBr
Dry DMF, 0 °C 
24 h
 
 
 
 
2.2.7 Biological activities 
Table 2 shows the IC50 values of the compounds synthesised in section 2.2.6 and their 
parent compounds from 2.2.5.  
 
 
 
 
 
 
Scheme 23 
(20) (40) 
(41) 
67% 
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Table 2:  
N
R
N O
H
OR1
 
Parent Compounds Analogues 
 R R1 IC50 (µM) Dd2luc  R R1 IC50 (µM) Dd2luc 
(31) Benzyl Benzyl 3.5 (37) Benzyl Cyclohexylmethyl 19 
(30) Benzyl Allyl 1.3 (36) Benzyl Propyl 2.8 
(39) Cyclohexylmethyl Allyl 9 
(41) Cyclobutylmethyl Allyl 7 
 
Comparison of these compounds shows that an increase in steric bulk at the R1 position 
leads to a decrease in anti-malarial activity. Compound (30) has an IC50 value of 1.3 µM. 
When the allyl group at the R1 position is changed to a benzyl (31), a cyclohexylmethyl 
(37) or a propyl group (36), the activity drops to 3.5 µM, 19 µM and 2.8 µM respectively.  
Due to the lack of the double bond in the propyl group, it is not planar and therefore it can 
rotate around, increasing steric bulk. It also lacks the electron density of the allyl group in 
compound (30) due to the absence of the π-bond. This finding is similar to that observed 
with the decrease in activity when the R1 substituent is changed from a benzyl (31) to a 
cyclohexylmethyl (37). Again there is a reduction in electron density and a reduction in 
planarity as the saturated cyclohexyl ring would be expected to favour a chair 
conformation.  
Compounds (39) and (41) also show a decrease in activity. Here the R substituent has 
been changed from a benzyl to a cyclobutylmethyl in (41) and a cyclohexylmethyl in (39) 
and the IC50 values have dropped from 1.3 µM to 7 µM and 9 µM respectively. In both 
cases it seems that the steric and electronic properties of benzyl are preferred for higher 
activity. A change in ring size from an unsaturated six membered ring to an unsaturated 
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four membered ring does show a slight increase in activity, but it is negligible compared to 
that of having a benzyl moiety in the R position. 
The properties of the benzyl substituent may explain why it is preferred to its saturated 
analogue. As a planar, hydrophobic structure, it can bind to flat hydrophobic regions of the 
target binding site (Figure 1). Neither a methyl or cyclohexylmethyl group would be able to 
bind in the same way; this is reflected in the IC50 values. The methyl group is too small for 
much interaction and a cyclohexylmethyl group as mentioned above, is not planar, and 
would have a larger steric influence (Figure 1). Both methyl and cyclohexylmethyl lack 
aromaticity and cannot π-bond. An allyl group might undergo π-bonding but it is also small 
and would not bind to the binding site as proficiently as a benzyl moiety. 
 
                                 
Figure 1 
 
 
 
 
 
 
 
R
H H
 
  
R
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2.3 Introduction of α,β – Unsaturation to the Indolizino[2,3-α]quinolizidine ring 
system 
2.3.1 α,β – Unsaturation 
α,β – Unsaturation of compounds was achieved following the Reich method mentioned in 
Chapter 1. 8 This technique was performed on two of the compounds, (30) and (31), 
introduced in the previous section.  
N
N O
H
O
                          
N
N O
H
O
 
 
Addition of n-butyl lithium to diisopropylamine in anhydrous tetrahydrofuran at -78 °C 
formed lithium diisopropylamide, which in turn, was used to generate the enolates of these 
compounds. Phenyl selenyl bromide was then added to give the α-selenide required for 
the subsequent elimination reaction. Sodium metaperiodiate and sodium bicarbonate 
dissolved in methanol and water were used as an oxidant to promote elimination of the 
selenoxide, introducing a double bond (Scheme 24). Due to solubility issues, the 
elimination reaction was carried out at 60 °C instead of room temperature. 
 
 
(30) (31) 
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(42)  R=Bn,  
         R
1
=Allyl 
(43)  R=R
1
=Bn 
N
R
N O
H NR
N O
H
N
R
N O
H
SePh
LDA, PhSeBr
Dry THF
 -78 °C to RT
NaIO4, NaHCO3
MeOH, H2O
60 °C, 18 h
OR1 OR1
OR1
 
 
 
 
This methodology gave rise to compounds (44) and (45) in 40% and 25% yields 
respectively. The IC50 value of each compound is shown in Table 3 along with the activity 
of the saturated analogues. 
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Scheme 24 
(30)  R=Bn, R
1
=Allyl 
(31)  R=R
1
=Bn 
(44)  R=Bn, R
1
=Allyl 
(45)  R=R
1
=Bn 
(45)  (44)  
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2.3.2 Biological activities 
Table 3: 
N
R
N O
H
OR1
 
Saturated Analogues Unsaturated Analogues 
 R R1 IC50 (µM) Dd2luc  R R1 IC50 (µM) Dd2luc 
(30) Benzyl Allyl 1.3 (44) Benzyl Allyl 1.7 
(31) Benzyl Benzyl 3.5 (45) Benzyl Benzyl 3.6 
 
Introduction of unsaturation to the lactam ring could cause a change in ring conformation. 
In both cases shown in Table 3 this difference has not led to improved activity on 
comparison with the saturated analogues.  
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2.4 Conjugate Additions 
2.4.1 Addition of a vinyl group 
With α,β-unsaturation of the lactam ring achieved, conjugate additions to the ring were 
now possible. Vinyl groups were added to unsaturated compounds (44) and (45) using a 
reagent system of vinyl magnesium bromide and copper cyanide. This gave rise to 
compounds (46) and (47) in 37% and 49% yields respectively. The rationalisation for the 
stereochemical outcome of the newly created chiral centre is discussed in Chapter 1. 
 
N
N O
H
OR1
R
N
N O
H
OR1
R
Vinyl MgBr
CuCN
TMSCl
-78 °C to RT
 
 
 
The copper cyanide is added in order to transmetalate the Grignard reagent, and create a 
copper vinyl species that will add to the C=C bond rather than the C=O bond. 
 
MgBr + CuCN Cu MgBrCN+
 
 
 
The exact structure of the vinyl copper species is unknown and more complicated than 
Scheme 26 shows, as that species is far too un-reactive for the reaction to occur. 4  
(44)  R=Bn, R
1
=Allyl 
(45)  R=R
1
=Bn 
(46)  R=Bn, R
1
=Allyl 
(47)  R=R
1
=Bn 
Scheme 25 
Scheme 26 
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Compounds (46) and (47) were formed by this method. Their activities are shown in 
Table 4, compared with their parent compounds. Compound (48) is an analogue of (47), 
synthesised by another member of the group from L-tryptophan, and its anti-malarial 
activity is also shown in Table 4. 
N
N O
H
O
                                        
N
N O
H
O
                                          
 
 
2.4.2 Biological Activities 
Table 4: 
N
R
N O
H
OR1
                                             
N
R
N O
H
OR1
 
Parent Compounds  Analogues with vinyl substituent  
(D-Series)   (D-Series)   
 R R1 
 IC50 (µM) Dd2luc  R R1 IC50 (µM) Dd2luc 
(30) Benzyl Allyl 1.3 (46) Benzyl Allyl 1.1 
(31) Benzyl Benzyl 3.5 (47) Benzyl Benzyl 13 
L-Series   L-Series   
(26) Benzyl Benzyl 12 (48) Benzyl Benzyl 20 
 
Table 4 shows conflicting results. Introduction of a vinyl group to the bis-benzyl compound 
(31) to give compound (47) has caused a decrease in activity (3.5 µM to 13 µM). This 
(46) (47) 
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finding is supported by IC50 values of the enantiomers of these compounds. Compound 
(26) 3 has an IC50 value of 12 µM; addition of a vinyl group to give compound (48), 3 
causes this to fall to 20 µM.  
N
N O
H
O
                                           
N
N O
H
O
 
 
 
Contrary to this, addition of a vinyl group to the compound (30), with a benzyl at R and an 
allyl at R1, has caused an increase in activity, giving the most active compound presented 
so far. As mentioned before it is likely that increased steric bulk, particularly at the R1 
position is unfavourable. With two benzyl moieties and a vinyl group, it could be that 
compound (47) is now too big and bulky and is not readily accommodated into the binding 
site, that there is limited space. In compound (46), with a less bulky allyl group at R1, the 
addition of the vinyl group causes a favourable increase in activity. This suggests that 
addition to the β-position of the lactam ring could be highly beneficial for anti-malarial 
activity; however there is limited space, and adding a substituent larger than a vinyl group 
could cause a decrease in activity.  Natural anti-malarial compounds such as 
dihydrousambarensine (34), ochrolifuanine A (49a) and a plethora of others all have 
β-carboline type ring systems in this position. What they lack however, is a substituent in 
the R1 position, in fact the hydroxy methyl moiety is not present at all and it is perhaps this 
that gives enough reduction in size to allow these natural compounds to have large 
structures bonded to the lactam ring and still retain high anti-malarial activity. 
(26) (48) 
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Therefore, it appears that removing the hydroxymethyl group from our indoloisoquinoline 
template is desirable, as it will allow us to investigate further additions to the lactam ring. 
The methodology for this is described in section 2.6. 
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(34) (49a) 
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2.5 Basicity 
2.5.1 Introduction 
The activity of chloroquine has, in part, been attributed to its basic nature, causing it to 
accumulate in the acidic digestive vacuole of the Plasmodium parasite. 9,10 Similar findings 
have been reported in compounds from various Strychnos species, exhibiting anti-
plasmodial activity. 7 Despite the similarities in structures, usambarine (50) (possessing a 
methyl substituent at N3, giving a tertiary amine) was found to be less active 
(IC50 = 2.5 µM) than ochrolifuanine A (49a) (IC50 = 0.12 µM) and E (51) (IC50 = 0.28 µM), 
which both possess an H atom instead, which would make the compound slightly more 
basic. Isostrychnopentamine (52) is also structurally similar to usambarine, yet possesses 
a third basic nitrogen atom in the pyrrolidine ring, and accordingly was found to be more 
active against the Plasmodium lines tested (IC50 = 0.12 µM). 
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(50) 
(51) (52) 
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With this is mind, modifications were made to see if increasing the basicity of these 
compounds could have a similar effect. 
 
2.5.2 Increasing the basicity 
Replacing the benzyl moiety at the R position with a pyridylmethyl group, and keeping the 
R1 substituent an allyl group, gives an analogue to compound (30) with very similar steric 
properties, but with an increase in basicity due to the extra nitrogen atom. The addition of 
the pyridylmethyl group was not as straightforward as with the other alkylations. Previous 
methods developed successfully with previous alkylating agents failed to yield the desired 
product in this series (Schemes 27 and 28). 
 
N
H
N O
H
OH
N
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H
OH
N
NaH, 
4-(bromomethyl)-pyridine 
hydrobromide
Dry DMF, 0 °C to RT
 
 
 
 
N
H
N O
H
OH
N
N O
H
OH
N
NaH, NaI
4-(bromomethyl)-pyridine 
hydrobromide
Dry DMF, 0 °C to 40 °C
 
Scheme 27 
Scheme 28 
(20) (53) 
(20) (53) 
No Reaction 
No Reaction 
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A method reported by Jilka et al. 11 for the dialkylation of carbocyclic analogues of Tröger’s 
base with pyridyl groups was investigated. Two methods were described; the first, in 
which the pyridine salt was deprotonated with triethylamine and added as a solution to 
anhydrous tetrahydrofuran, followed by sodium hydride (Scheme 29), was attempted by 
another member of the Allin group and was found to be unsuccessful. 
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N
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N
4-(Bromomethyl)-pyridine 
hydrobromide, NEt3, NaH
Dry THF 0 °C to RT
 
 
 
The second method described by Jilka et al. involved the bromomethylpyridine being 
treated with potassium tert-butoxide in dry dimethyl sulfoxide (Scheme 30). 11 This method 
proved to be successful and gave the desired compound (53) in 22% yield.  
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Dry DMSO, 0 °C to RT
 
 
 
 
Scheme 29 
Scheme 30 
(20) 
(20) 
(53) 
(53) 
No Reaction 
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An allyl group was then added to (53) in the usual way to give compound (54) in 90% 
yield. 
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NaH, allylBr
Dry DMF, 0 °C to RT
 
 
 
Another method investigated to increase the basicity of these compounds was to remove 
the carbonyl group, converting the amide functional group to a tertiary amine. Amides are 
very weak bases compared to amines since the adjacent carbonyl group is 
electron-withdrawing and causes the lone pair on the nitrogen to become delocalised. The 
carbonyl group was removed using 1 equivalent of lithium aluminium hydride in dry 
tetrahydrofuran under reflux conditions for 3 hours. The reaction was then stirred at room 
temperature overnight. This reaction was carried out on the two most biologically active 
compounds, (29) and (30), described in section 2.1 (Scheme 32). 
 
 
 
(53) (54) 
Scheme 31 
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Table 5 shows the anti-malarial activity of the compounds described in this section, 
compared to the parent compounds. 
 
2.5.3 Biological activity 
Table 5: 
N
R
N O
H
OR1
 
Parent Compounds Analogues 
 R R1 IC50 (µM) Dd2luc  R R1 IC50 (µM) Dd2luc 
(30) Benzyl Allyl 1.3 (54) 4- Pyridyl methyl Allyl 2.1 
(56) Benzyl Allyl 1.5 
(29) Benzyl Methyl 1.3 (55) Benzyl Methyl 3.3 
 
None of these compounds show any improvement in activity compared to the parent 
compounds (29) and (30) (both with an IC50 of 1.3 µM). Therefore it seems conclusive that 
the basicity of these compounds is not contributing to their activity. The drop in activity 
from the amide compounds (29) and (30) to the corresponding amines (55) and (56) is 
(55) R
1
=Me  45% 
(56) R
1
=Allyl   12% 
 Scheme 32 
(29) R
1
=Me 
(30) R
1
=Allyl 
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small. Amides have the ability to form a hydrogen bond to a binding site through the 
carbonyl oxygen, if this particular binding was important for the compound’s activity, a 
larger drop in activity might be expected. The nitrogen atom of an amide functional group 
cannot form a hydrogen bond since the lone pair of electrons will delocalise across with 
the neighbouring carbonyl group. However when converted into a tertiary amine, the N-
atom can form hydrogen bonds through the free lone pair of electrons. It may be possible 
that the amine N-atom is binding by hydrogen bonds to the same site that the carbonyl 
oxygen of the amide does, and this is why very little change in activity has occurred. 
Alternatively, the binding site is not influenced by this particular functionality and no 
bonding is occurring in this location at all. 
The addition of a nitrogen atom caused by swapping the benzyl moiety in compound (30) 
with a pyridyl group (54) gives the compound the ability to form new hydrogen bonds. Due 
to the decline in activity there seem to be no H bond donors in this region of the binding 
site. 
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2.6 Synthesis of a New Template 
2.6.1 Removal of the hydroxy methyl group 
The hydroxyl methyl moiety within the indolizino[2,3-α]quinolizidine ring system under 
investigation is not found in any natural compounds that exhibit anti-malarial activity. In 
section 2.4 it was also proposed that this moiety was preventing high levels of biological 
activity from being achieved by taking up chemical space. 
For these reasons, it was removed by a radical decarbonylation of an acyl selenide 12 
using tributyltin hydrideand azobisisobutyronitrile, giving the desired product (58a) in 72% 
yield. 
 
N
N O
HBoc
n-Bu3SnH, AIBN
Toluene
80 °C to RT, 4h
N
N
O
SePh
Boc
H
O
 
 
 
 
Heating azobisisobutyronitrile (59) causes its decomposition, eliminating a molecule of 
nitrogen gas and forming two 2-cyanoprop-2-yl radicals (60). These can then initiate 
further reactions (Scheme 34). 
 
Scheme 33 
(57) (58a) 
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Scheme 34 
(58a) 
(57) (63) 
(64) 
(59) (60) (61) 
(60) (62) 
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In order to create the phenylseleno ester, the OH group must be oxidised to the 
corresponding carboxylic acid. Previous research in the group showed that direct 
oxidation was not possible due the indole NH being sensitive to the use of all oxidising 
agents tried. 13 An indirect route of oxidising the alcohol to the aldehyde, followed by a 
protection of the indole nitrogen and then subsequent oxidation to the acid was proposed.  
The only oxidising agent found able to successfully give the aldehyde with our substrate 
was IBX. 13 
IBX (68) was synthesised from 2-iodobenzoic acid (67) and potassium bromate (66) 
(Scheme 35). 14 
KBrO3       +
CO2H
I
O
I
O
O OH
80 °C
3 h
 
 
 
The oxidation reaction was performed in anhydrous dimethyl sulfoxide at room 
temperature and yielded aldehyde (69) as a white solid. This reaction worked well on a 
small (0.1 g) scale, but attempts to scale up to a larger (1.0 g) scale failed. Commercial 
stabilised IBX was then used and gave the aldehyde in 80% yield on a 1.0 g scale. 
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Scheme 36 
Scheme 35 
(66) (67) (68) 
(20) (69) 
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Protection of the indole NH was achieved by using di-tert-butyl carbonate in anhydrous 
tetrahydrofuran with triethylamine and 4-(dimethylamino)pyridine. 
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To obtain the carboxylic acid, a Pinnick oxidation 15 was performed using sodium chlorite 
and sodium dihydrogen phosphate dissolved in a mixture of acetonitrile and tert-butyl 
alcohol (Scheme 38). This gave the desired acid in 88% yield. Cyclohexene was used as 
a chlorine scavenger to catch any hypochlorite ions formed, as these may cause 
unwanted side reactions. 
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Scheme 37 
(69) (70) 
Scheme 38 
(70) (71) 
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Selenation of the carboxylic acid was achieved in 55% yield by reacting the carboxylic 
acid with diphenyl diselenide and tributylphosphine in anhydrous dichloromethane.  
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2.6.2 Functionalisation of template (72a) 
The Boc protecting group was removed by heating under reflux with tetrabutylammonium 
fluoride in anhydrous tetrahydrofuran for 9 hours. This gave the free indole compound in 
79% yield (Scheme 40). 
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Scheme 39 
(71) (57) 
Scheme 40 
(58a) (72a) 
(58a) 
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A set of compounds derived from this new template (72a) were designed and synthesised. 
The aim was to test them against analogues that have the hydroxymethyl group in place 
to see if removal of this moiety leads to better anti-malarial activity and hence gain 
information on the necessity of functionality in this chemical space. 
The other compounds in this series were synthesised using methods already described 
above in this thesis. 
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Table 6 compares the activities of compounds (72a) and (73a) with their analogues. 
 
 
 
 
(72a)  (73a)  80% 
(74a) 
79%  
26%  
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2.6.3 Biological activities  
Table 6:  
N
R
N O
H
OR1
                                           
N
R
N O
H
 
 
Parent Compounds Analogues 
 R R1 IC50 (µM) Dd2luc  R R1 IC50 (µM) Dd2luc 
(20) H H 56 (72a) H N/A 36.7 
(27) Benzyl H 5 (73a) Benzyl N/A 5.3 
 
In the first instance (compounds (20) and (72a), with no modifications to either template, 
the removal of the hydroxymethyl group has caused a notable increase in activity, 
however it is still not comparable to the activity of compounds (29), (30) and (46). This 
increase in activity is most probably due to the OH group having been removed and 
lowering the overall polarity of the compound. 
Addition of a benzyl group (compound (73a)) to template (72a) causes the same high 
increase in activity seen previously when a benzyl group was added to template (20). 
Compound (73a) has an IC50 value very similar to analogue (27), showing that in this 
case, the removal of the hydroxymethyl moiety has caused no significant change in 
anti-malarial activity. This would suggest that functionality in this region is not necessary 
for high activity. 
The α,β-unsaturated compound (74a) shows an increase in activity (IC50 = 15.2 µM) 
compared to its saturated analogue (58a) (IC50 = 22.5 µM). This finding is different from 
the results described in section 2.3 which suggest that α,β-unsaturated compounds have 
a lower activity (albeit by only a small amount). The change from a benzyl (73a) to a Boc 
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(58a) protecting group on the indole nitrogen induces a decrease in activity. This result is 
unsurprising, as a Boc group shares none of benzyl’s steric or electronic properties. 
The Boc group on the α,β-unsaturated compound (74a) was removed using formic acid 16 
as the tetrabutylammonium fluoride Boc removal method described above (Scheme 40) 
has been shown to reduce the unsaturated lactam ring. 3 This yielded the desired 
compound (75a). 
The structure of this compound (75a) was confirmed by 1H NMR spectroscopy (showing 
that the C(CH3)3 peak, characteristic of a Boc group, was not present, and that an indole 
NH peak was present at 8.23 ppm). This compound was found to be unstable and no 
further data could be collected. 
N
H
N OH
 
 
Despite no real increase in anti-malarial activity, we felt it was desirable to continue 
making compounds without a hydroxymethyl substituent, due to the stronger resemblance 
to natural indole alkaloids. As the most active natural compounds (such as 
dihydrousambarensine (34) and ochrolifuanine A (49a)) have a free indole NH, the use of 
a Boc group in this position is better than a benzyl with our compound, due to its ease of 
removal. 
The synthesis of the indolizino[2,3-α]quinolizidine  core requires five steps, and a further 
five steps to remove the hydroxymethyl moiety. This requires large amounts of starting 
material and reagents, and the reactions to be scaled up to give enough template for a 
series of compounds. Due to the high cost of D-tryptophan and the time required for a 10 
(75a) 
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step synthesis, an alternative route was sought for creating an indolizino[2,3-
α]quinolizidine  core. 
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2.7 Alternative Synthesis to the Indolizino[2,3-α]quinolizidine  Ring System. 
2.7.1 Previous work 
Previous work in the Allin group towards the synthesis of the indoloizino[8,7-b]indole ring 
system (78) had shown that this template, similar to the indolizino[2,3-α]quinolizidine  ring 
system, could be synthesised in two steps by reaction of the β-amino derivative of 
L-tryptophan (3) with succinic anhydride (76), followed by a reductive cyclisation 
reaction. 17 
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We thought that this approach, via the corresponding imide (81), could be used to access 
the racemic indolizino[2,3-α]quinolizidine ring system (72a, b) using tryptamine (79) and 
glutaric anhydride (80) (Scheme 42). 
 
Scheme 41 
(76) 
(3) (77) 
(78) 
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Key features of product (72a, b) are that it is racemic and that it lacks the hydroxylmethyl 
substituent. The first step of this proposed synthesis is the formation of an imide derivative 
from tryptamine and glutaric anhydride. The method described in Scheme 42 was used, 
but proved unsuccessful in this case as the reagents did not dissolve. The method was 
repeated but with replacing toluene with anhydrous tetrahydrofuran as a solvent. This 
gave rise to the formation of undesired compound (82), showing that under these 
conditions the reaction is not reaching completion, but rather stopping half way. Different 
methods for the formation of this imide were then investigated. 
HN
H
N
O
O OH
 
 
Scheme 42 
(79) (80) 
(81) 
(72a, b) 
(82) 
No Reaction 
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2.7.2 Imide formation 
Ardeo et al. achieved the desired imide (81) in 67% yield, during their investigations into 
constructing the fused β-carboline framework found in corynanthe-type indole alkaloids. 18 
They reacted tryptamine with glutaric anhydride while heating under reflux in acetic acid.  
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Reflux
 
 
 
 
Morrison et al. accessed the same compound by a different method involving diethyl 
glutarate (83) as a substrate. 19 This was reacted with tryptamine at 175 °C for 1 hour, and 
subsequently heated under reflux in xylene with p-toluenesulfonic acid for 9 hours.  
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1. 175 °C, 1 h
2. p-toluenesulfonic
acid, reflux, 9 h
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Scheme 43 
18
 
Scheme 44 
19
 
(79) (80) (81) 
(79) (83) (81) 
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Raheem et al. formed a similar imide en route to the natural compound (+)-harmicine 
(87). 20 Tryptamine (79) was combined with succinic anhydride (76) in a mixture of toluene 
and acetic acid (1:3) and heated under reflux at 120 °C for 24 hours. The imide (85) was 
then cyclised to give compound (86) using sodium borohydride in methanol at 0 °C 
followed by trimethylchlorosilane, methyl tert-butyl ether and a chiral thiourea catalyst 
(84). This method gave (+)-harmicine (87) in 97% e,e. All compounds reported by 
Raheem which were synthesised this way gave a high percentage enantiomeric excess. 
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 Scheme 45 
20
 
(79) (76) (85) 
(86) (87) 
(84) 
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A method reported by Heaney, 21 that showed that an imide could be formed by heating 
tryptamine with glutaric anhydride at 200 °C with no solvent, was tried and found to be 
successful in our studies. Thin layer chromatography showed that after 2 hours there was 
still plenty of starting material left, so the reaction was left overnight and gave the desired 
imide (81) in 66% yield. 
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We found that under these conditions, the undesired intermediate (82) could also be 
converted into the imide (81). 
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Scheme 46 
(79) (80) (81) 
Scheme 47 
(81) (82) 
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2.7.3 N-Acyliminium cyclisation 
For cyclisation to occur, one of the carbonyl groups on the piperidinone ring must be 
reduced. In 1954, Tagmann et al showed that under mild conditions lithium aluminium 
hydride could be used to reduce compound (88) to the hydroxyl piperidinone compound 
(89). 22 
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Speckamp et al. developed this partial reduction of cyclic imides into high yielding 
procedures by using excess sodium borohydride in ethanol. 23, 24 During the reaction, 
dilute hydrochloric acid is added to stop the medium becoming too basic, as this would 
cause undesired ring opening. The reaction is performed at a low temperature which also 
helps to avoid ring opening. It has been reported that the addition of acid is not necessary 
if the reaction is performed using methanol as a solvent and carried out at -4 °C. 
Cyclisation of the reduced imide is achieved by addition of hydrochloric acid to the 
reaction (Scheme 49). 
 
Scheme 48 
22
 
(88) (89) 
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Rahman et al. in their synthesis towards β-carbolines, 25 report success using a variety of 
metals to catalyse reduction by sodium borohydride (Scheme 50). The imide was treated 
with 5 equivalents of sodium borohydride, and 1 equivalent of cobalt chloride in ethanol at 
0 °C. After two hours a 95% yield of the desired product was obtained. This was then 
cyclised using concentrated hydrochloric acid. Similar yields were achieved using nickel 
chloride, chromium chloride and stannous chloride. 
Scheme 49 
23, 24
 
(81) (90) 
(72a, b) 
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The method employed in this current project was adapted from that of Speckamp et 
al. 23, 24 The imide was dissolved in absolute ethanol and cooled to 0 °C degrees. Sodium 
borohydride was added followed by 2M hydrochloric acid in absolute ethanol which was 
added portionwise over a period of 3 hours. The reaction was then acidified to pH 1-3 by 
further addition of 2 M hydrochloric acid in absolute ethanol and the reaction mixture was 
stirred at room temperature overnight. The addition of further 2M hydrochloric acid is 
needed to promote the cyclisation reaction. After work-up the crude product was washed 
with absolute ethanol to give an off-white solid (72a, b) in 68% yield (Scheme 49). The 
proposed mechanism for this cyclisation reaction is shown in Scheme 51. 
(81) (90) 
(72a, b) 
Scheme 50 
25
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2.7.4 Racemic compounds 
Using a racemic template, although quicker and cheaper to synthesise, could pose 
problems when testing for anti-malarial activity. A racemic mixture could be considered 
comparable with administering two different drugs with differing pharmacological 
Scheme 51 
(81) (90) 
(72a, b) 
(94) 
(91) (92) 
(93) 
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properties; it is possible only one enantiomer has biological activity. One enantiomer may 
act as an agonist or an antagonist causing an increase, or decrease, in the overall 
effectiveness of the drug. In the case of the asthma treating drug salbutamol, only one 
enantiomer (the R enantiomer (95)) has any advantageous effect. 26 
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R -Salbutomol                                                                 S- Salbutamol 
 
Studies into the chiral drug thalidomide, commonly prescribed in the late 1950’s for 
morning sickness, but withdrawn a few years later after being linked to serious 
birth_defects, have shown some evidence that the two isomers have differing biological 
effects. The R-enantiomer (98) has been shown to be responsible for the drugs sedative 
effects and the S-enantiomer (97) has been shown to be responsible for its 
imunnomodulatory effects. 27, 28 It is important to test each enantiomer of a chiral drug 
separately to see exactly what biological effect it might produce. Thalidomide is racemised 
in vivo 29 and therefore administering a single enantiomer would not avoid the undesirable 
side effects of this drug. Therefore it is important to know what effects a racemic mixture 
could have.  
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S-Thalidomide                                                          R-Thalidomide 
(95) (96) 
(97) (98) 
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The in vitro testing done on the compounds produced in this project may show if using a 
racemic mixture will have any effect on the compounds anti-malarial activities. 
A series of compounds similar to the ones in section 2.6 were synthesised using methods 
described above. This was carried out to see what effect (if any) using a racemic template 
instead of an enantiomerically pure one might have on the activity of the compounds. 
Table 7 shows the IC50 values of the compounds (72a, b), (73a, b), and (58a, b) 
compared with their enantiomerically pure analogues; Table 8 shows the unsaturated 
compound (74a, b) compared to its enantiomerically pure analogue (74a). 
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(72a, b) (73a, b) 
(58a, b) (74a, b) 
68% 58% 
55% 37% 
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2.7.5 Biological activities 
Table 7: 
N
R
N O
H
                                     
N
R
N O
H
 
 
D-Series R IC50 (µM) Dd2luc Racemic R IC50 (µM) Dd2luc 
(72a) H 36.7 (72a, b) H 38.5 
(73a) Benzyl 5.3 (73a, b) Benzyl 8.26 
(58a) Boc 22.5 (58a, b) Boc 23.6 
 
Table 8: 
D-Series R IC50 (µM) Dd2luc Racemic R IC50 (µM) Dd2luc 
(74a) Boc 15.2 (74a, b) Boc 10.1 
 
The above tables show that the IC50 values of the racemic compounds are not especially 
different from those of their pure enantiomer analogues. Out of the four comparisons, 
three show the pure enantiomer is slightly more active and the other one shows the 
racemate to be more active. There are a few possible reasons for this lack of difference in 
activity. 
The racemic compounds contain both (-/+)-enantiomers; while previous results have 
shown compounds derived from (-)-enantiomer (20) to be far more active, there are some 
cases in which compounds derived from the (+)-enantiomer (8) have been shown to be 
active in the 10-30 µM range ((24), (25) and (26)), suggesting that compounds with this 
stereochemistry could, with structural modifications become more active. 
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The enantiomerically pure compounds from section 2.6 were derived from the (-)-template 
(20), they have not been synthesised with the opposite stereochemistry and therefore 
their biological activity is unknown. They could have been more potent than the 
compounds previously tested, and therefore their presence would not cause a decline in 
activity as would be expected. It is possible that stereochemistry is less important now the 
hydroxymethyl group has been removed and only one chiral centre is now present. It 
could be that it was the relative stereochemistry (cis/trans) at the chiral centre containing 
the hydroxymethyl moiety that made such a difference in the activity of the compounds in 
section 2.1. 
Previously mentioned in section 1.2 was the potent anti-malarial compound 
ochrolifuanine A (49a) and its far less potent enantiomer ochrolifuanine E (51). 7 The 
stereochemistry of the hydrogen atom at position 12b in ochrolifuanine A is the same as 
that of the our more potent (-)-enantiomer (20), whereas E shares the same 
stereochemistry as our less potent (+)-enantiomer (8), therefore we thought that the 
absolute stereochemistry at this position was important. However ochrolifuanine A and E 
have three asymmetric carbon atoms and the difference in their anti-malarial activities 
could be attributed to these other chiral centres. 
 
(8) (20) 
124 
 
N
H
N
HN
H
N
H
HH H
12b
                                                 
12b
N
H
N
HN
H
N
H
H H
 
 
This theory could be tested by deriving compounds from template (99), a diastereoisomer 
of the (-)-template (20). Previous work in our group shows that (99) could be synthesised 
from compound (20) by refluxing with trifluoroacetic acid in toluene (Scheme 52). 3   
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Groups could then be added to template (99) using methods described above to give 
compounds analogous to those derived from template (20). The IC50 values could then be 
compared to the parent compounds to see if there were any significant differences in 
activity arising from the change of stereochemistry at the hydrogen atom at position 12b.  
This would demonstrate whether the absolute stereochemistry at this asymmetric centre is 
important for anti-malarial activity. 
(49a) (51) 
Scheme 52 
(20) (99) 
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Due to the little difference in the activities between racemic compounds and their 
enantiomerically pure forms, the project was moved forward using the more readily 
accessible racemic template. Even if activity of the racemic compounds is lower, they will 
still give an indication of what modifications lead to increased anti-malarial activity. If a 
significant lead compound is developed, we have the knowledge base to synthesise an 
enantiomerically pure analogue.  
 
2.7.6 Other racemic derivatives and biological activities 
Other compounds in the racemic series that were synthesised using previously developed 
methods are shown. Their activities are displayed in Table 9. 
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(100a, b) (101a, b) 
(74a, b) 
58% 20% 
37% 
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Table 9: 
N
R
N O
H
 
Unsaturated Compounds Compounds with a Vinyl substituent 
 R IC50 (µM) Dd2luc  R IC50 (µM) Dd2luc 
(100a, b) Benzyl 1.9 (101a, b) Benzyl 4.7 
(74a, b) Boc 10.1 (102a, b) Boc 14.5 
   (103a, b) H 69.6 
 
The structure-activity relationships of these racemic compounds follow similar trends to 
those that were found with the enantiomerically pure series in section 2.6. 
Both compounds (100a, b) and (74a, b) show that introduction of α,β-unsaturation has 
caused an increase in activity when compared to their saturated analogues (73a, b) and 
(58a, b) (IC50 values of 8.26 µM and 23.6 µM respectively). This is also the case with the 
enantiomerically pure compound (74a) (IC50 = 15.2 µM) when compared to its saturated 
analogue (58a) ((IC50 = 22.5 µM). 
 
(102a, b) (103a, b) 45% 46% 
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The IC50 values of the compounds described in section 2.3 showed that when the 
hydroxymethyl group is present, introduction of α,β-unsaturation of the lactam ring did not 
lead to an increase in activity. Compound (30) has an IC50 value of 1.3 µM, whereas its 
unsaturated analogue (44) has a value of 1.7 µM. 
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Addition of a group to the indole nitrogen atom in the racemic template (72a, b) has 
caused an increase in activity, from (72a, b) (IC50 = 38.5 µM) to (73a, b) (IC50 = 8.26 µM) 
and (58a, b) (IC50 = 23.6 µM), a trend seen in section 2.2 and section 2.6. 
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(58a)  (74a) 
(72a, b) 
(30) (44) 
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The IC50 values of these compounds show that a benzyl substituent causes a greater 
increase in activity than a Boc group, as seen with the enantiomerically pure compounds 
(58a) and (73a) in section 2.6.  
The introduction of a vinyl group (compounds (101a, b) and (102a, b)) causes an increase 
in anti-malarial activity when compared to their parent compounds (73a, b) and (58a, b) 
(Table 10). This is consistent with the results from section 2.4, in which addition of a vinyl 
group to compound (30) (IC50 = 1.3 µM) gave compound (46) which has an IC50 value of 
1.1 µM.  
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(58a, b) (73a, b) 
(46) 
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Table 10: 
N
R
N O
H
 
Parent Compounds Vinyl Compounds 
 R IC50 (µM) Dd2luc  R IC50 (µM) Dd2luc 
(73a, b) Benzyl 8.26 (101a, b) Benzyl 4.7 
(58a, b) Boc 23.6 (102a, b) Boc 14.5 
(72a, b) H 38.5 (103a, b) H 69.4 
 
Both the enantiomerically pure series and the racemic series of compounds follow similar 
structure-activity trends. This provides evidence that further structural modifications to the 
easily obtainable racemic template (and the anti-malarial activities obtained) will be a 
good indication of the bio-activity of the enantiomerically pure compounds. 
 
2.7.7 Conclusion to the structure-activity relationship investigation of the 
indolizino[2,3-α]quinolizidine  ring system 
Thus far in this project, we conducted an investigation into the structure-activity 
relationship of the indolizino[2,3-α]quinolizidine  ring system. Structural modifications that 
have been explored include; stereochemistry, alkylations, α,β-unsaturation followed by 
conjugate addition, removal of the hydroxymethyl moiety and the use of a racemic 
template.  
From this we have discovered that: 
 Compounds derived from (-)-Indolizino[2,3-α]quinolizidine  are more active than 
those derived from (+)-Indolizino[2,3-α]quinolizidine.  
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 That the addition of groups to the indole nitrogen and the oxygen atom increases 
activity.  
 A benzyl group on the indole nitrogen and a methyl or allyl group on the oxygen 
atom give the best anti-malarial activity (IC50 = 1.3 µM) 
 Introduction of α,β-unsaturation causes a decrease in anti-malarial activity in 
compounds with the hydroxymethyl moiety, but an increase in compounds 
without. 
 Addition of a vinyl group, in general, causes an increase in activity and led to 
compound (46), our most active compound so far (IC50 = 1.1 µM). 
 Increasing the basicity of the compounds in this project did not increase anti-
malarial activity. 
 Using a readily accessible racemic template (72a, b) instead of an 
enantiomerically pure one gives a good indication of anti-malarial activity in this 
series. 
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2.8 Towards a Bis-Indole Derivative 
2.8.1 Ochrolifuanine A 
With the structure-activity relationships of the indolizino[2,3-α]quinolizidine template 
investigated, the project moved towards the synthesis of a compound containing an 
additional ring system. The most active compounds found in nature are those containing 
two indole ring systems. The total synthesis of the bis-indole anti-malarial compound 
ochrolifuanine A has been reported (49a), 30 but to the best of our knowledge no others 
have. The synthesis and subsequent structure-activity relationship investigation of 
bis-indole compounds could provide novel leads with high anti-malarial activity. 
The key step in this reaction is a Pictet-Spengler 31 reaction between tryptamine and an 
aldehyde group.  
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This gives the desired compound (49a, b) as a mixture of diastereoisomers that could 
then be separated. The Pictet-Spengler reaction provides a route for deriving compounds 
with an additional ring system.  In order for this to be successful, aldehyde functionality 
must be introduced to the lactam ring of compound (72a, b).  
Scheme 53 
(104) (49a, b) 
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2.8.2 Aldehyde functionalisation of racemic indolizino[2,3-α]quinolizidine  
Using the racemic version of the indolizino[2,3-α]quinolizidine  ring system, the previously 
reported synthesis of (+)-12b-epidevinylantirhine was followed. 32 
The first step involves a conjugate addition reaction between α,β-unsaturated compound 
(74a, b), and methyl-1,3-dithiolane-2-carboxylate (106). This compound is not readily 
available and therefore was prepared from ethyl-1,3-dithiolane-2-carboxylate (105) by 
refluxing in methanol with sodium hydroxide for 30 minutes with the exclusion of light. 33 
This gave the desired compound as a yellow oil. 
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(106) was then reacted with (74a, b) using lithium diisopropylamide as a base. This gave 
compound (107) in 54% yield (Scheme 55). 
 
 
Scheme 54 
(105) (106) 
(72a, b) 
133 
 
S
S
O
OMe
N
N O
HBoc
N
N O
HBoc
S
S OMe
O
LDA, 
Dry THF, -78 °C
 
 
 
Previous work has shown that with no hydroxymethyl group and a protecting group on the 
indole nitrogen atom, the incoming nucleophile always attacks one (the less hindered) 
face of the compound, giving only one relative stereochemistry. 32 This is discussed earlier 
in Chapter 1. The two enantiomers now present in the racemic mixture are as shown 
(107a) and (107b). 
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The removal of the dithiolane ring from (107a, b) was achieved using sodium borohydride 
with a nickel chloride catalyst in 61% yield. 34 As mentioned above in Chapter 1 the 
borohydride and nickel catalyst acts like Raney nickel, reducing the C-S bonds. 4 
(74a, b) 
(106) 
(107a, b) 
Scheme 55 
(107a) (107b) 
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The removal of the Boc group from (108a, b) was subsequently achieved cleanly in 82% 
yield on stirring with formic acid for 24 hours. 
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After removal of the Boc protecting group, the compound was treated with lithium 
aluminium hydride in dry tetrahydrofuran and heated under reflux for 3 hours, followed by 
9 hours stirring at room temperature. An excess of reducing agent was used to convert, in 
one pot, the ester to an alcohol and the amide to the corresponding amine, giving 
(+/-) -12b-epidevinylantirhine (110a, b) in 76% yield (Scheme 58). 
 
(107a, b) (108a, b) 
Scheme 56 
Scheme 57 
(108a, b) (109a, b) 
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2.8.3 Oxidation 
To obtain the aldehyde group, the primary alcohol must be oxidised. There are numerous 
agents that could be used to oxidise an alcohol to an aldehyde. PDC, 35 PCC, 36 
Dess-Martin Periodinane 37 and the Swern oxidation 38 are a few, however all these except 
PCC were attempted unsuccesfully on compound (8) by another member of the Allin 
group. The lack of success was possibly due to the indole NH, known to be unstable 
under oxidising conditions. 13, 39  
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Due to the similarities between PCC and PDC we assumed that PCC would also be an 
unsuitable oxidising agent. The oxidising agent IBX has been reported not to affect 
indoles with a free NH, 40 therefore an IBX oxidation was attempted (Scheme 59). 
 
Scheme 58 
(109a, b) (110a, b) 
(8) 
136 
 
IBX 
DMSO, RT, 24 h NH
N
H
O
N
H
N
H
HO
 
 
 
An aqueous work up was performed and the compound extracted into ethyl acetate. 1H 
NMR analysis of the crude material showed only the presence of by-products of the 
oxidising agent. We thought that, due to the insolubility of the starting material, the 
aldehyde would also be fairly insoluble and therefore was not extracted. The experiment 
was repeated but without the aqueous work up. Instead, after 24 hours stirring the 
reaction was put on a freeze dryer to remove the dimethyl sulfoxide. Unfortunately, this 
did not yield any positive results either. 
A different method was then employed that required no extraction or aqueous work up. 
IBX oxidations are usually carried out in dimethyl sulfoxide due to the inability of the 
oxidising agent to dissolve in any other solvent, but Moore et al. 41 reported that at 
elevated temperatures, IBX can be used to convert alcohols cleanly into the 
corresponding aldehydes in excellent yields. Once the solution has cooled, the reduced 
IBX can be filtered out and the solvent removed. They reported a 90% yield when using 
ethyl acetate. This reaction was attempted with compound (110a, b) (Scheme 60). 
 
 
Scheme 59 
(110a, b) (111a, b) 
No Reaction 
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1H NMR spectroscopy of the crude reaction mixture showed no characteristic aldehyde 
peak or starting material. 
We then decided to protect the indole NH, to see if this would make the oxidation reaction 
successful. Triethylamine with 4-(dimethylamino)pyridine and di-tert-butyl carbonate in 
anhydrous tetrahydrofuran was used. After 2 hours, analysis by TLC showed complete 
conversion of starting material to the product shown in Scheme 61. 
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The base was changed to sodium hydride which previously had shown selectivity for the 
indole NH due to the reaction proceeding by a different mechanism, and the Boc 
protection was successful. 
 
Scheme 60 
(110a, b) (111a, b) 
Scheme 61 
(110a, b) (112a, b) 
No Reaction 
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Oxidation attempts on compound (113a, b) also failed. This may be due to the amide in 
the lactam ring having been converted to an amine, an unforeseen problem, as IBX has 
been reported to be chemoselective towards alcohol groups in the presence of primary, 
secondary and tertiary amines. 40 Frigaro et al. successfully oxidised compound (114) to 
its corresponding aldehyde (115) in 91% yield, 40 in the presence of a tertiary amine and 
an unprotected indole moiety. 
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Due to the success of this reaction and the compound’s similarity to ours (110a, b), the 
effectiveness of the IBX being used was called into question. A test reaction, known to 
work and described in section 2.6 was performed. 1H NMR spectroscopy of the crude 
(110a, b) 
(113a, b) 
Scheme 62 
Scheme 63 
40
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material showed clean conversion from the alcohol to the aldehyde, with a strong CHO 
peak at 9.4 ppm. 
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2.8.4 DIBAL reduction 
After several unsuccessful methods trying to obtain the desired aldehyde through 
oxidation, a reduction method was employed. Diisobutylaluminium hydride is known for 
reducing esters to aldehydes at low temperatures. 4 A short reaction time was used and a 
cold reaction temperature to try to prevent over-reduction to the alcohol. 1 Equivalent of 
DIBAL was used at – 80 °C in anhydrous dichloromethane. After 1 hour the reaction was 
quenched with methanol. 1H NMR spectroscopy of the crude reaction mixture showed 
only starting material. The experiment was repeated using 3 equivalents of DIBAL. This 
gave a mixture of the desired aldehyde (111a, b) and the alcohol (110a, b). The amide 
was also reduced. 
 
Scheme 64 
(20) (69) 
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As expected the major product was the alcohol (110a, b). Unfortunately, as the amide was 
also reduced, the alcohol could not be oxidised to the aldehyde (111a, b) as originally 
planned. We had thought that the amide would not be reduced at such a low 
temperature. 42   
 
2.8.5 Biological activities 
The compounds described in this section were tested for anti-malarial activity, and their 
IC50 values are displayed in Table 11. As these compounds are intermediates towards a 
bis-indole target, high anti-malarial activity was not expected, but was sought to provide a 
more complete structure-activity profile. 
 
 
 
 
Scheme 65 
(109a, b) (110a, b) (111a, b) 
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Table 11: 
N
N O
HR
R1
 
Compound R R1 IC50 (µM) Dd2luc 
(107a, b) Boc Ethyl-1,3-dithiolane-2-carboxylate 9.17 
(108a, b) Boc CH2C=OOCH3 20.3 
(109a, b) H CH2C=OOCH3 55.1 
(110a, b) H CH2CH2OH 27.2 
(111a, b) H CH2CHO 24.7 
(112a, b) H CH2CH2Boc 65.1 
 
The results of these compounds show that (107a, b) had the highest anti-malarial activity, 
most probably due to having a 5 membered ring at the R1 position. This resembles an 
additional ring system more closely than the other R1 substituents of the compounds in 
this series. The removal of the Boc group from compound (108a, b) to (109a, b) shows a 
decrease in activity. This is expected as previous results showed that addition of a group 
at the indole nitrogen always increased activity. 
With aldehyde functionality in place (111a, b), a Pictet-Spengler reaction could now be 
performed. 
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2.9 Addition of a Second Ring System 
2.9.1 Pictet-Spengler reaction 
The Pictet-Spengler reaction is one in which a β-arylethylamine such as tryptamine (79) 
undergoes a condensation reaction with an aldehyde or ketone, followed by ring closure 
(Scheme 66). Usually heat and the presence of an acidic catalyst are required. This forms 
a β-carboline unit (116), which we would like to add our compound (111a, b) 
(Scheme 67).   
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Scheme 66 
(79) (116) 
Scheme 67 
(111a, b) (117) 
(79) 
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This would potentially give a mixture of 4 diastereoisomers. 
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More nucleophilic rings such as indole give better reaction yields under mild conditions. 
The mechanism for this reaction is shown in Scheme 68. 
 
(117c) 
(117a) (117b) 
(117d) 
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The Pictet-Spengler reaction has been employed by various research groups as a route 
towards β-carbolines, it is commonly carried out using trifluoroacetic acid in anhydrous 
dichloromethane. Ducrot et al. 43 used it to generate β-carboline precursors to 
1-aminoindole[2,3-α]quinolizidines (123) (Scheme 69). 
(79) 
(116) 
(120) (119) 
(118) 
Scheme 68 
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Kundu et al. 44 used a novel varient of the Pictet-Spengler reaction using trifluoroacetic 
acid in water as a method of synthesising β-carbolines in high yields (Scheme 70). 
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Scheme 69 
43
 
Scheme 70 
44
 
(79) 
(121) 
(122) 
(123) 
(124) (125) 
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2.9.2 Imine formation 
The first step of this reaction was to form an imine between compound (111a, b) and 
tryptamine (79). 
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The conditions employed were those described by Bailey et al. 45 in which the imine is 
formed by combining tryptamine and the aldehyde under a nitrogen atmosphere in 
anhydrous dichloromethane. 3Å molecular sieves were added since the by-product of this 
reaction is water. Once the imine is formed, trifluoroacetic acid is added. 
Compound (111a, b) and tryptamine (79) were combined as described. After 30 minutes it 
was noted that the compounds had not dissolved and therefore the reaction was heated to 
30 °C. After 4 hours a small portion of the reaction mixture was extracted, the solvents 
removed and a 1H NMR spectrum obtained, which showed the presence of tryptamine. 
The reaction was left overnight. Thin layer chromatography showed presence of both 
tryptamine (79) and aldehyde (111a, b). The reaction was run again at a higher 
temperature using anhydrous tetrahydrofuran for 12 hours.  After this time, analysis by 
thin layer chromatography showed no presence of tryptamine. Column chromatography 
Scheme 71 
(126a, b) 
(111a, b) 
(79) 
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was performed, but unfortunately none of the desired product could be obtained. No 
further action could be taken due to the project finishing. 
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2.10 Validity of these Compounds as Anti-Malarials 
For a compound to be considered a viable candidate for a drug, it must adhere to three 
main criteria. It must be cost effective, effective and safe. The first synthetic method 
towards the targets described in this thesis (Scheme 72), starting from D-tryptophan is 
highly costly and time consuming.  
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However the second, shorter method (Scheme 73) starting from tryptamine and resulting 
in racemic compounds is much more affordable, the IC50 results show that using racemic 
compounds gives very similar activity to that of the pure enantiomers and therefore 
provides a quicker, cheaper route to the compounds described in this project. 
 
(20) 
(6) (18) 
(19a) 
(19b) 
Scheme 72 
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These compounds, although they display anti-malarial activity, are not yet effective 
enough to be seriously considered as drug candidates (an IC50 value in the low nM range 
is desirable). They do however comply with three out of four of Lipinski’s rule of 5, a 
standard guideline for developing drugs. 46 
The rule of 5 states that, in general, for a drug to be orally active, it must have no more 
than one violation of the following criteria: 
1) No more that 5 hydrogen bond donors 
2) No more than 10 hydrogen bond acceptors 
3) A molecular mass less than 500 
4) An octanol-water partition coefficient (log P) less than five 
The compounds described in this thesis definitely comply with rules 1-3. The octanol-
water partition coefficient has not been tested. It is therefore likely that with further 
Scheme 73 
(72a, b) 
(90) (81) 
150 
 
structural modifications to increase activity, this class of compounds could make viable 
drug candidates for malaria. 
The safety of these compounds has not been fully assessed as they are not active 
enough to warrant much further investigation. However, cytotoxicity screening of natural 
structurally related indole alkaloids has been conducted and selectivity index (SI) 
determined. The selectivity index can be defined as the ratio of cytotoxicity over anti-
plasmodial activity; a high number displays selectivity for the plasmodium parasite and 
therefore makes a compound a more desirable drug candidate. The selectivity index for 
dihydrousambarensine has been reported as 375 (with an IC50 value of 0.032 µM) against 
the chloroquine resistance strain W2, 447 showing high anti-malarial activity, and low 
cytotoxicity. It is therefore possible for structurally related compounds to have this 
selectivity too. 
Preliminary toxicity screenings were conducted for 5 of the compounds described in this 
thesis and they were found to be non-toxic (see appendix 4.2). 48 
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2.11 Conclusion 
In summary, we have developed several anti-malarial compounds derived from both 
enantiomers of the indolizino[2,3-α]quinolizidine template (8) and (20). Those derived from 
(20) were more active. We have investigated several structural modifications to the 
templates to try to obtain a compound with high anti-malarial activity.  
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Addition of protecting groups to both the indole nitrogen and the hydroxyl group increase 
anti-malarial activity. The combination of N-benzyl, O-methyl (29) or N-benzyl, O-allyl (30) 
yielded the most potent compounds. 
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With the hydroxymethyl moiety present, incorporation of α,β-Unsaturation in the lactam 
ring does not increase activity, however when followed by a conjugate addition reaction 
using vinyl magnesium bromide gave the most active compound in this series 
(46) (IC50=1.1 µM). 
(8) (20) 
(29) (30) 
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Increasing the basicity of the compounds by converting the amide into an amine and by 
adding a pyridyl group to the indole NH did not increase activity.  
Following previously described methodology, the hydroxyl methyl group was removed 
from (20) and a series of compounds were derived from this new template (72a), which 
bore a closer resemblance to natural anti-malarials. 
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We have developed a novel synthetic route to a racemic template that is quicker and 
cheaper to make than (72a) and a set of compounds derived from it showed that the 
racemic versions of these compounds are comparable in anti-malarial activity with the 
enantiomerically pure ones. 
 
Scheme 74 
(46) 
(20) (72a) 
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We have developed a novel route to the aldehyde (111a, b), which could then undergo a 
Pictet-Spengler reaction with tryptamine (79) to give a bis-indole compound. Unfortunately 
our attempts so far have proved unsuccessful.  
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Scheme 75 
Scheme 76 
(109a, b) (110a, b) (111a, b) 
(81) (90) 
(72a, b) 
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Future work will focus on developing bis-indole compounds. The method reported by 
Malhorta 30 in the synthesis of ochrolifuanine A should prove successful in attaching a 
second ring system to our aldehyde (111a, b) to give the desired bis-indole compound 
(117). Derivatives of tryptamine, such as 5-hydroxytryptamine (127) or tryptophan (2), (17) 
could also be used to form a second ring system and to give insight as to whether extra 
functionality in this area could affect anti-malarial activity. 
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The functional groups on the above compounds could also be further functionalised, and 
in the case of tryptophan, effects of stereochemistry could be investigated. 
 
 
 
 
 
 
 
 
 
 
(127) (2) (17) 
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Chapter 3 
Experimental 
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3.1 General Information 
3.1.1 Solvents and reagents  
All solvents, where necessary, were dried and stored over 3 Å molecular sieve prior to 
use. 
Reagent chemicals were purchased from the following companies: Alfa Aesar UK, Sigma-
Aldrich UK, Fischer Scientific and Acros Organics. 
 
3.1.2 Chromatographic procedures 
Analytical thin layer chromatography (TLC) was conducted using aluminium backed plates 
with 0.20 mm silica gel with fluorescent indicator UV254 and using polyester backed plates 
with 0.20 mm aluminium oxide with fluorescent indicator N/UV254. 
Plates were examined under UV light (254 nm).  
Column chromatography over silica gel was conducted using Geduran Si 60 (40-63 µm). 
Samples were pre-absorbed onto the minimum amount of silica.  
Column chromatography over alumina was conducted using Acros Organics aluminium 
oxide, basic, Brockman 1 for chromatography. 50-200 µm, 60 A. Samples were pre-
absorbed onto the minimum amount of alumina. 
Pressure was applied by the use of hand bellows. 
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3.1.3 Spectra 
Infrared spectra (IR) was conducted in the range of 4000-500 cm-1, using a Thermo 
Scientific Nicolet is10 with a Pike Technologies GladiATR. Samples were applied directly 
to the ATR plate. 
Nuclear Magnetic Resonance (NMR) spectra (1H and 13C) were recorded at 300 MHz 
using a Bruker Spectrospin DPX 300 Spectrometer. Multiplicities were recorded as broad 
peaks (br), singlets (s), doublets (d), triplets (t), quartets (q), quintets (qu), sextets (si), 
septets (se) double doublets (dd), doublet of double doublets (ddd), doublet of triplets (dt), 
doublet of quartets (dq), triplet of doublets (td), quartet of quartets (qq), sextet of doublets 
(sid) and multiplets (m). All NMR samples were made up in deuterated solvents with all 
values quoted in ppm relative to tetramethylsilane (TMS) as an internal reference. 
Coupling constants (J values) are reported in Hertz (Hz). 
Mass Spectrometry Samples were sent for EI/CI and Accurate Mass measurement to 
EPSRC National Mass Spectrometry Centre at the University of Wales, Swansea.  
 
3.1.4 Other data 
Melting points were determined using a Stuart Scientific SMP3 Melting point instrument. 
Specific Rotations were performed using a Rudolph Research Analytical Autopol 
Automatic Polarimeter and are reported in units of deg° dm−1cm3 g−1
.
 
 
 
                                              
 
 
158 
 
3.2 Synthesis of Indolizino[2,3-α]quinolizidines 
(2S)-2-Amino-3-(1H-indole-3-yl)propan-1-ol (3) 3 
 
N
H
OH
NH2
 
 
Anhydrous tetrahydrofuran (75 ml) was added to lithium borohydride (1.07 g, 49.0 mmol) 
under a nitrogen atmosphere. Trimethylsilyl chloride (12.4 ml, 97.9 mmol) was added over 
the course of two minutes, followed by L-tryptophan (2) (5 g, 24.5 mmol) which was added 
slowly over the course of 5 minutes. The reaction was left stirring at room temperature for 
24 hours.  
Methanol (30 ml) was added cautiously to quench the reaction. The solvents were 
evaporated and the resulting oil was treated with 20% potassium hydroxide solution 
(40 ml).  The solution was washed with ethyl acetate (3 x 100 ml) and the organic extracts 
were combined and dried using anhydrous magnesium sulphate. The drying agent was 
then removed by filtration and the solvent removed under reduced pressure to yield a 
brown oil (3.36 g 72.2%). No further purification was carried out. 
δH(300 MHz; DMSO) 2.50-2.60 (1H, m, CH(H)CHNH2), 2.78 (1H, dd, J 14.1, 6, 
CH(H)CHNH2), 2.93-3.01 (1H, m, CH2CHNH2), 3.18-3.37 (2H, m, CH2OH), 6.95 (1H, t, J 
6.9, ArH), 7.05 (1H, t, J 7.2, ArH), 7.14 (1H, s, C=CHNH), 7.33 (1H, d, J  7.8, ArH), 7.53 
(1H, d, J  7.8, ArH), 10.83 (1H, br s, NH). 
OH proton was not observed. 
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Methyl 5-hydroxypentanoate (5) 3 
 
O
OMe
OH
 
 
Concentrated sulfuric acid (25 drops) was added to a solution of δ-valerolactone (4) 
(25.8 g, 257.7 mmol) in methanol (250ml) and heated under reflux at 80°C for 5 hours. 
The mixture was cooled using an ice/salt bath and sodium hydrogen carbonate (2.5 g) 
was added and stirred for 10 minutes. This was then filtered and the solvent removed 
under reduced pressure to yield a colourless oil (30.23 g, 89%). The product was not 
purified as re-lactonisation occurs on aqueous work up or distillation. 
δH(300 MHz; CDCl3) 1.52-1.59 (2H, m, CH2CH2OH), 1.62-1.69 (2H, m, CH2CH2CH2OH), 
2.31 (2H, t, J 7.5, CH2COOCH3), 3.56-3.60 (2H, m, CH2OH), 3.63 (3H, s, OCH3). 
OH proton was not observed 
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Methyl 5-oxopentanoate (6) 3 
 
O
OMe
O
 
 
Methyl 5-hydroxypentanoate (5) (11.8 g, 89.4 mmol) was added slowly to a suspension of 
pyridinium chlorochromate (29.0 g, 134.5 mmol) and celite (29.0 g) in dichloromethane 
(200 ml) and stirred at room temperature for 4 hours. The solution was decanted and the 
solids were washed with diethyl ether (4 x 100 ml) until the solvent ran clear. The 
combined organic solutions were filtered through an alumina column and the solvent was 
removed under reduced pressure to give a green oil (9.65 g, 83%) which was not purified 
further. 
δH(300 MHz; CDCl3) 1.62-1.65 (2H, m, CH2CH2CHO), 1.86-1.95 (2H, m, CH2CHO), 2.26-
2.31 (2H, m, CH2CH2CH2CHO), 3.63 (3H, s, OCH3), 9.73 (1H, s, CHO). 
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(3S)-3-((1H-Indol-3-yl)methyl)-hexahydrooxazolo[3,2-a]pyridin-5-one (7a, b) 3  
 
NH
N
O
O
H  
 
(2S)-2-Amino-3-(1H-indole-3-yl)propan-1-ol (3) (7.36 g, 38.70 mmol) and methyl 5-
oxopentanoate (6) (5.04 g, 38.70 mmol) were combined in toluene (150 ml) and refluxed 
under Dean-Stark conditions for 48 hours.  
The mixture was cooled and the remaining toluene was removed under reduced pressure. 
The resulting brown oil was absorbed onto silica and purified by flash column 
chromatography over silica using ethyl acetate as the eluent to produce the desired 
compound as a mixture of diastereoisomers which were not separated (2.13 g, 20%). The 
1H NMR data for the major isomer (7a) is shown below.  
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δH(300 MHz; CDCl3) 1.29-2.00 (4H, m, CH2CH2CH2CO), 2.31-2.42 (2H, m, CH2CO), 2.57-
2.60 (1H, m, CH(H)C=C), 3.61-3.70 (1H, m, CH(H)C=C), 3.95-4.07 (2H, m, CH2O), 4.21-
4.24 (1H, m, NCHCH2O), 4.60-4.65 (1H, m, NCHOCH2), 6.98 (1H, s, C=CHNH), 7.04-7.20 
(2H, m, ArH), 7.30 (1H, d, J  7.8 ArH), 7.77 (1H, d, J 8.1 ArH), 8.02 (1H, br s, NH). 
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(6S,12bR)-6-Hydroxymethyl-2,3,6,7,12,12b-hexahrydro-1Hindolo[2,3-a]quinolizim-4-one 
(8) 3 
 
N
H
N O
OH
H
 
   
(3S,8aS)-3-(1H-Indol-3-ylmethyl)-hexahydro-oxazolo[3,2-a]pyridine-5-one (7a, b) (1.39 g, 
5.10 mmol) was dissolved in absolute ethanol (70 ml) and acidified to pH 1 using 2 M 
hydrochloric acid in absolute ethanol. This was then stirred at room temperature for 
20 hours.  
The reaction was quenched by the addition of saturated sodium hydrogen carbonate 
solution and extracted with ethyl acetate (3 x 100 ml). The organic extracts were 
combined, dried using anhydrous magnesium sulphate, and the drying agent was 
removed by filtration. The solvent was removed under reduced pressure to give a brown 
solid (1.33 g, 95%). A portion of this was re-crystallised from absolute ethanol to give a 
white solid. 
δH(300 MHz; DMSO) 1.57-1.65 (1H, m, CH(H)CH2CH2CO), 1.78-1.85 (2H, m, 
CH2CH2CO), 2.30-2.42 (2H, m, CH2CO), 2.55 (1H, s, CH(H)CH2CH2CO), 2.64-2.74 (1H, 
m, C=CCH(H)), 2.85 (1H, d, J  15, C=CCH(H)), 3.41 (2H, s, CH2OH), 4.70 (1H, d, J 8.7, 
NCHC=C), 4.84 (1H, br s, OH), 5.27 (1H, dt, J 6, 6, NCHCH2OH), 6.97 (1H, t, J 7.4, ArH), 
7.11 (1H, t, J 7.4, ArH), 7.37 (1H, d, J 7.8, ArH), 7.45 (1H, d, J 7.8, ArH), 10.95 (1H, br s, 
NH). 
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(2R)-2-Amino-3-(1H-indole-3-yl)propan-1-ol (18) 3 
 
N
H
OH
NH2
 
 
Anhydrous tetrahydrofuran (75 ml) was added to lithium borohydride (1.07 g, 49.0 mmol) 
under a nitrogen atmosphere. Trimethylsilyl chloride (12.4 ml, 97.9 mmol) was added over 
the course of two minutes, followed by D-tryptophan (17) (5 g, 24.5 mmol) which was 
added slowly over the course of 5 minutes. The reaction was left stirring at room 
temperature for 24 hours.  
Methanol (30 ml) was added cautiously to quench the reaction. The solvents were 
evaporated and the resulting oil was treated with 20% potassium hydroxide solution 
(40 ml).  The solution was washed with ethyl acetate (3 x 100 ml) and the organic extracts 
were combined and dried using anhydrous magnesium sulphate. This was then filtered 
and the solvent removed under reduced pressure to yield a brown oil (4.14 g, 89%). No 
further purification was carried out. 
δH(300 MHz; DMSO) 2.58 (1H, dd, J 14.1, 7.2, CH(H)CHNH2), 2.79 (1H, dd, J 14.1, 6, 
CH(H)CHNH2), 2.94-3.02 (1H, m, CH2CHNH2), 3.19-3.30 (1H, m, CH(H)OH), 3.31-3.39 
(1H, m, CH(H)OH) 6.94 (1H, t, J 6.9, ArH), 7.03 (1H, td, J 8.1, 1.2, ArH), 7.13 (1H, s, 
CHNH), 7.32 (1H, d, J  7.8, ArH), 7.52 (1H, d, J  7.8, ArH), 10.89 (1H, br s, NH). 
OH proton was not observed. 
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(3R)-3-((1H-Indol-3-yl)methyl)-hexahydrooxazolo[3,2-a]pyridin-5-one (19a, b) 3  
 
NH
N
O
O
H
 
 
(2R)-2-Amino-3-(1H-indole-3-yl)propan-1-ol (18) (5.97 g, 31.42 mmol) and methyl 5-
oxopentanoate (6) (4.08 g, 31.42 mmol) were combined in toluene (150 ml) and refluxed 
under Dean-Stark conditions for 48 hours.  
The mixture was cooled and the remaining toluene removed by rotary evaporation. The 
resulting brown oil was absorbed onto silica and purified by flash column chromatography 
over silica using ethyl acetate as the eluent to produce the desired compound as a 
mixture of diastereoisomers that were not separated (2.76 g, 33%). The 1H NMR data for 
the major isomer (19a) is shown below. 
 
NH
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δH(300 MHz; CDCl3) 1.34-1.47 (1H, m, CH(H)CH2CH2CO), 1.59-1.65 (1H, m, 
CH2CH(H)CH2CO), 1.74-1.90 (1H, m, CH2CH(H)CH2CO), 2.27-2.30 (1H, m, 
CH(H)CH2CH2CO),  2.44-2.49 (2H, m, CH2CO), 2.54-2.63 (1H, m, CH(H)C=C), 3.60-3.68 
(1H, m, CH(H)C=C), 3.93 (1H, d, J 9, CH(H)O), 3.98-4.02 (1H, m, CH(H)O), 4.20-4.27 
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(1H, m, NCHCH2CO), 4.58 (1H, dd, J 9.6, 2.7, NCHOCH2), 6.92 (1H, s, C=CHNH), 7.03-
7.26 (2H, m, ArH), 7.60 (1H, d, J 7.8, ArH), 7.72 (1H, d, J 7.5, ArH), 8.52 (1H, br s NH). 
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(6R,12bS)-6-Hydroxymethyl-2,3,6,7,12,12b-hexahrydro-1Hindolo[2,3-a]quinolizim-4-one 
(20) 3 
N
H
N O
H
OH
 
(3R,8aR)-3-(1H-Indol-3-ylmethyl)-hexahydro-oxazolo[3,2-a]pyridine-5-one (19a, b) 
(0.60 g, 2.11 mmol) was dissolved in absolute ethanol (50 ml) and acidified to pH 1 using 
2 M hydrochloric acid in absolute ethanol and stirred at room temperature for 20 hours.  
The reaction was quenched by the addition of saturated sodium hydrogen carbonate 
solution and extracted with ethyl acetate (3 x 100 ml). The organic extracts were 
combined, dried using anhydrous magnesium sulphate and the drying agent was removed 
by filtration. The solvent was removed under reduced pressure to yield a brown solid 
(0.57 g, 95%). A small portion was re-crystallised from absolute ethanol to give white 
crystals. 
δH(300 MHz; DMSO) 1.57-1.70 (1H, m, CH(H)CH2CH2CO), 1.81-1.90 (2H, m, 
CH2CH2CO), 2.30-2.43 (2H, m, CH2CO), 2.56-2.58 (1H, m, CH(H)= CH(H)CH2CH2CO), 
2.64-2.79 (1H, m, C=CCH(H)), 2.86 (1H, d, J 15.9, C=CCH(H)), 3.39-3.45 (2H, m, 
CH2OH), 4.71 (1H, d, J  7.2, NCHC=C), 4.85 (1H, t, J 5.4, OH), 5.28 (1H, dt, J 6, 6, 
NCHCH2OH), 7.03 (1H, t, J 6.9, ArH), 7.12 (1H, t, J 7.2, ArH), 7.38 (1H, d, J 7.8, ArH), 
7.45 1H, d, J 7.5, ArH), 10.95 (1H, br s, NH). 
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3.3 Synthesis of Indolizino[2,3-α]quinolizidine Substrates 
(6S,12bR)-12-Benzyl-6-(hydroxymethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-
4(12H)-one (21) 13 
N
N
O
H
OH
 
 
Sodium hydride (60% dispersion in mineral oil, 0.13 g, 3.35 mmol) and (6S,12bR)-6-
hydroxymethyl-2,3,6,7,12,12b-hexahydro-1H-indole[2,3-a]quinolizin-4-one (8) (0.60 g, 
2.23 mmol) were combined under a nitrogen atmosphere and cooled to 0 °C using an ice 
bath. Anhydrous dimethylformamide (10 ml) was added and the ice bath removed. The 
reaction was then stirred at room temperature for 30 minutes. After this time, benzyl 
bromide (0.4 ml, 3.35 mmol) was added and the reaction was stirred for 24 hours.  
The reaction was quenched by the addition of ice water (15 ml), washed with ethyl acetate 
(3 x 100 ml) and brine (3 x 100 ml). The combined organic extracts were dried over 
anhydrous magnesium sulphate, which was then removed by filtration and the solvent 
was removed under reduced pressure. The crude product was absorbed onto silica and 
purified by flash column chromatography over silica using 5% methanol in ethyl acetate as 
the eluent. This yielded a white solid (0.51 g, 63%). 
Mp: 235-237 °C; [α]D = +150.99 (c = 0.01, CHCl3); νmax (cm-1) 3290 OH, 1591 NC=O  
δH (300 MHz; CDCl3) 1.55-1.69 (1H, m, CH(H)CH2CH2CO), 1.77-1.91 (2H, m, 
CH2CH2CO), 2.33-2.42 (1H, m, CH(H)CH2CH2CO), 2.44-2.64 (2H, m, CH2CO), 2.87 (1H, 
d J 15.9, C=CCH(H)), 3.03 (1H, ddd J 15.9, 6, 2.1, C=CCH(H)), 3.47-3.52 (1H, m, 
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CH(H)OH), 3.59-3.64 (1H, m, CH(H)OH), 4.61 (1H, d, J 12, NCHC=C), 5.26 (1H, d, J 17.5 
NCH(H)Ph), 5.38 (1H, d, J 17.5 NCH(H)Ph), 5.46-5.53 (1H, m, NCHCH2OH), 6.94-6.97 
(2H, m, ArH), 7.13-7.19 (3H, m, ArH), 7.26-7.33 (3H, m, ArH), 7.52-7.56 (1H, m, ArH) 
OH proton was not observed 
δC (300 MHz;  CDCl3) 19.34 (CH2), 21.78 (CH2), 30.48 (CH2), 31.89 (CH2), 47.71 (CH), 
49.04 (CH2), 51.14 (CH), 62.91 (CH2), 107.41 (C), 109.92 (CH), 118.46 (CH), 119.88 
(CH), 122.30 (CH), 125.73 (2xCH), 126.77 (C), 127.64 (CH), 128.98 (2xCH), 133.02 (C), 
137.15 (C), 138.24 (C), 172.25 (NC=O) 
MS (CI) m/z 361 [MH+, 100%]; (Found: MH+, 361.1909. C23H24N2O2 requires 361.1911). 
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(6S,12bR)-12-Benzyl-6-(methoxymethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-
4(12H)-one (22) 
N
N
O
H
O
 
 
Sodium hydride (60% dispersion in mineral oil, 0.071 g, 1.77 mmol) and (6S,12bR)-12-
benzyl-6-(hydroxymethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-4(12H)-one (21) 
(0.29 g, 0.803 mmol) were combined under a nitrogen atmosphere and cooled to 0°C. 
Anhydrous dimethylformamide (5 ml) was added and the reaction was stirred at room 
temperature for 30 minutes. After this time, methyl iodide (0.17 ml, 1.20 mmol) was added 
and the reaction was stirred for 24 hours. 
The reaction was quenched by the addition of ice water (15 ml), washed with ethyl acetate 
(3 x 100 ml) and brine (3 x 100 ml). The combined organic extracts were dried over 
anhydrous magnesium sulphate, which was then removed by filtration and solvent was 
removed under reduced pressure. The crude product was absorbed onto silica and 
purified by flash column chromatography over silica using 5% methanol in ethyl acetate as 
the eluent to give a yellow solid (0.043 g, 14%). 
Mp: 194-195 °C; [α]D = +161.25 (c = 0.008, CHCl3); νmax (cm-1) 1259 O-Me, 1629 NC=O.  
δH (300 MHz; CDCl3) 1.44-1.57 (1H, m, CH(H)CH2CH2CO), 1.62-1.82 (2H, m, 
CH2CH2CO), 2.28-2.36 (1H, m, CH(H)CH2CH2CO), 2.38-2.42 (1H, m, CH(H)CO), 2.46-
2.54 (1H, m, CH(H)CO),  2.76 (1H, d J 15.6, C=CCH(H)), 2.92 (1H, ddd, J 15.9, 5.7, 2.1, 
C=CCH(H)), 3.12-3.26 (2H, m, CH2OMe), 3.16 (3H, s, OCH3), 4.40 (1H, d, J 12, 
NCHC=C),  5.17 (1H, d, J 17.5, NCH(H)Ph), 5.33 (1H, d, J 17.5, NCH(H)Ph),  5.57 (1H, 
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dt, J 6, 6, NCHCH2OMe), 6.85-6.87 (2H, m, ArH), 7.04-7.08 (3H, m, ArH), 7.16-7.24 (3H, 
m, ArH), 7.45-7.49 (1H, m, ArH). 
δC (300 MHz;  CDCl3) 18.31 (CH2), 20.95 (CH2), 29.32 (CH2), 30.98 (CH2), 44.53 (CH), 
46.71 (CH2), 50.26 (CH), 57.74 (CH2), 70.13 (CH3), 106.87 (C), 108.73 (CH), 117.46 (CH), 
118.74 (CH), 121.15 (CH), 124.70 (2xCH), 125.87 (C), 126.55 (CH), 127.86 (2xCH), 
132.39 (C), 136.21 (C), 137.28 (C), 169.25 (NC=O). 
MS (CI) m/z 375 [MH+, 100%]; (Found: MH+, 375.2064. C24H27N2O2 requires 375.2067). 
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(6S,12bR)-6-(Allyloxymethyl)-12-benzyl-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-
4(12H)-one (23) 
N
N
O
H
O
 
 
Sodium hydride (60% dispersion in mineral oil, 0.07 g, 1.65 mmol) and (6S,12bR)-12-
benzyl-6-(hydroxymethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-4(12H)-one (21) 
(0.27 g, 0.75 mmol) were combined under a nitrogen atmosphere and cooled to 0°C. 
Anhydrous dimethylformamide (5 ml) was then added the reaction was stirred for 
30 minutes at room temperature. After this time allyl bromide (0.10 ml, 1.12 mmol) was 
added and the reaction was left to stir for 24 hours. 
The reaction was quenched by the addition of ice water (15 ml), washed with ethyl acetate 
(3 x 100 ml) and brine (3 x 100 ml). The combined organic extracts were dried over 
anhydrous magnesium sulphate, which was then removed by filtration and solvent was 
removed under reduced pressure. The crude product was absorbed onto silica and 
purified by flash column chromatography over silica using 5% methanol in ethyl acetate as 
the eluent to give a yellow solid (0.11 g, 37%). 
Mp: 147-149 °C; [α]D = +140.00 (c = 0.011); νmax (cm-1) 1633 NC=O. 
δH (300 MHz; CDCl3) 1.44-1.57 (1H, m, CH(H)CH2CH2CO), 1.60-1.82 (2H, m, 
CH2CH2CO), 2.28-2.34 (1H, m, CH(H)CH2CH2CO), 2.36-2.42 (1H, m, CH(H)CO), 2.45-
2.54 (1H, m, CH(H)CO), 2.80 (1H, d J 15.9, C=CCH(H)), 2.92 (1H, ddd, J 15.9, 5.7, 2.1, 
C=CCH(H)), 3.20-3.30 (2H, m, CH2OAllyl), 3.74-3.88 (2H, m , OCH2CH=CH2), 4.42 (1H, 
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d, J 12, NCHC=C), 4.98-5.12 (2H, m, OCH2CH=CH2), 5.17 (1H, d, J 17.5, NCH(H)Ph), 
5.32 (1H, d, J 17.5, NCH(H)Ph), 5.52-5.59 (1H, m, NCHCH2OAllyl), 5.64-5.77 (1H, m, 
NCHCH2OCH2CH), 6.85-6.87 (2H, m, ArH), 7.05-7.09 (3H, m, ArH), 7.17-7.23 (3H, m, 
ArH), 7.46-7.49 (1H, m, ArH). 
δC (300 MHz;  CDCl3) 18.31 (CH2), 20.89 (CH2), 29.34 (CH2), 30.95 (CH2), 44.74 (CH), 
46.69 (CH2), 50.31 (CH), 67.40 (CH2), 70.59 (CH2), 106.83 (C), 108.73 (CH), 115.78 
(CH2), 117.47 (CH), 118.74 (CH), 121.14 (CH), 124.70 (2xCH), 125.92 (C), 126.53 (CH), 
127.86 (2xCH), 132.37 (C), 133.68 (CH), 136.23 (C), 137.27 (C), 169.28 (NC=O). 
MS (CI) m/z 401 [MH+, 100%]; (Found: MH+, 401.2222. C26H29N2O2 requires 401.2224). 
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(6R,12bS)-12-Benzyl-6-(hydroxymethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-
4(12H)-one (27) 
 
N
N O
H
OH
 
 
(6R,12bS)-6-Hydroxymethyl-2,3,6,7,12,12b-hexahrydro-1Hindolo[2,3-a]quinolizim-4-one 
(20) (0.60 g, 2.23 mmol) and sodium hydride (60% dispersion in mineral oil, 0.13 g, 
3.35 mmol) were combined under a nitrogen atmosphere. An ice bath was placed 
underneath and anhydrous dimethylformamide (5 ml) was added. The ice bath was 
removed and the reaction was left to stir at room temperature for half an hour. Benzyl 
bromide (0.40 ml, 3.35 mmol) was added and the reaction was left for 24 hours.  
The reaction was quenched using ice water (15 ml), washed with ethyl acetate (3 x 50 ml) 
then brine (3 x 50 ml) and dried using anhydrous magnesium sulphate, which was then 
removed by filtration. The solvent was removed under reduced pressure. The crude 
product was absorbed onto silica and purified using flash column chromatography over 
silica with 5% methanol in ethyl acetate as the eluent. This gave a yellow solid (0.33 g, 
41%). 
Mp: 233-235 °C; [α]D = -119.62 (c = 0.004, CHCl3); νmax (cm-1) 3290 (OH), 1591 NC=O.  
δH (300 MHz; CDCl3) 1.49-1.63 (1H, m, CH(H)CH2CH2CO), 1.70-1.82 (2H, m, 
CH2CH2CO), 2.26-2.31 (1H, m, CH(H)CH2CH2CO), 2.35-2.58 (2H, m, CH2CO), 2.80 (1H, 
d J 15.9, C=CCH(H)), 2.96 (1H, ddd J 15.6, 5.7, 1.8, C=CCH(H)), 3.41 (1H, m, CH(H)OH), 
3.52-3.58 (1H, m, CH(H)OH), 4.54 (1H, d, J 10.8, NCHC=C), 5.19 (1H, d, J 17.5, 
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NCH(H)Ph), 5.31 (1H, d, J 17.5, NCH(H)Ph), 5.39-5.46 (1H, m, NCHCH2OH), 6.87-6.90 
(2H, m, ArH), 7.06-7.11 (3H, m, ArH), 7.19-7.26 (3H, m, ArH), 7.47-7.50 (1H, m, ArH). 
OH proton was not observed. 
δC (300 MHz;  CDCl3) 19.35 (CH2), 21.76 (CH2), 30.49 (CH2), 31.87 (CH2), 47.70 (CH2), 
49.01 (CH), 51.13 (CH), 63.03 (CH2), 107.39 (C), 109.91 (CH), 118.45 (CH), 119.88 (CH), 
122.31 (CH), 125.72 (2xCH), 126.77 (C), 127.65 (CH), 128.97 (2xCH), 133.00 (C), 137.14 
(C), 138.25 (C), 172.26 (NC=O). 
MS (CI) m/z 361 [MH+, 100%]; (Found: MH+, 361.1913. C23H24N2O2 requires 361.1911). 
 
 
 
 
 
 
 
 
 
 
 
 
175 
 
(6R,12bS)-12-Allyl-6-(hydroxymethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-
4(12H)-one (28) 
 
N
N O
OH
H
 
 
Sodium hydride (60% dispersion in mineral oil, 0.043 g, 1.11 mmol) was added to 
(6R,12bS)-6-Hydroxymethyl-2,3,6,7,12,12b-hexahydro-1Hindolo[2,3-a]quinolizim-4-one 
(20) (0.2 g, 0.74 mmol) under a nitrogen atmosphere. The reaction was cooled with an ice 
bath and dry dimethylformamide (5 ml) was added. The ice bath was removed and the 
reaction was left stirring at room temperature for half an hour. After this time, allyl bromide 
(0.097 ml, 1.11 mmol) was added and the reaction was left overnight. 
The reaction was quenched using ice water (20 ml) and extracted into ethyl acetate 
(3 x 20 ml). The combined organic extracts were washed with brine (3 x 50 ml), dried over 
anhydrous magnesium sulphate, which was then removed by filtration and the solvent 
was removed under reduced pressure. The crude product was absorbed onto silica and 
purified using flash column chromatography over silica with 5% methanol in ethyl acetate 
as the eluent. This gave a pale yellow solid (0.17 g, 74%). 
Mp: 161-164 °C; [α]D = -138.25 (c = 0.00217 CHCl3); νmax (cm-1) 1603 NC=O, 3332 OH. 
δH (300 MHz; CDCl3) 1.58-1.66 (1H, m, CH(H)CH2CH2CO), 1.78-1.89 (2H, m, 
CH2CH2CO), 2.39-2.50 (1H, m, CH(H)CH2CH2CO), 2.39-2.50 (1H, m, CH(H)CO), 2.53-
2.62 (1H, m, CH(H)CO), 2.75 (1H, d J 16.2, C=CCH(H)), 2.93 (1H, dd, J 15.9, 4.2, 
C=CCH(H)), 3.43 (1H, t, J 10.5 CH(H)OH), 3.53-3.59 (1H, m, CH(H)OH), 4.61-4.69 (1H, 
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m, NCHC=C), 4.61-4.69 (1H, m, NCH(H)CHCH2), 4.61-4.69 (1H, m, NCH2CHCH(H)), 4.83 
(1H, d, J 17.1,  NCH(H)CHCH2), 5.15 (1H, d, J 10.5, NCH2CHCH(H)), 5.39-5.46 (1H, m,  
NCHCH2OH), 5.83-5.93  (1H, m, NCH2CH), 7.05-7.19 (3H, m, ArH), 7.45 (1H, d, J 7.5, 
ArH). 
OH proton was not observed. 
δC (300 MHz; CDCl3) 18.34 (CH2), 20.70 (CH2), 29.50 (CH2), 30.88 (CH2), 45.40 (CH2), 
48.02 (CH), 50.01 (CH), 61.94 (CH2), 105.91 (C), 108.80 (CH), 115.91 (CH2), 117.34 
(CH), 118.68 (CH), 121.05 (CH), 125.68 (C), 131.75 (C), 131.93 (CH), 136.90 (C), 171.32 
(NC=O). 
MS (CI) m/z 311 [MH+, 100%]; (Found: MH+, 311.1757. C19H23N2O2 requires 311.1754). 
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(6R,12bS)-12-Benzyl-6-(methoxymethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-
4(12H)-one (29) 
 
N
N O
O
H
 
 
Sodium Hydride (60% dispersion in mineral oil, 0.046 g, 1.16 mmol) was combined with 
(6R,12bS)-12-benzyl-6-(hydroxymethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-
4(12H)-one (27) (0.21 g, 0.581 mmol) under a nitrogen atmosphere and cooled to 0°C 
using an ice bath. Dimethylformamide (5 ml) was added and the ice bath removed. The 
reaction was stirred at room temperature for 30 minutes. Methyl Iodide (0.073 ml, 
1.16 mmol) was added and the reaction was stirred for 24 hours at room temperature.  
The reaction was quenched by the addition of ice water (15 ml), washed with ethyl acetate 
(3 x 50 ml) and brine (3 x 50 ml). The combined organic extracts were dried over 
anhydrous magnesium sulphate, which was then removed by filtration and the solvent 
was removed by rotary evaporation. The crude product was absorbed onto silica and 
purified by flash column chromatography over silica using 5% methanol in ethyl acetate as 
the eluent to give a yellow solid (0.11g, 51%). 
Mp: 191-192 °C; [α]D = -144.23 (c = 0.00208 CHCl3); νmax (cm-1) 1629 NC=O.  
δH (300 MHz; CDCl3) 1.41-1.56 (1H, m, CH(H)CH2CH2CO), 1.59-1.82 (2H, m, 
CH2CH2CO), 2.27-2.42 (1H, m, CH(H)CH2CH2CO), 2.46-2.49 (1H, m, CH(H)CO), 2.52-
2.55 (1H, m, CH(H)CO), 2.76 (1H, d J 15.9, C=CCH(H)), 2.92 (1H, ddd, J 15.9, 5.7, 2.1, 
C=CCH(H)), 3.12-3.27 (2H, m, CH2OMe), 3.17 (3H, s, OCH3), 4.41 (1H, d, J 11.1, 
178 
 
NCHC=C), 5.18 (1H, d, J 17.5, NCH(H)Ph), 5.34 (1H, d, J 17.5, NCH(H)Ph),  5.57 (1H, dt, 
J 6.9, 6 NCHCH2OMe), 6.85-6.88 (2H, m, ArH), 7.03-7.09 (3H, m, ArH), 7.17-7.24 (3H, m, 
ArH), 7.46-7.50 (1H, m, ArH). 
δC (300 MHz;  CDCl3) 19.39 (CH2), 22.03 (CH2), 30.41 (CH2), 32.06 (CH2), 45.62 (CH), 
47.80 (CH2), 51.35 (CH), 58.82 (CH2), 71.22 (CH2), 107.97 (C), 109.81 (CH), 118.54 (CH), 
119.83 (CH), 122.24 (CH), 125.79 (2xCH), 126.97 (C), 127.63 (CH), 128.95 (2xCH), 
133.46 (C), 137.30 (C), 138.37 (C), 170.36 (NC=O). 
MS (CI) m/z 375 [MH+, 100%]; (Found: MH+, 375.2069. C24H27N2O2 requires 375.2067). 
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(6R,12bS)-6-(Allyloxymethyl)-12-benzyl-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-
4(12H)-one (30) 
 
N
N O
H
O
 
 
Sodium hydride (60% dispersion in mineral oil, 0.13 g, 3.27 mmol) and (6R,12bS)-12-
benzyl-6-(hydroxymethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-4(12H)-one (27) 
(0.59 g, 1.63 mmol) were combined under a nitrogen atmosphere. An ice bath was placed 
underneath the flask and anhydrous dimethylformamide (10 ml) was added. The ice bath 
was removed and the reaction was stirred at room temperature for 30 minutes. After this 
time, allyl bromide (0.28 ml, 3.27 mmol) was added and the reaction was left for 24 hours.  
The reaction was quenched with the addition of ice water (30 ml) and washed with ethyl 
acetate (3 x 50 ml) and brine (3 x 50 ml). The organic extracts were combined and dried 
using anhydrous magnesium sulphate. This was then filtered out and the solvent was 
removed under reduced pressure. The crude product was absorbed onto silica and 
purified by flash column chromatography over silica using 5% methanol in ethyl acetate as 
the eluent. This produced a yellow solid (0.61 g, 93%).  
Mp: 140-142 °C; [α]D = -110.76 (c = 0.032 CHCl3); νmax (cm-1) 1633 NC=O. 
δH (300 MHz; CDCl3) 1.45-1.58 (1H, m, CH(H)CH2CH2CO), 1.62-1.83 (2H, m, 
CH2CH2CO), 2.27-2.35 (1H, m, CH(H)CH2CH2CO), 2.40-2.43 (1H, m, CH(H)CO), 2.46-
2.55 (1H, m, CH(H)CO), 2.80 (1H, d J 15.6, C=CCH(H)), 2.92 (1H, ddd, J 15.9, 5.7, 2.1, 
C=CCH(H)), 3.20-3.30 (2H, m, CH2OAllyl), 3.74-3.89 (2H, m , OCH2CH=CH2), 4.43 (1H, 
180 
 
d, J 10.8, NCHC=C), 5.06 (2H, m, OCH2CH=CH2), 5.18 (1H, d, J 17.5, NCH(H)Ph), 5.33 
(1H, d, J 17.5, NCH(H)Ph), 5.52-5.59 (1H, m, NCHCH2OAllyl) 5.65-5.78 (1H, m, 
NCHCH2OCH2CH), 6.85-6.88 (2H, m, ArH), 7.05-7.10 (3H, m, ArH), 7.17-7.22 (3H, m, 
ArH), 7.46-7.50 (1H, m, ArH). 
δC (300 MHz; CDCl3) 18.30 (CH2), 20.91 (CH2), 29.35 (CH2), 30.93 (CH2), 44.79 (CH), 
46.72 (CH2), 50.33 (CH), 67.43 (CH2), 70.61 (CH2), 106.87 (C), 108.74 (CH), 115.81 
(CH2), 117.49 (CH), 118.76 (CH), 121.17 (CH), 124.71 (2xCH), 125.94 (C), 126.55 (CH), 
127.88 (2xCH), 132.35 (C), 133.67 (CH), 136.23 (C), 137.30 (C), 169.38 (NC=O). 
MS (CI) m/z 401 [MH+, 100%]; (Found: MH+,  401.2222. C26H29N2O2 requires 401.2224). 
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(6R,12bS)-12-Benzyl-6-(benzyloxymethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-
4(12H)-one (31) 49 
 
N
N O
O
H
 
 
Sodium hydride (60% dispersion in mineral oil, 1.28 g, 32.09 mmol) and (6R,12bS)-6-
Hydroxymethyl-2,3,6,7,12,12b-hexahrydro-1Hindolo[2,3-a]quinolizim-4-one (20) (1.97 g, 
7.29 mmol) under a nitrogen atmosphere. This was cooled to 0°C using an ice bath. 
Anhydrous dimethylformamide (40 ml) was added and the ice bath removed. The reaction 
was left stirring at room temperature for 30 minutes. After this time benzyl bromide 
(2.61 ml, 21.83 mmol) was added and the reaction left for 24 hours.  
The reaction was quenched with the addition of ice water (30 ml) and washed with ethyl 
acetate (3 x 100 ml) and brine (3 x 100 ml). The organic extracts were combined and 
dried over anhydrous magnesium sulphate, which was then filtered out, and the solvent 
removed under reduced pressure. The crude product was absorbed onto silica and 
purified using flash column chromatography over silica with ethyl acetate as the eluent. 
This gave a pale yellow foam (1.90 g, 58%). 
δH (300 MHz; CDCl3) 1.47-1.67 (1H, m, CH(H)CH2CH2CO), 1.70-1.80 (2H, m, 
CH2CH2CH2CO), 2.23-2.35 (1H, m, CH(H)CH2CH2CO), 2.38-2.43 (1H, m, 
CH2CH2CH(H)CO), 2.45-2.53 (1H, m, CH2CH2CH(H)CO), 2.85 (1H, d, J 15.9, 
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C=CCH(H)), 2.94 (1H, ddd, J 15.6, 5.4, 1.8, C=CCH(H)), 3.23-3.33 (2H, m, CH2OBn), 
4.31 (1H, d, J 10.8, NCHC=C), 4.33 (1H, d, J 12, OCH(H)Ph), 4.40 (1H, d, J 12.3, 
OCH(H)Ph), 5.12 (1H, d, J 17.5, NCH(H)Ph), 5.25 (1H, d, J 17.5, NCH(H)Ph), 5.58-5.65 
(1H, m, C=CCH2CH). 6.80-6.82 (2H, m, ArH), 7.06-7.19 (11H, m, ArH), 7.47-7.51 (1H, m, 
ArH). 
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(6R,12bS)-12-Allyl-6-(allyloxymethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-
4(12H)-one (32) 
 
N
N O
H
O
 
 
(6R,12bS)-6-Hydroxymethyl-2,3,6,7,12,12b-hexahrydro-1Hindolo[2,3-a]quinolizim-4-one 
(20) (0.20 g, 0.74 mmol) and sodium hydride (60% dispersion in mineral oil, 0.13 g, 
3.26 mmol) were combined under a nitrogen atmosphere. An ice bath was placed 
underneath and anhydrous dimethylformamide (5 ml) was added. The ice bath was then 
removed and the reaction was stirred at room temperature for 30 minutes. After this time, 
allyl bromide (0.20 ml, 2.22 mmol) was added and the reaction was left stirring for 
24 hours.  
Ice water (15 ml) was added to quench the reaction, which was then washed with ethyl 
acetate (3 x 50 ml) and brine (3 x 50 ml). The organic extracts were combined and dried 
using anhydrous magnesium sulphate, which was then removed by filtration and the 
solvent removed under reduced pressure. The crude product was absorbed onto silica 
and purified using flash column chromatography over silica with 5% methanol in ethyl 
acetate as the eluent to give an orange solid (0.08 g, 31%). 
Mp: 74-76°C; [α]D = -140.00  (c = 0.016, CHCl3); νmax (cm-1) 1624 NC=O. 
δH (300 MHz; CDCl3)  1.48-1.62 (1H, m , CH(H)CH2CH2CO), 1.71-1.92 (2H, m, 
CH2CH2CO),  2.37-2.48 (1H, m, CH(H)CH2CH2CO), 2.52-2.55 (1H, m, CH(H)CO), 2.58-
2.61 (1H, m, CH(H)CO), 2.76 (1H, d, J 15.9, C=CCH(H)), 2.90 (1H, ddd, J 15.6, 5.7, 2.1, 
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C=CCH(H)), 3.21-3.37 (2H, m, CH2OAllyl), 3.81 (1H, ddt, J 12.9, 5.7, 1.2, 
NCHCH2OCH(H)), 3.92 (1H, ddt, J 12.6, 5.4, 1.2, NCHCH2OCH(H)), 4.53-4.64 (2H, m, 
NCH2), 4.81 (1H, d, J 17.1, NCHC=C), 5.00-5.09 (2H, m, CHOCH2CHCH2), 5.11-5.14 (2H, 
m, NCH2CHCH2), 5.57 (1H, dt, J 6, 6, NCHCH2OAllyl), 5.67-5.80 (1H, m, CHOCH2CH) 
5.82-5.94 (1H, m, NCH2CH), 7.03-7.19 (3H, m ArH), 7.45 (1H, d, J 7.8, ArH). 
 δC (300 MHz; CDCl3)  19.45 (CH2), 21.89 (CH2), 30.52 (CH2), 32.07 (CH2), 45.73 (CH) 
46.51 (CH2), 51.31 (CH), 68.49 (CH2), 71.62 (CH2), 107.39 (C), 109.76 (CH), 116.86 
(CH2), 116.95 (CH2), 118.48 (CH), 119.66 (CH), 122.01 (CH), 126.94 (C), 133.05 (CH), 
133.20 (C), 134.74 (CH), 137.97 (C), 170.45 (NC=O). 
MS (CI) m/z 351 [MH+, 100%]; (Found: MH+, 351.2062. C22H27N2O2 requires 351.2067). 
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(6R,12bS)-6-(Methoxymethyl)-12-methyl-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-
4(12H)-one (33) 
 
N
N O
H
O
 
 
(6R,12bS)-6-Hydroxymethyl-2,3,6,7,12,12b-hexahrydro-1Hindolo[2,3-a]quinolizim-4-one 
(20) (0.2 g, 0.74 mmol) and sodium hydride (60% dispersion in mineral oil, 0.13 g, 
3.26 mmol) were combined under a nitrogen atmosphere and cooled to 0°C using and ice 
bath. Anhydrous dimethylformamide (5 ml) was added and the ice bath removed. The 
reaction was left stirring at room temperature for 30 minutes. After this time methyl iodide 
(0.14 ml, 2.22 mmol) was added and the reaction was left to stir for a further 24 hours.  
The reaction was quenched with the addition of ice water (15 ml) and washed with ethyl 
acetate (3 x 50 ml) and then brine (3 x 50 ml). The organic extracts were combined and 
dried over anhydrous magnesium sulphate, which was then removed by filtration and the 
solvent removed under reduced pressure. The crude product was absorbed onto silica 
and purified by flash chromatography over silica using 5% methanol in ethyl acetate as 
the eluent. This gave a bronze solid (0.17 g, 77%). 
Mp:  156-157 °C; [α]D = -230.77  (c = 4.42 x 10-3, CHCl3); νmax (cm-1) 1624 NC=O. 
δH (300 MHz; CDCl3)  1.49-1.63 (1H, m , CH(H)CH2CH2CO), 1.75-1.92 (2H, m, 
CH2CH2CO),  2.36-2.46 (2H, m, CH2CO), 2.48-2.63 (1H, m, CH(H)CH2CH2CO), 2.70 (1H, 
d, J 15.6, C=CCH(H)), 2.88 (1H, ddd, J 15.6, 5.4, 1.8, C=CCH(H)), 3.13-3.19 (1H, m, 
CH(H)OCH3), 3.21 (3H, s, OCH3), 3.29-3.35 (1H, m, CH(H)OCH3), 3.63 (3H, s, NCH3), 
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4.62 (1H, d, J 11.1, NCHC=C), 5.57 (1H, dt, J 6.9, 6, NCHCH2OCH3),  7.04 (1H, t, J  7.5, 
ArH), 7.12-7.22 (2H, m, ArH), 7.42 (1H, d, J 7.8, ArH).  
δC(300 MHz; CDCl3)  18.35 (CH2), 20.76 (CH2), 29.11 (CH2), 30.24 (CH3), 31.02 (CH2), 
44.65 (CH), 50.18 (CH), 57.74 (CH3), 70.09 (CH2), 105.62 (C), 107.92 (CH), 117.36 (CH), 
118.34 (CH), 120.81 (CH), 125.52 (C), 132.18 (C), 137.13 (C), 169.40 (NC=O). 
MS (CI) m/z 299 [MH+, 100%]; (Found: MH+, 299.1750. C18H23N2O2 requires 299.1754). 
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(6R,12bS)-12-Benzyl-6-(propoxymethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-
4(12H)-one (36) 
N
N O
O
H
 
 
Sodium hydride (60% dispersion in mineral oil, 0.05 g, 1.31 mmol) was added to 
(6R,12bS)-12-benzyl-6-(hydroxymethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-
4(12H)-one (27) (0.23 g, 0.60 mmol) under a nitrogen atmosphere. This was cooled to 
0 °C using an ice bath and anhydrous dimethylformamide (10 ml) was added. The 
reaction was stirred at room temperature for half an hour. After this time, propyl bromide 
(0.12 ml, 1.20 mmol) was added and the reaction was left stirring overnight. 
Ice cold water (20 ml) was added to quench the reaction which was then extracted into 
ethyl acetate (3 x 50 ml). The organic extracts were combined and washed with brine 
(3 x 50 ml). These were then dried over anhydrous magnesium sulphate, which was then 
removed by filtration and the solvent removed under reduced pressure. The crude product 
was absorbed onto silica and purified using flash column chromatography over silica with 
5% methanol in ethyl acetate as the eluent. This gave a yellow solid (0.12 g, 50%). 
Mp: 153-155 °C; [α]D = -127.36 (c = 0.00212 CHCl3); νmax (cm-1) 1634 NC=O. 
δH (300 MHz; CDCl3) 1.15-1.80 (1H, m, CH(H)CH2CH2CO), 1.15-1.80 (2H, m, 
CH2CH2CO), 1.15-1.80 (2H, m, OCH2CH2CH3), 1.15-1.80 (3H, m, OCH2CH2CH3), 2.28-
2.42 (1H, m, CH(H)CH2CH2CO), 2.28-2.42  (1H, m, CH(H)CO), 2.44-2.53  (1H, m, 
CH(H)CO), 2.78 (1H, d J 15.9, C=CCH(H)), 2.91  (1H, ddd, J 15.6, 5.4, 1.8, C=CCH(H)), 
3.13-3.18 (1H, m, CH(H)OC3H7) 3.13-3.18 (1H, m, OCH(H)CH2CH3), 3.23-3.31 (1H, m, 
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CH(H)OC3H7), 3.23-3.31 (1H, m, OCH(H)CH2CH3),  4.42 (1H, d, J 9.6, NCHC=C), 5.17 
(1H, d, J 17.5, NCH(H)Ph), 5.33 (1H, d, J 17.5, NCH(H)Ph), 5.55 (1H, dt, J 7.5, 6, 
NCHCH2OC3H7), 6.85-6.88 (2H, m, ArH), 7.03-7.08 (3H, m, ArH), 7.17-7.24 (3H, m, ArH), 
7.46-7.49 (1H, m, ArH). 
δC (300 MHz;  CDCl3) 10.58 (CH3), 19.40 (CH2), 21.88 (CH2), 22.87 (CH2), 30.37 (CH2), 
32.05 (CH2), 45.77 (CH), 47.81 (CH2), 51.39 (CH), 68.98 (CH2), 72.52 (CH2), 108.01 (C), 
109.78 (CH), 118.55 (CH), 119.81 (CH), 122.21 (CH), 125.79 (2xCH), 127.05 (C), 127.60 
(CH), 128.94 (2xCH), 133.49 (C), 137.33 (C), 138.39 (C), 170.34 (C). 
MS (CI) m/z 403 [MH+, 100%]; (Found: MH+, 403.2375. C26H31N2O2 requires 403.2380). 
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(6R,12bS)-12-Benzyl-6-((cyclohexylmethoxy)methyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-
a]quinolizin-4(12H)-one (37) 
 
N
N O
O
H
 
 
Sodium hydride (60% dispersion in mineral oil, 0.034 g, 0.853 mmol) was added to 
(6R,12bS)-12-benzyl-6-(hydroxymethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-
4(12H)-one (27) (0.14 g, 0.388 mmol) under a nitrogen atmosphere. This was cooled to 
0 °C using an ice bath and anhydrous dimethylformamide (10 ml) was added. The 
reaction was stirred at room temperature for half an hour. After this time, 
(bromomethyl)cyclohexane (0.108 ml, 0.775 mmol) and sodium iodide (0.12 g, 
0.775 mmol) were added and the reaction was heated to 60 °C and left overnight. 
Ice cold water (20 ml) was added to quench the reaction which was then extracted into 
ethyl acetate (3 x 50 ml). The organic extracts were combined and washed with brine 
(3 x 50 ml). These were then dried over anhydrous magnesium sulphate, which was then 
removed by filtration and the solvent removed under reduced pressure. The crude product 
was absorbed onto silica and purified using flash column chromatography over silica with 
5% methanol in ethyl acetate as the eluent. This gave a yellow oil (0.11 g, 31%). 
[α]D = -34.55 (c = 0.011 CHCl3); νmax (cm-1) 1633 NC=O. 
δH (300 MHz; CDCl3) 1.05-1.82 (1H, m, CH(H)CH2CH2CO), 1.05-1.82 (2H, m, 
CH2CH2CO), 1.05-1.82 (11H, m, OCH2C6H11), 2.29-2.37 (1H, m CH(H)CH2CH2CO), 2.39-
2.48 (1H, m, CH(H)CO), 2.51-2.53 (1H, m, CH(H)CO), 2.77 (1H, d J 15.9, C=CCH(H)), 
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2.89 (1H, dd, J 5.7, 2.1, OCH(H)C6H11), 2.93-2.98 (1H, m, C=CCH(H)), 3.10-3.15 (1H, m, 
CH(H)OCH2C6H11), 3.10-3.15 (1 H, m, OCH(H)C6H11), 3.22 (1H, dd, J 7.5, 2.4, 
CH(H)OCH2C6H11), 4.41 (1H, d, J 10.2, NCHC=C), 5.18 (1H, d, J 17.5, NCH(H)Ph), 5.34 
(1H, d, J 17.5, NCH(H)Ph), 5.55 (1H, dt, J 7.2, 6.3 NCHCH2OCH2C6H11), 6.87-6.92 (2H, 
m, ArH), 7.04-7.09 (3H, m, ArH), 7.19-7.24 (3H, m, ArH), 7.46-7.49 (1H, m, ArH). 
δC (300 MHz;  CDCl3) 19.40 (CH2), 21.84 (CH2), 25.84 (CH2), 25.87 (CH2), 26.60 (CH2), 
29.88 (CH2), 29.92 (CH2), 30.32 (CH2), 32.04 (CH2), 37.99 (CH), 45.70 (CH), 47.81 (CH2), 
51.42 (CH), 69.17 (CH2), 76.69 (CH2), 108.05 (C), 109.73 (CH), 118.53 (CH), 119.79 
(CH), 122.18 (CH), 125.79 (2xCH), 127.03 (C), 127.61 (CH), 128.94 (2xCH), 133.49 (C), 
137.33 (C), 138.36 (C), 170.32 (NC=O). 
MS (CI) m/z 457 [MH+, 100%]; (Found: MH+, 457.2843. C30H37N2O2 requires 457.1754). 
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(6R,12bS)-6-(Allyloxymethyl)-12-(cyclohexylmethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-
a]quinolizin-4(12H)-one (39) 
N
N O
O
H
 
Sodium hydride (60% dispersion in mineral oil, 0.04 g, 1.11 mmol) was added to 
(6R,12bS)-6-Hydroxymethyl-2,3,6,7,12,12b-hexahrydro-1Hindolo[2,3-a]quinolizim-4-one 
(20) (0.25 g, 0.925 mmol) under a nitrogen atmosphere. This was cooled to 0 °C using an 
ice bath and anhydrous dimethylformamide (10 ml) was added. The reaction was stirred 
at room temperature for half an hour. After this time, (bromomethyl)cyclohexane (0.16 ml, 
1.11 mmol) and sodium iodide (0.17 g, 1.11 mmol) were added and the reaction was 
heated to 60 °C and left overnight. 
Ice cold water (20 ml) was added to quench the reaction which was then extracted into 
ethyl acetate (3 x 50 ml). The organic extracts were combined and washed with brine 
(3 x 50 ml). These were then dried over anhydrous magnesium sulphate, which was then 
removed by filtration and the solvent removed under reduced pressure. The crude product 
was absorbed onto silica and purified using flash column chromatography over silica with 
5% methanol in ethyl acetate as the eluent. This gave a white foam (38) (0.14 g, 41%). 
Sodium hydride (60% dispersion in mineral oil 0.034 g, 0.842 mmol) was added to the 
product (38) (0.14 g, 0.383 mmol) under a nitrogen atmosphere. This was cooled to 0 °C 
using an ice bath and dry dimethylformamide (10 ml) was added. The reaction was stirred 
at room temperature for half an hour. After this time allyl bromide (0.07 ml, 0.765 mmol) 
was added and the reaction was left overnight. 
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Ice cold water (20 ml) was used to quench the reaction which was then extracted into 
ethyl acetate (3 x 50 ml). The organic extracts were combined and washed with brine 
(3 x 50 ml). These were then dried over anhydrous magnesium sulphate, which was then 
removed by filtration and the solvent removed under reduced pressure. The crude product 
was absorbed onto silica and purified using flash column chromatography over silica with 
5% methanol in ethyl acetate as the eluent. This gave a yellow solid (0.07 g, 45%). 
Mp:  130-133 °C; [α]D = -  70.80 (c =  0.00226); νmax (cm-1) 1636 NC=O. 
δH (300 MHz; CDCl3) 0.77-1.99 (1H, m, CH(H)CH2CH2CO), 0.77-1.99 (2H, m, 
CH2CH2CO), 0.77-1.99 (11H, m, NCH2C6H11), 2.38-2.50 (1H, m, CH(H)CH2CH2CO), 2.38-
2.50 (1H, m, CH(H)CO), 2.53-2.63 (1H, m, CH(H)CO), 2.77 (1H, d J 15.9, C=CCH(H)), 
2.84-2.91 (1H, m, C=CCH(H)), 3.42 (2H, si, J 9.9, CH2OAllyl),  3.65 (1H, q, J 8.7, 
NCH(H)C6H11), 3.78-3.92 (2H, m , OCH2CH=CH2), 4.06 (1H, dd, J 14.4,  5.7, 
NCH(H)C6H11), 4.64 (1H, d, J 10.8, NCHC=C), 4.99-5.13 (2H, m, OCH2CH=CH2),  5.54 
(1H, dt, J 6.6, 6.6, NCHCH2OAllyl),  5.67-5.78 (1H, m, NCHCH2OCH2CH), 7.04 (1H, t, J 
6.9, ArH), 7.13 (1H, t, ArH), 7.21 (1H, t, J 6.9, ArH), 7.43 (1H, d, J 7.8, ArH) 
δC (300 MHz; CDCl3) 19.36 (CH2), 21.98 (CH2), 25.64 (CH2), 25.79 (CH2), 26.22 (CH2), 
30.41 (CH2), 31.04 (2xCH2), 31.93 (CH2), 38.14 (CH), 45.89 (CH), 50.82 (CH2), 51.49 
(CH), 68.67 (CH2) 71.78 (CH2), 107.01 (C), 110.20 (CH), 116.96 (CH2), 118.44 (CH), 
119.29 (CH), 121.60 (CH), 126.91 (C), 133.48 (C), 134.75 (CH), 137.72 (C), 170.60 
(NC=O). 
MS (CI) m/z 407 [MH+, 100%]; (Found: MH+, 407.2694. C26H35N2O2 requires 407.2693). 
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(6R,12bS)-6-(Allyloxymethyl)-12-(cyclobutylmethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-
a]quinolizin-4(12H)-one (41) 
 
N
N O
O
H
 
 
Sodium hydride (60% dispersion in mineral oil, 0.04 g, 1.11 mmol) was added to 
(6R,12bS)-6-Hydroxymethyl-2,3,6,7,12,12b-hexahrydro-1Hindolo[2,3-a]quinolizim-4-one 
(20) (0.25 g, 0.925 mmol) under a nitrogen atmosphere. This was cooled to 0 °C using an 
ice bath and anhydrous dimethylformamide (10 ml) was added. The reaction was stirred 
at room temperature for half an hour. After this time, (bromomethyl)cyclobutane (0.13 ml, 
1.11 mmol) and sodium iodide (0.17 g, 1.11 mmol) were added and the reaction was 
heated to 60 °C and left overnight. 
Ice cold water (20 ml) was used to quench the reaction which was then extracted into 
ethyl acetate (3 x 50 ml). The organic extracts were combined and washed with brine 
(3 x 50 ml). These were then dried over anhydrous magnesium sulphate, filtered and the 
solvent removed under reduced pressure. The crude product was absorbed onto silica 
and purified using flash column chromatography over silica with 5% methanol in ethyl 
acetate as the eluent. This gave a solid (40) (0.21 g, 67%). 
Sodium hydride (60 % dispersion in mineral oil, 0.055g, 1.37 mmol) was added to the 
product (40) (0.21 g, 0.621 mmol) under a nitrogen atmosphere. This was cooled to 0 °C 
using an ice bath and anhydrous dimethylformamide (10 ml) was added. The reaction was 
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stirred at room temperature for half an hour. After this time allyl bromide (0.11 ml, 
1.24 mmol) and the reaction was left overnight. 
Ice cold water (20 ml) was used to quench the reaction which was then extracted into 
ethyl acetate (3 x 50 ml). The organic extracts were combined and washed with brine 
(3 x 50 ml). These were then dried over anhydrous magnesium sulphate, this was then 
removed by filtration and the solvent was removed under reduced pressure. The crude 
product was absorbed onto silica and purified using flash column chromatography over 
silica with 5% methanol in ethyl acetate as the eluent. This gave a yellow oil (0.15 g, 
46%). 
[α]D = - 62.86 (c = 0.007); νmax (cm-1) 1636 NC=O. 
δH (300 MHz; CDCl3) 1.48-1.95 (1H, m, CH(H)CH2CH2CO), 1.48-1.95 (2H, m, 
CH2CH2CO), 1.48-1.95 (6H, m, NCH2CHC3H6), 2.39-2.50 (1H, m, CH(H)CH2CH2CO), 
2.39-2.50 (1H, m, CH(H)CO), 2.54-2.69 (1H, m, CH(H)CO), 2.54-2.69 (1H, m, 
NCH2CHC3H6), 2.75 (1H, d J 15.9, C=CCH(H)), 2.87 (1H, ddd, J 15.9, 5.7, 1.8, 
C=CCH(H)), 3.27 (2H, m, J 7.2, CH2OAllyl), 3.78-3.95 (2H, m, OCH2CH=CH2), 3.78-3.95 
(1H, m, NCH(H)C4H7), 4.18 (1H, dd, J 14.7, 6, (NCH(H)C4H7), 4.67 (1H, d, J 11.1, 
NCHC=C), 5.07 (2H, m, OCH2CH=CH2), 5.55 (1H, dt, J 6.6, 6.6, NCHCH2OAllyl), 5.67-
5.80 (1H, m, NCHCH2OCH2CH), 7.01-7.06 (1H, m, ArH), 7.13 (1H, td, J 15.3, 8.1, 1.2, 
ArH), 7.25 (1H, d, J 8.1, ArH), 7.42 (1H, d, J 7.5, ArH). 
δC (300 MHz; CDCl3) 18.32 (CH2), 19.39 (CH2), 21.97 (CH2), 26.42 (CH2), 27.46 (CH2). 
30.47 (CH2), 31.96 (CH2), 36.12 (CH), 45.80 (CH), 49.66 (CH2), 51.45 (CH), 68.54 (CH2), 
71.66 (CH2), 107.31 (C), 109.97 (CH), 116.96 (CH2), 118.41 (CH), 119.33 (CH), 121.66 
(CH), 126.97 (C), 133.03 (C), 134.75 (CH), 137.84 (C), 170.56 (NC=O). 
MS (CI) m/z 379 [MH+, 100%]; (Found: MH+, 379.2383. C24H31N2O2 requires 379.2380). 
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(6R,12bS)-12-Benzyl-6-(benzyloxymethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-
4(12H)-one (45) 13 
N
N O
O
H
 
Diisopropylamine (0.67 ml, 4.79 mmol) was added to dry tetrahydrofuran (5 ml) under a 
nitrogen atmosphere at 0 °C. n-Butyllithium (2.5 M in hexanes, 1.92 ml, 4.79 mmol) was 
added and the reaction stirred for 15 minutes. This was then cooled to -78 °C. (6R,12bS)-
12-benzyl-6-(benzyloxymethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-4(12H)-one 
(31) (1.9 g, 1.60 mmol) in dry tetrahydrofuran (15 ml) was added via cannula. The reaction 
was stirred at -78 °C for one hour. Following this, phenyl selenium bromide (0.57 g, 
2.40 mmol) in dry tetrahydrofuran (10ml) was added via cannula and the reaction was left 
stirring for 24 hours. 
The reaction was quenched with saturated ammonium chloride solution (40 ml) and 
extracted into diethyl ether (3 x 75 ml). The organic extracts were combined and washed 
with saturated ammonium chloride solution (100 ml), dried over anhydrous magnesium 
sulphate, which was removed by filtration and the solvents were removed under reduced 
pressure. This produced a brown oil, which was used with no further purification. 
The crude selenide (1.12 g, 1.85 mmol) was dissolved in methanol (220 ml) and water 
(45 ml). Sodium metaperiodate (0.91 g, 4.25 mmol) and sodium bicarbonate (0.19 g, 
2.22 mmol) were added and the reaction was heated at 60 °C for 24 hours. 
The reaction was quenched with saturated sodium bicarbonate solution (100 ml) and 
diethyl ether (150 ml). The organic layer was washed with water (100 ml) followed by 
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brine (100 ml), dried over anhydrous magnesium sulphate which was removed by filtration 
and the solvents were removed under reduced pressure. 
The crude product was absorbed onto silica and purified by flash column chromatography 
over silica using ethyl acetate as the eluent to give a pale yellow solid (0.33 g, 40%).  
Mp: 60-61 °C; [α]D = -254.77 (c = 0.00577 CHCl3) νmax (cm-1) 1662 NC=O. 
δH (300 MHz; CDCl3) 2.13-2.24 (1H, m, CH(H)CH2CH2CO), 2.49 (1H, dq, J 17.4, 6.3, 3.9, 
CH(H)CH2CH2CO), 2.95 (1H, ddd, J 15.6, 5.4, 1.8, C=CCH(H)), 3.08 (1H, d, J 15.9, 
C=CCH(H)), 3.22-3.32 (2H, m, CH2OBn), 4.38 (2H, s, OCH2Ph), 4.52-4.57 (1H, m, 
NCHC=C), 5.11 (1H, d, J 17.5, CH(H)Ph), 5.20 (1H, d, J 17.5, CH(H)Ph), 5.34-5.40 (1H, 
m, NCHCH2OBn), 5.99 (1H, dd, J 9.6, 2.7, CH2CHCHCO), 6.41-6.48 (1H, m, 
CH2CHCHCO), 6.76-6.79 (2H, m, ArH), 7.06-7.17 (11H, m, ArH), 7.51-7.56 (1H, m, ArH). 
δC (300 MHz;  CDCl3) 22.00 (CH2), 32.03 (CH2), 46.07 (CH), 47.31 (CH2), 49.84 (CH), 
68.10 (CH2), 72.60 (CH2), 107.70 (C), 109.85 (CH), 118.73 (CH), 119.96 (CH), 122.34 
(CH), 125.61 (2xCH), 126.01 (CH), 127.03 (C), 127.37 ( 3xCH), 127.60 (CH), 128.25 
(2xCH), 128.96 (2xCH), 132.62 (C), 137.07 (C), 138.19 (C), 138.26 (CH), 138.30 (C), 
164.92 (NC=O). 
MS (CI) m/z 449 [MH+, 100%]; (Found: MH+, 449.2222. C30H29N2O2 requires 449.2224). 
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(2R,6R,12bS)-12-Benzyl-6-(benzyloxymethyl)-2-vinyl-1,2,3,6,7,12b-hexahydroindolo[2,3-
a]quinolizin-4(12H)-one (47) 13 
N
N O
O
H
 
 
A 0.7 M solution of vinyl magnesium bromide in tetrahydrofuran (10.6 ml, 7.43 mmol) was 
added to a suspension of copper cyanide (0.34 g, 3.75 mmol) in anhydrous 
tetrahydrofuran (20 ml) at -78 °C while stirring. The reaction was warmed to 0 °C for 
3 minutes then re-cooled to -78 °C. (6R,12bS)-12-benzyl-6-(benzyloxymethyl)-1,6,7,12b-
tetrahydroindolo[2,3-a]quinolizin-4(12H)-one (45) (0.33 g, 0.736 mmol) in anhydrous 
tetrahydrofuran (15 ml) was added via cannula at -78 °C. After 5 minutes, 
chlorotrimethylsilane (0.48 ml, 3.75 mmol) was added and the reaction was left to warm 
slowly to room temperature overnight.  
The reaction as quenched with the addition of saturated ammonium chloride solution 
(20 ml) and water (20 ml) and left stirring for 20 minutes. A 1.0 M solution of 
tetrabutylammonium fluoride in tetrahydrofuran (6 ml) was added and the stirring 
continued for 15 minutes. The reaction was extracted into ethyl acetate (3 x 50 ml) and 
the combined organic extracts were dried over anhydrous magnesium sulphate. This was 
then filtered out and the solvents removed under reduced pressure.  
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The crude product was absorbed onto silica and purified by flash column chromatography 
over silica with 1:1 ethyl acetate: petroleum ether as the eluent. This gave a pale yellow 
solid (0.17 g, 49%). 
Mp: 133-136 °C; [α]D = -52.81 (c = 0.00303 CHCl3); νmax (cm-1) 1636 NC=O. 
δH (300 MHz; CDCl3) 1.74-1.84 (1H, m, CH(H)CHCH2CO), 2.08-2.18 (1H, m, 
CH(H)CHCH2CO), 2.40-2.57 (2H, m, CH2CHCH2CO), 2.40-2.57 (1H, m, CH2CHCH2CO), 
2.83 (1H, d, J 15.9, C=CCH(H)),  2.94 (1H, ddd, J 15.6, 5.4, 1.8, C=CCH(H)), 3.24 (2H, d, 
J 7.5, CH2OBn), 4.33 (2H, s, OCH2Ph), 4.39-4.44 (1H, m, NCHC=C), 4.84-4.95 (2H, m, 
CHCH=CH2), 5.10 (1H, d, J 17.5, NCH(H)Ph), 5.24 (1H, d, J 17.5, CH(H)Ph), 5.53-5.59 
(1H, m, NCHCH2OBn), 5.60-5.72 (1H, m, CHCH=CH2), 6.79-6.82 (2H, m, ArH), 7.05-7.17 
(11H, m, ArH), 7.47-7.50(1H, m, ArH). 
δC (300 MHz;  CDCl3) 20.90 (CH2), 31.63 (CH), 33.83 (CH2), 35.10 (CH2), 45.06 (CH), 
46.40 (CH), 46.71 (CH2), 67.22 (CH2), 71.54 (CH2), 107.16 (C), 108.64 (CH), 114.61 
(CH2), 117.38 (CH), 118.81 (CH), 121.16 (CH), 124.75 (2xCH), 125.97 (C), 126.39 (CH), 
126.42 (2xCH), 126.57 (CH), 127.17 (2xCH), 127.88 (2xCH), 132.26 (C), 136.16 (C), 
137.13 (C), 137.36 (C), 138.10 (CH), 169.06 (NC=O).  
MS (CI) m/z 477 [MH+, 100%]; (Found: MH+, 477.2530. C32H33N2O2 requires 477.2537). 
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(6R,12bS)-6-(Allyloxymethyl)-12-benzyl-1,6,7,12b-tetrahydroindolo[2,3-a]quinolizin-
4(12H)-one (44) 
N
N O
O
H
 
 
Diisopropylamine (0.14 ml, 0.999 mmol) was added to anhydrous tetrahydrofuran (5 ml) 
under a nitrogen atmosphere at 0 °C. n-Butyllithium (2.5 M in hexanes, 0.4 ml, 0.999 
mmol) was added and the reaction stirred for 15 minutes. This was then cooled to -78 °C. 
(6R,12bS)-6-(allyloxymethyl)-12-benzyl-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-
4(12H)-one (30) (0.4 g, 0.999mmol) in anhydrous tetrahydrofuran (10 ml) was added via 
cannula. The reaction was stirred at -78 °C for one hour. Following this, phenyl selenium 
bromide (0.26 g, 1.099 mmol) in anhydrous tetrahydrofuran (10ml) was added via cannula 
and the reaction was left stirring for 24 hours. 
The reaction was quenched with saturated ammonium chloride solution and extracted into 
diethyl ether (3 x 20 ml). The organic extracts were combined and washed with saturated 
ammonium chloride solution (100 ml), dried over anhydrous magnesium sulphate, which 
was then removed by filtration and the solvents removed under reduced pressure. This 
produced a brown oil, which was used with no purification. 
The crude selenide (0.54 g, 0.972 mmol) was dissolved in methanol (55 ml) and water 
(11 ml). Sodium metaperiodate (0.48 g, 2.24 mmol) and sodium bicarbonate (0.098 g, 
1.17 mmol) were added and the reaction was heated at 60 °C for 24 hours. 
The reaction was quenched with saturated sodium bicarbonate solution (50 ml) and 
diethyl ether (75 ml). The organic layer was washed with water (50 ml) followed by brine 
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(50 ml), dried over anhydrous magnesium sulphate which was then removed by filtration 
and the solvents removed under reduced pressure. The crude product was absorbed onto 
silica and purified by flash column chromatography on silica using ethyl acetate as the 
eluent to give a yellow oil (0.10 g, 25%). 
[α]D = - 129.00  (c = 0.01); νmax (cm-1) 1663 NC=O. 
δH (300 MHz; CDCl3) 2.13-2.26 (1H, m, CH(H)CH2CH2CO), 2.54 (1H, dq, J 17.7, 6.6, 3.9, 
CH(H)CH2CH2CO), 2.94 (1H, ddd, J 15.6, 5.1, 1.8, C=CCH(H)), 3.03 (1H, d J 15.9, 
C=CCH(H)), 3.19-3.31 (2H, m, CH2OAllyl), 3.81-3.85 (2H, m , OCH2CH=CH2), 4.63-4.69 
(1H, m, NCHC=C), 4.98-5.12 (2H, m, OCH2CH=CH2), 5.16-5.23 (2H, m, NCH2Ph), 5.28-
5.35 (1H, m, NCHCH2OAllyl), 5.65-5.78 (1H, m, NCHCH2OCH2CH), 6.00 (1H, dd, J 9.9, 3, 
CH2CH=CHCO), 6.45-6.51 (1H, m, CH2CH=CHCO), 6.84-6.89 (2H, m, ArH), 7.05-7.14 
(3H, m, ArH), 7.19-7.25 (3H, m, ArH), 7.51-7.54 (1H, m, ArH). 
δC (300 MHz; CDCl3) 21.88 (CH2), 32.07 (CH2), 45.99 (CH), 47.38 (CH2), 49.83 (CH), 
68.25 (CH2), 71.79 (CH2), 107.77 (CH), 109.87 (C), 116.76 (CH2), 118.78 (CH), 119.91 
(CH), 122.36 (CH), 125.65 (2xCH), 126.04 (CH), 127.03 (C), 127.65 (CH), 128.99 (2xCH), 
132.59 (C), 134.73 (CH), 137.12 (C), 138.19 (CH), 164.90 (NC=O).  
MS (CI) m/z 399 [MH+, 100%]; (Found: MH+, 399.2057 C26H27N2O2 requires 399.2067). 
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(2R,6R,12bS)-6-(Allyloxymethyl)-12-benzyl-2-vinyl-1,2,3,6,7,12b-hexahydroindolo[2,3-
a]quinolizin-4(12H)-one (46) 
 
N
N O
O
H
 
 
A 0.7 M solution of vinyl magnesium bromide in tetrahydrofuran (3.6 ml, 2.53 mmol) was 
added to a suspension of copper cyanide (0.12 g, 1.28 mmol) in anhydrous 
tetrahydrofuran (10 ml) at -78 °C while stirring. The reaction was warmed to 0 °C for 
3 minutes then re-cooled to -78 °C. (6R,12bS)-6-(allyloxymethyl)-12-benzyl-1,6,7,12b-
tetrahydroindolo[2,3-a]quinolizin-4(12H)-one (44) (0.10 g, 0.251 mmol) in anhydrous 
tetrahydrofuran (5 ml) was added via cannula at -78 °C. After 5 minutes trimethylsily 
chloride (0.16 ml, 1.28 mmol) was added and the reaction was left to warm slowly to room 
temperature overnight. 
The reaction was quenched with the addition of saturated ammonium chloride solution 
(10 ml) and water (10 ml) and then left stirring for 20 minutes.  A 1.0 M solution of 
tetrabutylammonium fluoride in tetrahydrofuran (6 ml) was added and the stirring 
continued for a further 15 minutes. The reaction was extracted into ethyl acetate 
(3 x 50 ml) and the combined organic extracts were dried over anhydrous magnesium 
sulphate. This was then filtered out and the solvents removed under reduced pressure. 
The crude product was absorbed onto silica and purified by flash column chromatography 
over silica with ethyl acetate as the eluent. This gave a brown oil (0.04 g, 37%). 
[α]D = -29.41 (c =0.00068 CHCl3); νmax (cm-1) 1633 NC=O. 
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δH (300 MHz; CDCl3) 1.76-1.86 (1H, m, CHCH(H)CHCH2CO), 2.15-2.20 (1H, m, 
CHCH(H)CHCH2CO), 2.48-2.61 (2H, m, CHCH2CO), 2.48-2.61 (1H, m, CHCH2CO), 2.78 
(1H, d, J 15.9, C=CCH(H)), 2.95 (1H, ddd, J 13.8, 3.9, 1.8, C=CCH(H)), 3.17-3.23 (2H, m, 
CH2OAllyl), 3.79 (2H, m, OCH2CH=CH2), 4.49 (1H, d, J 8.7, NCHC=C), 4.94-5.11 (2H, m, 
OCH2CH=CH2), 4.94-5.11 (2H, m, CHCH2CHCH=CH2), 5.16 (1H, d, J 17.5, NCH(H)Ph), 
5.31 (1H, d, J 17.5, NCH(H)Ph), 5.52 (1H, dt, J 6.9, 6.3, NCHCH2OAllyl), 5.64-5.77 (1H, 
m, NCHCH2OCH2CH=CH2), 5.64-5.77 (1H, m, CHCH2CHCH=CH2), 6.87-6.90 (2H, m, 
ArH), 7.05-7.11 (3H, m, ArH), 7.20-7.23 (3H, m, ArH), 7.46-7.50 (1H, m, ArH). 
δC (300 MHz; CDCl3) 20.88 (CH2), 31.61 (CH), 33.66 (CH2), 35.02 (CH2), 44.97 (CH), 
46.33 (CH), 46.82 (CH2), 67.33 (CH2), 70.67 (CH2), 107.26 (C), 108.67 (CH), 114.72 
(CH2), 115.78 (CH2), 117.38 (CH), 118.77 (CH), 121.18 (CH), 124.79 (2xCH), 125.95 (C), 
126.60 (CH), 127.91 (2xCH), 132.28 (C), 133.60 (CH), 136.20 (C), 137.37 (C), 137.98 
(CH).  
MS (CI) m/z 427 [MH+, 100%]; (Found: MH+, 427.2379. C28H31N2O2 requires 427.2380). 
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(6R,12bS)-6-(Hydroxymethyl)-12-(pyridin-4-ylmethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-
a]quinolizin-4(12H)-one (53) 
 
N
N
OH
O
N
H
 
 
(6R,12bS)-6-Hydroxymethyl-2,3,6,7,12,12b-hexahrydro-1Hindolo[2,3-a]quinolizim-4-one 
(20) (0.20 g, 0.740 mmol) was dissolved in anhydrous dimethyl sulfoxide under a nitrogen 
atmosphere. 4-(Bromomethyl)-pyridine hydrobromide (0.28 g, 1.11 mmol) was added and 
the reaction cooled to 0 °C before addition of potassium tert-butoxide (0.12 g, 1.11 mmol). 
The reaction then left to warm slowly overnight. 
After this time the reaction was quenched with water (10 ml), extracted with ethyl acetate 
(3 x 20 ml) and washed with brine (3 x 50 ml). It was then dried over anhydrous 
magnesium sulphate, which was then removed by filtration and the solvent removed 
under pressure. The crude product was absorbed onto silica and purified by flash column 
chromatography over silica using 5% methanol in ethyl acetate as the eluent. This yielded 
a white solid (0.06 g, 22%). 
Mp: 227-229 °C; [α]D = -67.80 (c = 0.00059 CHCl3); νmax (cm-1) 1591 NC=O, 3290 OH. 
δH (300 MHz; CDCl3) 1.52-1.66 (1H, m, CH(H)CH2CH2CO), 1.72-1.81 (2H, m, 
CH2CH2CO), 2.26-2.31 (1H, m, CH(H)CH2CH2CO), 2.35-2.54 (2H, m, CH2CH2CO), 2.79 
(1H, d, J 15.9, C=CCH(H)), 2.96 (1H, ddd, J 15.9, 5.7, 1.8, C=CCH(H)), 3.41 (1H, t, J 
10.5, CHCH(H)OH), 3.52-3.60 (1H, m, CHCH(H)OH), 4.54 (1H, d, J 11.1, CHC=C), 5.19 
(1H, d, J 17.5, NCH(H)Pyr), 5.31 (1H, d, J 17.5, NCH(H)Pyr), 5.39-5.49 (1H, m, 
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CHCH2OH), 6.87-6.90 (12H, m, ArH), 7.06-7.12 (3H, m ArH), 7.16-7.26 (2H, m, ArH), 
7.46-7.49 (1H, m, ArH).  
No further data was obtained due to this being an intermediate compound. 
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(6R,12bS)-6-(Allyloxymethyl)-12-(pyridin-4-ylmethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-
a]quinolizin-4(12H)-one (54) 
N
N
O
O
N
H
 
 
Sodium hydride (60% dispersion in mineral oil, 0.013 g, 0.33 mmol) and (6R,12bS)-6-
(hydroxymethyl)-12-(pyridin-4-ylmethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-
4(12H)-one (53) (0.06 g, 0.17 mmol) were combined under a nitrogen atmosphere. An ice 
bath was placed underneath the flask and anhydrous dimethylformamide (5 ml) was 
added. The ice bath was removed and the reaction stirred at room temperature for 
30 minutes. After this time allyl bromide (0.03 ml, 0.33 mmol) was added and the reaction 
was left for 24 hours.  
The reaction was quenched with the addition of ice water (10 ml) and washed with ethyl 
acetate (3 x 50 ml) and brine (3 x 50 ml). The organic extracts were combined and dried 
using anhydrous magnesium sulphate. This was then removed by filtration and the solvent 
removed under reduced pressure. The crude product was absorbed onto silica and 
purified by flash column chromatography over silica using 5% methanol in ethyl acetate as 
the eluent. This produced a white oil (0.06 g, 90%). 
[α]D = -118.88 (c = 0.00077 CHCl3); νmax (cm-1) 1633 NC=O. 
δH (300 MHz; CDCl3) 1.45-1.58 (1H, m, CH(H)CH2CH2CO), 1.64-1.76 (2H, m, 
CH2CH2CO), 2.29-2.53 (1H, m, CH(H)CH2CH2CO), 2.29-2.53 (2H, m, CH2CH2CO), 2.80 
(1H, d, J 15.3, C=CCH(H)), 2.93 (1H, dd, J 15.9, 3.3, C=CCH(H)), 3.20-3.30 (2H, m, 
CHCH2OAllyl), 3.75-3.87 (2H, m, OCH2CH=CH2), 4.43 (1H, d, J 10.2, CHC=C), 4.99-5.12 
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(2H, m, OCH2CH=CH2), 5.18 (1H, d, J, 17.5, NCH(H)Pyr), 5.33 (1H, d, J 17.5, 
NCH(H)Pyr), 5.55-5.57 (1H, m, C=CCH2CH), 5.67-5.82 (1H, m, OCH2CH=CH2), 6.86-6.88 
(2H, m, ArH), 7.08-7.09 (3H, m ArH), 7.19-7.20 (2H, m, ArH), 7.47-7.48 (1H, m, ArH). 
δC (300 MHz; CDCl3) 18.32 (CH2), 20.91 (CH2), 29.36 (CH2), 30.96 (CH2), 44.76 (CH), 
46.72 (CH2), 50.33 (CH), 67.43 (CH2), 70.61 (CH2), 106.87 (C), 108.74 (CH), 115.82 
(CH2), 117.50 (CH), 118.77 (CH), 121.17 (CH), 124.71 (2xCH), 125.94 (C), 126.56 (CH), 
127.89 (2xCH), 132.36 (C), 133.68 (CH), 136.23 (C), 137.29 (C), 169.35 (NC=O). 
MS (CI) m/z 401 [M+, 100%]; (Found: M+, 401.2224. C25H27N3O2 requires 401.2224) 
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(6R,12bS)-12-Benzyl-6-(methoxymethyl)-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-
a]quinolizine (55) 
N
N
O
H
 
 
Anhydrous tetrahydrofuran (5 ml) was added to lithium aluminium hydride (0.032 g, 
0.855 mmol) in a pre-dried, 3 necked flask under a nitrogen atmosphere and cooled to 
0 °C. (6R,12bS)-12-benzyl-6-(methoxymethyl)-1,2,3,6,7,12b-hexahydroindolo[2,3-
a]quinolizin-4(12H)-one (29) (0.16 g, 0.427 mmol) in anhydrous tetrahydrofuran (5 ml) was 
added via cannula. The reaction was heated under reflux for 3 hours and then stirred at 
room temperature overnight. 
The reaction was quenched with the addition of diethyl ether (10 ml) and sodium 
potassium tartrate solution (20 ml) and left to stir for one hour. The organic layer was 
separated and dried over anhydrous magnesium sulphate, which was then removed by 
filtration and the solvents removed under reduced pressure. The crude product was 
absorbed onto alumina and purified by flash column chromatography over alumina using 
1% methanol in chloroform as the eluent. This yielded a brown oil (0.07 g, 45%). 
[α]D = -22.86(c = 0.007, CHCl3); νmax (cm-1) 2924 CH. 
δH (300 MHz; CDCl3) 1.32-1.63 (1H, m, CHCH(H)CH2CH2), 1.32-1.63 (2H, m, 
CHCH2CH2CH2CH2), 1.69-1.84 (1H, m, CHCH(H)CH2CH2), 2.27-2.97 (2H, m, 
CHCH2CH2CH2CH2), 3.10-3.16 (2H, m CHCH2CH2CH2CH2), 3.24 (3H, s, OCH3), 3.26-
3.36 (2H, m, C=CCH2), 3.51-3.55 (2H, m, CH2OCH3), 3.64 (1H, d, J 9.6, NCHC=C), 5.14 
(1H, d, J 17.5, NCH(H)Ph), 5.26 (1H, d, J 17.5, NCH(H)Ph), 5.11-5.29 (1H, m, 
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C=CCH2CH), 6.88-6.91 (2H, m, ArH), 7.00-7.04 (3H, m, ArH), 7.15-7.21 (3H, m, ArH), 
7.43-7.47 (1H, m ArH). 
δC (300 MHz; CDCl3) 23.96 (CH2), 25.12 (CH2), 25.23 (CH2), 30.52 (CH2), 47.49 (CH2), 
52.53 (CH2), 55.59 (CH), 55.70 (CH), 59.02 (CH3), 71.44 (CH2), 107.35 (C), 109.64 (CH), 
118.24 (CH), 119.19 (CH), 121.23 (CH), 125.95 (2xCH), 127.22 (CH), 127.52 (C), 128.72 
(2xCH), 136.60 (C), 137.71 (C), 137.84 (C). 
MS (CI) m/z 361 [MH+, 100%]; (Found: MH+, 361.2279. C24H29N2O requires 361.2274). 
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(6R,12bS)-6-(Allyloxymethyl)-12-benzyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-
a]quinolizine (56) 
N
N
O
H
 
 
Anhydrous tetrahydrofuran (5 ml) was added to lithium aluminium hydride (0.028 g, 
0.750 mmol) in a pre-dried, 3 necked flask under a nitrogen atmosphere and cooled to 
0 °C. (6R,12bS)-6-(allyloxymethyl)-12-benzyl-1,2,3,6,7,12b-hexahydroindolo[2,3-
a]quinolizin-4(12H)-one (30)  (0.15 g, 0.375 mmol) in anhydrous tetrahydrofuran (5 ml) 
was added via cannula. The reaction was heated under reflux for 3 hours and then stirred 
at room temperature overnight. 
The reaction was quenched with the addition of diethyl ether (10 ml) and sodium 
potassium tartrate solution (20 ml) and left to stir for one hour. The organic layer was 
separated and dried over anhydrous magnesium sulphate, which was then removed by 
filtration and the solvents removed under reduced pressure. The crude product was 
absorbed onto alumina and purified by flash column chromatography over alumina using 
5% ethyl acetate in chloroform as the eluent. This yielded a brown oil (0.017 g, 12%). 
[α]D = -29.41 (c = 0.00068, CHCl3); νmax (cm-1) 2920 CH. 
δH (300 MHz; CDCl3) 1.33-2.22 (2H, m, CHCH2CH2CH2CH2), 1.33-2.22 (2H, m, 
CHCH2CH2CH2CH2), 2.74-3.00 (2H, m, CHCH2CH2CH2CH2), 2.74-3.00 (2H, m, C=CCH2), 
3.13 (1H, d, J 12.3, NCHC=C), 3.31-3.36 (2H, m, CH2OAllyl), 3.59-3.61 (2H, m, 
CHCH2CH2CH2CH2), 3.86 (2H, d, J 5.4, OCH2CH=CH2), 5.06-5.30 (1H, m, 
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NCHCH2OAllyl), 5.06-5.30 (2H, m, NCH2Ph), 5.06-5.30 (2H, m, OCH2CH=CH2), 5.73-5.88 
(1H, m, OCH2CH=CH2), 6.90 (2H, d, J 7.8, ArH), 7.01-7.04 (3H, m, ArH), 7.15-7.23 (3H, 
m, ArH), 7.44-7.47 (1H, m, ArH). 
δC (300 MHz; CDCl3) 23.15 (CH2), 24.09 (CH2), 24.27 (CH2), 29.67 (CH2), 46.45 (CH2), 
51.71 (CH2), 54.63 (CH), 54.94 (CH), 67.83 (CH2), 71.15 (CH2), 106.33 (C), 108.58 (CH), 
115.86 (CH2), 117.17 (CH), 118.11 (CH), 120.16 (CH), 124.88 (2xCH), 126.15 (CH), 
126.50 (C), 127.65 (2xCH), 133.77 (CH), 135.55 (C), 136.70 (C), 136.81 (C).  
MS (CI) m/z 387 [MH+, 100%]; (Found: MH+, 387.2434. C26H31N2O requires 387.2431) 
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2-((6R,12bS)-4-Oxo-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-6-yl)acetaldehyde 
(69) 3 
N
H
N O
CHO
H
 
Commercial stabilised IBX 45% (5.00 g, 7.77 mmol) was added to a solution of 
(6R,12bS)-6-Hydroxymethyl-2,3,6,7,12,12b-hexahrydro-1Hindolo[2,3-a]quinolizim-4-one 
(20) (1.05 g, 3.89 mmol) in dimethyl sulfoxide (20 ml) under a nitrogen atmosphere. The 
reaction was stirred at room temperature for 24 hours. 
After this time the reaction was poured into water (50 ml), extracted into ethyl acetate 
(3 x 20 ml) and washed with brine (3 x 20 ml). The combined organic fractions were dried 
with anhydrous magnesium sulphate, which was then removed by filtration and the 
solvent removed under reduced pressure. The crude product was absorbed onto silica 
and purified using flash column chromatography over silica using ethyl acetate as the 
eluent. This gave an off white solid (0.83 g, 80%). 
δH (300 MHz; CDCl3) 1.55-1.68 (1H, m, CH(H)CH2CH2CO), 1.87-1.96 (2H, m, 
CH2CH2CH2CO), 2.34-2.47 (1H, m, CH(H)CH2CH2CO), 2.34-2.47 (1H, m, 
CH2CH2CH(H)CO), 2.61-2.68 (1H, m, CH2CH2CH(H)CO), 3.02 (1H, ddd, J 15.9, 6.6, 2.1, 
C=CCH(H)), 3.35 (1H, d, J 15.9, C=CCH(H)), 4.82 (1H, d, J 11.4, NCHC=C), 5.90 (1H, d, 
J 6.3, C=CCH2CH), 7.03-7.13 (2H, m, ArH), 7.22 (1H, t, J 6.3, ArH), 7.47 (1H, d, J 7.5, 
ArH), 8.32 (1H, s br, NH), 9.41 (1H, s, CHO).  
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(6R,12bS)-tert-Butyl 4-oxo-6-(2-oxoethyl)-1,2,3,4,6,7-hexahydroindolo[2,3-a]quinolizine-
12(12bH)-carboxylate (70) 3 
 
N
N O
CHO
HBoc
 
 
2-((6R,12bS)-4-oxo-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-6-yl)acetaldehyde 
(69) (2.59 g, 9.59 mmol) was dissolved in anhydrous tetrahydrofuran (30 ml) under a 
nitrogen atmosphere. Triethylamine (2.68 ml, 19.18 mmol), dimethylaminopyridine (0.59 g, 
4.80 mmol) and di-tert-butyl dicarbonate (2.72 g, 12.47 mmol) were added in sequence.  
The reaction was left stirring for 5 hours.  
After this time the volatiles were removed and the remaining oil was re-dissolved in ethyl 
acetate and washed with saturated ammonium chloride solution (2 x 50 ml), saturated 
sodium bicarbonate solution (2 x 50 ml) and brine (2 x 50 ml). The organic extract was 
dried over anhydrous magnesium sulphate, which was then removed by filtration and the 
solvent was removed under reduced pressure. The crude product was absorbed onto 
silica and purified with flash column chromatography over silica using 1:1 ethyl 
acetate: petroleum ether as the eluent. This gave a yellow oil (2.08 g, 59%). 
δH (300 MHz; CDCl3) 1.29-1.44 (1H, m CH(H)CH2CH2CO), 1.50 (9H, s, OC(CH3)3), 1.87-
1.96 (2H, m, CH2CH2CO), 2.39-2.48 (1H, m, CH2CH(H)CO), 2.51-2.57 (1H, m 
CH(H)CH2CH2CO), 2.61-2.70 (1H, m, CH2CH(H)CO), 2.86 (1H, ddd, J 16.5, 6.0, 2.4, 
C=CCH(H)), 3.29 (1H, d, J 16.2, C=CCH(H)), 5.18 (1H, dd, J 10.5, 1.8, NCHC=C), 5.84 
(1H, d, J 5.1, C=CH2CH), 7.15-7.25 (2H, m, ArH), 7.39 (1H, d, J 6.9, ArH), 7.96 (1H, d, J 
7.8, ArH), 9.43 (1H, s, CHO).  
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2-((6R,12bS)-12-(tert-Butoxycarbonyl)-4-oxo-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-
a]quinolizin-6-yl)acetic acid (71) 3 
 
N
N O
COOH
HBoc
 
 
(6R,12bS)-tert-butyl4-oxo-6-(2-oxoethyl)-1,2,3,4,6,7-hexahydroindolo[2,3-a]quinolizine-
12(12bH)-carboxylate (70) (1.52 g, 4.12 mmol) was dissolved in acetonitrile (18 ml), tert-
butyl alcohol (67.50 ml) and cyclohexene (33 ml). The reaction was cooled to 0°C using 
an ice bath. Sodium chlorite (2.87 g, 31.70 mmol) and sodium dihydrogen phosphate 
(3.47 g, 28.82 mmol) in water (67.50 ml) were added slowly at 0°C. The reaction was 
warmed to room temperature and left stirring for 18 hours. 
The reaction was extracted into ethyl acetate and washed with 1 M sodium dithionite 
solution (2 x 50 ml). It was then dried over anhydrous magnesium sulphate, which was 
then removed by filtration and the solvents removed under reduced pressure. The crude 
product was absorbed onto silica and purified using flash column chromatography over 
silica using 5% methanol in ethyl acetate as the eluent. This gave a pale yellow foam 
(1.40 g, 88%).  
δH (300 MHz; CDCl3) 1.30-1.43 (1H, m CH(H)CH2CH2CO), 1.59 (9H, s, OC(CH3)3), 1.81-
1.86 (2H, m, CH2CH2CO), 2.34-2.49 (1H, m, CH2CH(H)CO), 2.53-2.59 (1H, m 
CH(H)CH2CH2CO), 2.62-2.65 (1H, m, CH2CH(H)CO), 2.83 (1H, ddd, J 15.9, 6.0, 2.1, 
C=CCH(H)), 3.33 (1H, d, J 16.2, C=CCH(H)), 5.28 (1H, d, J 9, NCHC=C), 5.95 (1H, d, J 
4.5, C=CH2CH), 7.13-7.24 (2H, m, ArH), 7.36-7.38 (1H, m,  ArH), 7.98 (1H, d, J 7.8, ArH). 
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(6R,12bS)-tert-Butyl4-oxo-6-(2-oxo-2-(phenylselanyl)ethyl)-1,2,3,4,6,7 
hexahydroindolo[2,3-a]quinolizine-12(12bH)-carboxylate (57) 3 
 
N
Boc
N O
H
O
SePh
 
 
Anhydrous dichloromethane (20 ml) was added to 2-((6R,12bS)-12-(tert-butoxycarbonyl)-
4-oxo-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-6-yl)acetic acid (71) (1.40 g, 
3.64 mmol) under a nitrogen atmosphere. Diphenyl diselenide (1.71 g, 5.46 mmol) was 
added and the reaction cooled to 0°C. Tributyl phosphine (1.82 ml, 7.28 mmol) was added 
dropwise and the reaction was warmed to room temperature and left for 24 hours. 
Dichloromethane (100 ml) and water (100 ml) were added and the aqueous layer was 
extracted further with dichloromethane. The combined organic extracts were washed with 
brine (100 ml), dried over anhydrous magnesium sulphate, which was then removed by 
filtration and the solvent removed under reduced pressure. The crude product was 
absorbed onto silica and purified by flash column chromatography over silica using ethyl 
acetate followed by 5% methanol in ethyl acetate to give pale yellow foam (1.06 g, 55%). 
δH (300 MHz; CDCl3) 1.34-1.47 (1H, m CH(H)CH2CH2CO), 1.60 (9H, s, OC(CH3)3), 1.88-
2.07 (2H, m, CH2CH2CO), 2.45-2.60 (1H, m, CH2CH(H)CO), 2.45-2.60 (1H, m 
CH(H)CH2CH2CO), 2.68-2.85 (1H, m, CH2CH(H)CO), 2.68-2.85 (1H, m, C=CCH(H)), 3.41 
(1H, d, J 16.5, C=CCH(H)), 5.50 (1H, d, J 10.5, NCHC=C), 6.08 (1H, d, J 4.8, C=CH2CH), 
7.13-7.24 (5H, m, ArH), 7.28-7.32 (2H, m,  ArH), 7.36 (1H, d, J 7.2, ArH), 7.97 (1H, d, J 
8.1, ArH).  
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(S)-tert-Butyl 4-oxo-1,2,3,4,6,7-hexahydroindolo[2,3-a]quinolizine-12(12bH)-carboxylate 
(58a) 3 
N
Boc
N O
H
 
 
(6R,12bS)-tert-butyl4-oxo-6-(2-oxo-2-(phenylselanyl)ethyl)-1,2,3,4,6,7 
hexahydroindolo[2,3-a]quinolizine-12(12bH)-carboxylate (57) (0.4 g, 0.764 mmol) in 
anhydrous toluene (10 ml) was added via cannula to a three necked flask under a 
nitrogen atmosphere, and flushed with nitrogen for 15 minutes. Tributylin hydride (0.82 ml, 
3.06 mmol) was added via syringe. The reaction was then heated to 80 °C and 
azobisisobutyronitrile (0.03 g, 0.153 mmol) was added portion wise over two hours. The 
reaction was left for a further two hours and then cooled to room temperature and the 
solvent removed under reduced pressure. 
The crude product was absorbed onto silica and purified using flash column 
chromatography over silica eluting with petroleum ether followed by ethyl acetate to give a 
colourless oil (0.19 g, 72%). 
δH (300 MHz; CDCl3) 1.25-1.40 (2H, m, CH2CH2CH2CO), 1.60 (9H, s, N-Boc), 1.75-1.80 
(2H, m, CH2CH2CO), 2.27-2.39 (1H, m, CH2CH(H)CO), 2.48-2.75 (1H, m, CH2CH(H)CO), 
2.48-2.75 (2H, m, C=CCH2), 2.48-2.75 (1H, m, C=CCH2CH(H)), 4.98-5.09 (1H, m, 
C=CCH2CH(H)), 4.98-5.09 (1H, m, NCHC=C), 7.13-7.23 (2H, m, ArH), 7.34 (1H, d, J 7.2, 
ArH), 7.96 (1H, d, J 8.1, ArH). 
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(S)-1,2,3,6,7,12b-Hexahydroindolo[2,3-a]quinolizin-4(12H)-one (72a) 13 
 
N
H
N O
H
 
 
Anhydrous tetrahydrofuran (20 ml) was added to (S)-tert-butyl 4-oxo-1,2,3,4,6,7-
hexahydroindolo[2,3-a]quinolizine-12(12bH)-carboxylate (58a) (0.2 g, 0.578 mmol) under 
a nitrogen atmosphere. Tetrabutylammonium fluoride 1.0 M solution (5.78 ml, 5.78 mmol) 
was added and the reaction heated under reflux for 9 hours.  
After this time the reaction was cooled and water (20 ml) was added. The product was 
extracted into ethyl acetate (3 x 20 ml) and dried using anhydrous magnesium sulphate, 
which was then removed by filtration and the solvents were removed under reduced 
pressure. The crude product was absorbed onto silica and purified by flash column 
chromatography using 5% methanol in ethyl acetate as the eluent. This yielded a white oil 
(0.11 g, 79%). 
[α]D = -136.36 (c = 0.00022 CHCl3); νmax (cm-1) 3233.33 NH, 1609 NC=O. 
δH (300 MHz; CDCl3) 1.50-1.89 (1H, m, CH(H)CH2CH2CO), 1.50-1.89 (2H, m, 
CH2CH2CO), 2.28-2.42 (1H, m, CH(H)CH2CH2CO), 2.51-2.57 (2H, m, CH2CH2CO), 2.67-
2.87 (1H, m, C=CCH2CH(H)), 2.67-2.87 (2H, m, C=CCH2), 4.69-4.74 (1H, m, NCHC=C), 
5.06-5.16 (1H, m, C=CCH2CH(H)), 7.09 (2H, sid, J 14.4, 7.2, 0.9, ArH), 7.27 (1H, d, J 7.5, 
ArH), 7.44 (1H, d, J 7.2, ArH), 7.98 (1H, br s, NH). 
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δC (300 MHz;  CDCl3) 19.39 (CH2), 21.01 (CH2), 29.07 (CH2), 32.42 (CH2), 40.16 (CH2), 
54.39 (CH), 109.61 (C), 110.95 (CH), 118.44 (CH), 119.86 (CH), 122.18 (CH), 126.88 (C), 
133.30 (C), 136.19 (C), 169.28 (NC=O). 
MS (CI) m/z 241 [MH+, 100%]; (Found: MH+, 241.1337. C15H17N2O requires 241.13335). 
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 (S)-12-Benzyl-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-4(12H)-one (73a) 
 
N N O
H
 
(S)-1,2,3,6,7,12b-Hexahydroindolo[2,3-a]quinolizin-4(12H)-one (72a) (0.09 g, 0.375 mmol) 
and sodium hydride (60 % dispersion in mineral oil, 0.023 g, 0.750 mmol) were combined 
under a nitrogen atmosphere and cooled to 0 °C using an ice bath. Anhydrous 
dimethylformamide (20 ml) was added and the ice bath removed. The reaction was stirred 
at room temperature for 30 minutes. After this time benzyl bromide (0.07 ml, 0.750 mmol) 
was added and the reaction was left for 24 hours. 
The reaction was quenched by the addition of ice water (20 ml) and extracted into ethyl 
acetate (3 x 50 ml). It was then washed with brine (2 x 50 ml), dried over anhydrous 
magnesium sulphate, which was then removed by filtration and the solvent was removed 
under pressure. The crude product was absorbed onto silica and purified by flash column 
chromatography over silica using 5% methanol in ethyl acetate as the eluent to give a 
yellow oil (0.11 g, 80%). 
[α]D = -181.82 (c = 0.00077); νmax (cm-1) 2922 CH, 1625 NC=O. 
δH (300 MHz; CDCl3) 1.42-1.80 (1H, m, CH(H)CH2CH2CO), 1.42-1.80 (2H, m, 
CH2CH2CO),  2.26-2.37 (1H, m, CH(H)CH2CH2CO), 2.26-2.37 (1H, m, CH2CH(H)CO), 
2.44-2.52 (1H, m, CH2CH(H)CO), 2.59-2.85 (2H, m, C=CCH2), 2.59-2.85 (1H, m, 
C=CCH2CH(H)), 4.58-4.62 (1H, m, NCHC=C), 5.06-5.12 (1H, m, C=CCH2CH(H)), 5.20 
(1H, d, J 17.5, NCH(H)Ph), 5.30 (1H, d, J 17.5, NCH(H)Ph), 6.90-6.93 (2H, m, ArH), 7.04-
7.09 (3H, m, ArH), 7.16-7.26 (3H, m, ArH), 7.46-7.50 (1H, m,  ArH). 
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δC (300 MHz;  CDCl3) 18.41 (CH2), 20.52 (CH2), 29.32 (CH2), 31.01 (CH2), 39.17 (CH2), 
46.87 (CH2), 53.71 (CH), 108.77 (C), 110.00 (CH), 117.43 (CH), 118.83 (CH), 121.15 
(CH), 124.73 (2xCH), 125.51 (C), 126.48 (CH), 127.87 (2xCH), 133.73 (C), 136.19 (C), 
137.03 (C), 168.70 (NC=O). 
MS (CI) m/z 331 [MH+, 100%]; (Found: MH+, 331.1809. C22H23N2O requires 331.1805). 
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(S)-tert-Butyl 4-oxo-1,6,7,12b-tetrahydroindolo[2,3-a]quinolizine-12(4H)-carboxylate 
(74a) 3 
 
N N O
HBoc
 
 
Diisopropylamine (0.72 ml, 5.04 mmol) was added to anhydrous tetrahydrofuran (5 ml) 
under a nitrogen atmosphere at 0 °C. n-Butyllithium (2.5 M in hexanes, 2.02 ml, 
5.04 mmol) was added and the reaction stirred for 15 minutes. This was then cooled 
to -78 °C. (S)-tert-butyl 4-oxo-1,2,3,4,6,7-hexahydroindolo[2,3-a]quinolizine-12(12bH)-
carboxylate) (58a) (0.58 g, 1.68 mmol) in anhydrous tetrahydrofuran (10 ml) was added 
via cannula. The reaction was stirred at -78 °C for one hour. Following this, phenyl 
selenium bromide (0.59 g, 2.52 mmol) in anhydrous tetrahydrofuran (10ml) was added via 
cannula and the reaction was left stirring for 24 hours. 
The reaction was then quenched with saturated ammonium chloride solution and 
extracted into diethyl ether (3 x 20 ml). The organic extracts were combined and washed 
with saturated ammonium chloride solution (100 ml), dried over anhydrous magnesium 
sulphate, which was then removed by filtration and the solvents were removed under 
reduced pressure. This produced a brown oil, which was used with no further purification. 
The crude selenide (1.04 g, 2.10 mmol) was dissolved in methanol (220 ml) and water 
(45 ml). Sodium metaperiodate (1.03 g, 4.83 mmol) and sodium bicarbonate (0.21 g, 
2.52 mmol) were added and the reaction was heated at 60 °C for 24 hours. 
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The reaction was quenched with saturated sodium bicarbonate solution (100 ml) and 
ether (150 ml). The organic layer was washed with water (200 ml) followed by brine 
(200 ml), dried over anhydrous magnesium sulphate, which was then removed by filtration 
and the solvents were removed under reduced pressure. The crude product was 
absorbed onto silica and purified by flash column chromatography on silica using ethyl 
acetate as the eluent to give a yellow oil (0.15 g, 26%). 
[α]D = -410.26 (c = 0.00078 CHCl3); νmax (cm-1) 1725 NC=O. 
δH (300 MHz; CDCl3) 1.61 (9H, s, (CH3)3), 2.09 (1H, tt, J 17.1, 4.8, 2.7, CH(H)CH=CHCO), 
2.62-2.84 (1H, m, C=CCH2CH(H)), 2.62-2.84 (2H, m, C=CCH2), 2.95 (1H, dq, J 17.4, 3.9, 
(CH(H)CH=CHCO), 4.91-4.97 (1H, m, C=CCH2CH(H)), 5.16-5.21 (1H, m, NCHC=C), 6.01 
(1H, dd, J 9.9, 3, CH2CH=CHCO), 6.58-6.64 (1H, m, CH2CH=CHCO), 7.19-7.27 (2H, m, 
ArH), 7.40 (1H, d, J 8.4, ArH), 8.00 (1H, d, J 8.1, ArH). 
δC (300 MHz; CDCl3) 20.52 (CH2), 27.20 (CH3)3, 30.61 (CH2), 36.50 (CH2), 52.27 (CH), 
83.51 (C), 114.77 (CH), 116.98 (C), 117.37 (CH), 122.08 (CH), 123.71 (CH), 124.41 (CH), 
127.50 (C), 133.09 (C), 135.53 (C), 138.10 (CH), 149.01 (C), 163.81 (NC=O).  
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3.4 Racemic compounds 
1-(2-(1H-Indol-3-yl)ethyl)piperidine-2,6-dione (81) 
 
HN
N
O
O
 
 
Anhydrous tetrahydrofuran (10 ml) was added to tryptamine (79) (1.0 g, 6.24 mmol) and 
glutaric anhydride (80) (0.71 g, 6.24 mmol) under a nitrogen atmosphere. Triethylamine 
(1 ml, 6.55 mmol) was added and the mixture was heated under reflux for 18 hours. After 
this time the volatiles were removed under reduced pressure to yield a brown oil. The 
crude product was absorbed onto silica and purified using flash column chromatography 
over silica with 2:1 ethyl acetate: petroleum ether as the eluent. A compound was isolated, 
and then re-crystallised from chloroform to give and off white solid. This was the 
undesired compound shown below (82). 
HN
H
N
O
O OH
 
 
Mp: 141- 142 °C; νmax (cm-1) 1634 C=O, 1687 C=O, 3054 OH, 3317 NH, 3390 NH. 
δH (300 MHz; DMSO) 1.72 (2H, qu, J 7.2, NHCOCH2CH2), 2.09 (2H, t, J 6.9, NHCOCH2), 
2.20 (2H, t, J 7.2, CH2COOH), 2.80 (2H, t, J 7.2, NHCH=CCH2), 3.27-3.34 (2H, m, 
NCH=CCH2CH2), 6.97 (1H, t, J 7.2, ArH), 7.06 (1H, t, J 7.8, ArH), 7.13 (1H, s, NHCH=C), 
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7.33 (1H, d, J 7.8, ArH), 7.52 (1H, d, J 7.8, ArH), 7.95 (1H, s, NHCO), 10.82 (1H, br s, 
NH).  
δC (300 MHz; DMSO) 20.65 (CH2), 25.24 (CH2), 33.03 (CH2), 34.45 (CH2), 39.37 (CH2), 
111.31 (CH), 111.80 (C), 118.15 (CH), 118.20 (CH), 120.85 (CH), 122.53 (CH), 127.16 
(C), 136.15 (C), 171.40 (C=O), 174.22 (NHC=O). 
This was converted into the desired compound by heating at 200 °C for 24 hours with no 
solvent. 
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1-(2-(1H-Indol-3-yl)ethyl)piperidine-2,6-dione (81) 
 
HN
N
O
O
 
 
Tryptamine (79) (20 g, 124.83 mmol) and glutaric anhydride (80) (14.24 g, 124.83 mmol) 
were combined and heated at 200 °C for 24 hours. The brown oil formed was absorbed 
onto silica and purified by flash column chromatography over silica with 3:2 ethyl 
acetate: petroleum ether as the eluent. This yielded a burnt orange solid (21.21 g, 66%). 
Mp: 171-172 °C; νmax (cm-1) 3324 NH, 1661 NC=O. 
δH (300 MHz; CDCl3) 1.80 (2H, qu, J 6.6, NCOCH2CH2), 2.54 (4H, t, J 6.6, NCOCH2), 2.91 
(2H, t, J 7.8, CH2CH2N), 4.00 (2H, t, J 8.1, CH2CH2N), 6.98 (1H, d, J 1.8, NHCH=C), 7.09 
(2H, qu, J 7.2, ArH), 7.27 (1H, d, J 7.5, ArH), 7.71 (1H, d, J 7.5, ArH), 8.01 (1H, br s, NH). 
δC (300 MHz; CDCl3) 16.08 (CH2), 22.68 (CH2), 31.81 (2xCH2), 39.29 (CH2), 110.03 (CH), 
111.79 (C), 118.07 (CH), 118.36 (CH), 120.93 (CH), 121.12 (CH), 126.56 (C), 135.07 (C), 
171.56 (2xNC=O). 
MS (CI) m/z 257 [MH+, 100%]; (Found: MH+, 257.1289. C15H17N2O2 requires 257.1285). 
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1,2,3,6,7,12b-Hexahydroindolo[2,3-a]quinolizin-4(12H)-one (72a, b) 
 
N
H
N O
H
 
 
1-(2-(1H-indol-3-yl)ethyl)piperidine-2,6-dione (81) (2 g, 7.81 mmol) was dissolved in 
absolute ethanol and cooled to 0 °C with an ice bath. Sodium borohydride (2.9 g, 
78.1 mmol) was added, followed by 2M hydrochloric acid in absolute ethanol (3.9 ml), 
added portion wise over a three hour period via syringe. After this time the solution was 
acidified to pH 1-3 with 2M hydrochloric acid in absolute ethanol over a 15 minute period, 
the ice bath was removed and the reaction was left stirring at room temperature overnight.  
Saturated sodium bicarbonate solution (200 ml) was used to quench the reaction which 
was then extracted into ethyl acetate (2 x 100 ml) and washed with brine (2 x 100 ml). It 
was then dried over anhydrous magnesium sulphate, which was removed by filtration and 
the solvent was removed under reduced pressure. The crude product was heated in 
absolute ethanol, cooled to 0 °C overnight and filtered to give an off white solid (1.27 g, 
68%). A small portion of this was re-crystallised to give white crystals. 
Mp: 245-247 °C; νmax (cm-1) 3259 NH, 1592 NC=O. 
δH (300 MHz; CDCl3) 1.74-2.04 (1H, m, CH(H)CH2CH2CO), 1.74-2.04 (2H, m, 
CH2CH2CO), 2.37-2.51 (1H, m, CH(H)CH2CH2CO), 2.37-2.51 (1H, m, CH2CH(H)CO), 
2.59-2.65 (1H, m, CH2CH(H)CO), 2.76-2.90 (1H, m, C=CCH2CH(H)), 2.76-2.90 (2H, m, 
C=CCH2), 4.80-4.83 (1H, m, NCHC=C), 5.15-5.26 (1H, m, C=CCH2CH(H)), 7.12-7.23 (2H, 
m, ArH), 7.37 (1H, d, J 8.1, ArH), 7.53 (1H, d, J 7.5, ArH), 8.15 (1H, br s, NH). 
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δC (300 MHz;  CDCl3) 19.41 (CH2), 21.01 (CH2), 29.07 (CH2), 32.44 (CH2), 40.14 (CH2), 
54.39 (CH), 109.58 (C), 110.95 (CH), 118.43 (CH), 119.84 (CH), 122.16 (CH), 126.87 (C), 
133.33 (C), 136.18 (C), 169.24 (NC=O). 
MS (CI) m/z 241 [MH+, 100%]; (Found: MH+, 241.1338. C15H17N2O requires 241.1335). 
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12-Benzyl-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-4(12H)-one (73a, b) 
 
N
N O
H
 
 
1,2,3,6,7,12b-Hexahydroindolo[2,3-a]quinolizin-4(12H)-one (72a, b) (1.27 g, 5.29 mmol) 
and sodium hydride (60 % dispersion in mineral oil, 0.42 g, 10.58 mmol) were combined 
under a nitrogen atmosphere and cooled to 0 °C. Dimethylformamide (40 ml) was added 
and the solution stirred at room temperature for 30 minutes. After this time benzyl bromide 
(1.27 ml, 10 .58 mmol) was added and the solution was left stirring for 24 hours.  
The reaction was quenched with the addition of ice cold water (30 ml) and extracted into 
ethyl acetate (3 x 50 ml), then washed with brine (2 x 100 ml). The combined organic 
extracts were dried over anhydrous magnesium sulphate, which was then removed by 
filtration and the solvent was removed under reduced pressure. The crude product was 
absorbed onto silica and purified by column chromatography over silica using 5% 
methanol in ethyl acetate as the eluent. This gave an off white solid (1.02 g, 58%). 
Mp: 188-190 °C; νmax (cm-1)1636 NC=O. 
δH (300 MHz; CDCl3) 1.26-1.60 (1H, m, CH(H)CH2CH2CO), 1.26-1.60 (2H, m, 
CH2CH2CO), 2.10-2.22 (1H, m, CH(H)CH2CH2CO), 2.10-2.22 (1H, m, CH(H)CO), 2.30-
2.37 (1H, m, CH(H)CO), 2.46-2.73 (2H, m, C=CCH2), 2.46-2.73 (1H, m, C=CCH2CH(H)), 
4.45 (1H, d, J 8.7, NCHC=C), 5.00 (1H, dd, J 9.9, 2.7, C=CCH2CH(H)), 5.30 (1H, d, J 
17.5, NCH(H)Ph), 5.40 (1H, d, J 17.5, NCH(H)Ph), 6.79 (2H, d, J 6.3, ArH), 6.93-6.96 (3H, 
m, ArH), 7.04-7.13 (3H, m, ArH), 7.35-7.38 (1H, m, ArH). 
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δC (300 MHz;  CDCl3) 19.45 (CH2), 21.68 (CH2), 30.56 (CH2), 32.16 (CH2), 40.24 (CH2), 
47.89 (CH2), 54.76 (CH), 109.94 (CH), 110.90 (C), 118.53 (CH), 119.91 (CH), 122.23 
(CH), 125.82 (2xCH), 126.66 (C), 127.5665 (CH), 128.97 (2xCH), 134.97 (C), 137.39 (C), 
138.14 (C), 169.65 (NC=O).  
MS (CI) m/z 331 [MH+, 100%]; (Found: MH+, 331.1810. C22H23N2O requires 331.1805). 
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tert-Butyl 4-oxo-1,2,3,4,6,7-hexahydroindolo[2,3-a]quinolizine-12(12bH)-carboxylate 
(58a, b) 
 
N
N O
H
Boc
 
 
1,2,3,6,7,12b-Hexahydroindolo[2,3-a]quinolizin-4(12H)-one (72a, b) (3.79 g, 15.77 mmol) 
was dissolved in anhydrous tetrahydrofuran (100 ml) under a nitrogen atmosphere. 
Triethylamine (9.29 ml, 66.58 mmol), dimethylaminopyridine (0.5 g, 8.32 mmol) and 
di-tert-butyl dicarbonate (7.27 g, 33.29 mmol) were subsequently added. 
After three hours, thin layer chromatography was used to determine that the reaction had 
completed and the solvents were removed under reduced pressure to give a brown oil. 
This was dissolved in ethyl acetate (50 ml) and washed with saturated ammonium 
chloride solution (2 x 100 ml), saturated sodium bicarbonate solution (2 x 100 ml) and 
brine (100 ml). The organic layer was dried over anhydrous magnesium sulphate, which 
was then removed by filtration and the solvent was removed under reduced pressure. The 
crude oil was absorbed onto silica and purified by column chromatography over silica 
using ethyl acetate as the eluent. This yielded a white solid (2.98 g, 55%). 
Mp: 153-154 °C; νmax (cm-1) 1639 NC=O. 
δH (300 MHz; CDCl3) 1.26-1.43 (1H, m, C(H)HCH2CH2CO), 1.62 (9H, s, NCOOC(CH3)3), 
1.74-1.83 (2H, m, CH2CH2CO), 2.27-2.39 (1H, m, CH2CH(H)CO), 2.49-2.74 (1H, m, 
CH2CH(H)CO), 2.49-2.74 (1H, m, C(H)HCH2CH2CO),  2.49-2.74 (2H, m, C=CCH2), 2.49-
2.74 (1H, m, C=CCH2CH(H)), 4.99-5.08 (1H, m, C=CCH2CH(H)), 4.99-5.08 (1H, m, 
NCHC=C), 7.19 (2H, si, J 6.3, ArH), 7.33 (1H, d, J 7.2, ArH), 8.00 (1H, d, J 8.4, ArH). 
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δC (300 MHz; CDCl3) 19.49 (CH2), 21.59 (CH2), 28.14 (CH3)3, 30.15 (CH2), 32.16 (CH2), 
38.80 (CH2), 56.00 (CH), 84.16 (C), 115.45 (CH), 118.23 (CH), 118.26 (CH), 122.95 (CH), 
124.55 (CH), 128.59 (C), 135.23 (C), 136.74 (C), 151.46 (C), 169.40 (NC=O). 
MS (CI) m/z 341 [MH+, 100%]; (Found: MH+, 341.1864. C20H25N2O3 requires 341.1860). 
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12-Benzyl-1,6,7,12b-tetrahydroindolo[2,3-a]quinolizin-4(12H)-one (100a, b) 
 
N
N O
H
 
 
Diisopropylamine (1.63 ml, 11.56 mmol) was added to anhydrous tetrahydrofuran (10 ml) 
under a nitrogen atmosphere at 0 °C. n-Butyllithium (2.5 M in hexanes, 4.62 ml, 
11.56 mmol) was added and the reaction stirred for 15 minutes. After this time the 
reaction was cooled to -78 °C and 12-benzyl-1,2,3,6,7,12b-hexahydroindolo[2,3-
a]quinolizin-4(12H)-one (73a, b) (1.91 g, 5.78 mmol) dissolved in anhydrous 
tetrahydrofuran (30 ml) was added via cannula. The reaction was left to stir for one hour 
upon which phenyl selenium bromide (2.05 g, 8.67 mmol) dissolved in anhydrous 
tetrahydrofuran (20 ml) was added via cannula. The reaction was left to warm slowly to 
room temperature overnight. 
Saturated ammonium chloride solution (50 ml) was used to quench the reaction. It was 
then extracted into diethyl ether (2 x 50 ml), washed with saturated ammonium chloride 
solution (2 x 50ml), and dried over anhydrous magnesium sulphate which was then 
removed by filtration. The solvents were removed under reduced pressure to give a brown 
oil which was used with no further purification. 
The crude selenide (2.68 g, 5.52 mmol) was dissolved in methanol (220 ml) and water 
(45 ml). Sodium metaperiodite (5.43 g, 25.39 mmol) and sodium bicarbonate (1.11 g, 
13.25 mmol) were added and the reaction was heated to 60 °C and left overnight. 
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The reaction was poured into saturated sodium bicarbonate solution (100 ml) and diethyl 
ether (150). The organic layer was washed with water (100 ml) and brine (100 ml), then 
dried over anhydrous magnesium sulphate, which was then removed by filtration and the 
solvents removed under reduced pressure.  
The crude product was absorbed onto silica and purified by flash column chromatography 
over silica with ethyl acetate as the eluent. This yielded a brown solid (1.05 g, 58%). 
Mp: 121-124 °C; νmax (cm-1) 1658 NC=O. 
δH (300 MHz; CDCl3) 2.02-2.16 (1H, m, CH(H)CH2CH2CO), 2.46 (1H, dt, J 7.4, 4.8, 
CH(H)CH2CH2CO), 2.60-2.83 (2H, m, C=CCH2), 2.60-2.83 (1H, m, C=CCH2CH(H)), 4.68 
(1H, dd, J 13.5, 3, NCHC=C), 4.87-4.94 (1H, m, C=CCH2CH(H)), 5.10-5.14 (2H, m, 
NCH2Ph), 5.92 (1H, dd, J 9.6, 2.1, CH2CHCHCO), 6.35-6.40 (1H, m, CH2CHCHCO), 6.84 
(2H, d, J 6.9, ArH), 7.00-7.04 (3H, m, ArH), 7.13-7.17 (3H, m, ArH), 7.44-7.47 (1H, m, 
ArH).  
δC (300 MHz;  CDCl3) 21.51 (CH2), 32.17 (CH2), 38.76 (CH2), 47.42 (CH2), 51.68 (CH), 
110.03 (CH), 110.65 (C), 118.65 (CH), 120.00 (CH), 122.37 (CH), 125.66 (CH), 125.77 
(2xCH), 126.48 (C), 127.65 (CH), 129.02 (2xCH), 133.82 (C), 137.15 (C), 137.94 (C), 
138.48 (CH), 164.93 (NC=O). 
MS (CI) m/z 329 [MH+, 100%]; (Found: MH+, 329.1653. C22H21N2O requires 329.1648). 
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tert-Butyl 4-oxo-1,6,7,12b-tetrahydroindolo[2,3-a]quinolizine-12(4H)-carboxylate (74a, b) 
 
N
N O
H
Boc
 
 
Diisopropylamine (2.49 ml, 17.60 mmol) was added to anhydrous tetrahydrofuran (20 ml) 
under a nitrogen atmosphere at 0 °C. n-Butyllithium (2.5 M in hexanes, 7.04 ml, 
17.60 mmol) was added and the reaction stirred for 15 minutes. After this time the 
reaction was cooled to -78 °C and tert-butyl 4-oxo-1,2,3,4,6,7-hexahydroindolo[2,3-
a]quinolizine-12(12bH)-carboxylate (58a, b) (2.00 g, 5.88 mmol) dissolved in anhydrous 
tetrahydrofuran (40 ml) was added via cannula. The reaction was left to stir for one hour 
upon which phenyl selenium bromide (2.78 g, 11.76 mmol) dissolved in anhydrous 
tetrahydrofuran (20 ml) was added via cannula. The reaction was left slowly to warm to 
room temperature overnight. 
Saturated ammonium chloride solution (50 ml) was used to quench the reaction. It was 
then extracted into diethyl ether (2 x 100 ml), washed with saturated ammonium chloride 
solution (2 x 100 ml) and dried over anhydrous magnesium sulphate which was then 
removed by filtration. The solvents were removed under reduced pressure to give a  
brown oil which was used with no further purification. 
The crude selenide (3.71 g, 7.49 mmol) was dissolved in methanol (220 ml) and water 
(45 ml). Sodium metaperiodite (7.36 g, 34.44 mmol) and sodium bicarbonate (1.51 g, 
17.97 mmol) were added and the reaction was heated to 60 °C and left overnight. 
The reaction was poured into saturated sodium bicarbonate solution (100 ml) and diethyl 
ether (150). The organic layer was washed with water (100 ml) and brine (100 ml), then 
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dried over anhydrous magnesium sulphate, which was then removed by filtration and the 
solvents removed under reduced pressure.  
The crude product was absorbed onto silica and purified by flash column chromatography 
over silica with 3:2 ethyl acetate: petroleum ether as the eluent. This yielded a yellow solid 
(0.55 g, 37%). 
Mp: 187-189 °C; νmax (cm-1) 1662 NC=O. 
δH (300 MHz; CDCl3) 1.60 (9H, s, NCOOC(CH3)3), 2.01-2.12 (1H, m, CH(H)CH2CH2CO), 
2.64-2.78 (2H, m, C=CCH2), 2.64-2.78 (1H, m, C=CCH2CH(H)), 2.94 (1H, dq, J 17.1, 9.9, 
3.6, CH(H)CH2CH2CO), 4.89-4.95 (1H, m, C=CCH2CH(H)), 5.14-5.18 (1H, m J 12.3, 
NCHC=C), 5.99 (1H, dd, J 9.6, 2.7, CH2CHCHCO), 6.56-6.62 (1H, m, CH2CHCHCO), 
7.15-7.25 (2H, m, ArH), 7.37 (1H, d, J 7.5, ArH), 7.99 (1H, d, J 8.1, ArH). 
δC (300 MHz; CDCl3) 21.56 (CH2), 28.25 (CH3)3, 31.66 (CH2), 37.54 (CH2), 53.31 (CH), 
84.55 (C), 115.82 (CH), 118.01 (C), 118.42 (C), 123.13 (CH), 124.77 (CH), 125.45 (CH), 
128.53 (C), 134.12 (C), 136.57 (C), 139.17 (CH), 150.04 (C), 164.83 (NC=O). 
MS (CI) m/z 339 [MH+, 100%]; (Found: MH+, 339.1708. C20H23N2O3 requires 339.1703). 
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12-Benzyl-2-vinyl-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-4(12H)-one (101a, b) 
 
N
N O
H
 
 
A 1.0 M solution of vinyl magnesium bromide in tetrahydrofuran (15.20 ml, 15.20 mmol) 
was added to a suspension of copper cyanide (0.68 g, 7.61 mmol) in anhydrous 
tetrahydrofuran (20 ml) at -78 °C while stirring. The reaction was warmed to 0 °C for 
3 minutes then re-cooled to -78 °C. 12-benzyl-1,6,7,12b-tetrahydroindolo[2,3-a]quinolizin-
4(12H)-one (100a, b) (0.50 g, 1.52 mmol) in anhydrous tetrahydrofuran (30 ml) was added 
via cannula at -78 °C. After 5 minutes trimethylsily chloride (1.00 ml, 7.61 mmol) was 
added and the reaction left to warm to room temperature overnight.  
The reaction as quenched with the addition of saturated ammonium chloride solution 
(20 ml) and water (20 ml) and left stirring for 20 minutes.  A 1.0 M solution of 
tetrabutylammonium fluoride in tetrahydrofuran (6 ml) was added and the stirring 
continued for 15 minutes. The reaction was extracted into ethyl acetate (3 x 50 ml) and 
the combined organic extracts were dried over anhydrous magnesium sulphate. This was 
then removed by filtration and the solvents removed under reduced pressure. The crude 
product was absorbed onto silica and purified by flash column chromatography over silica 
with 2:1 ethyl acetate: petroleum ether as the eluent. This gave a yellow oil (0.11 g, 20%). 
νmax (cm-1) 1662 NC=O. 
δH (300 MHz; CDCl3) 1.76-1.85 (1H, m, CH(H)CHCH2CO), 2.07-2.14 (1H, m, 
CH(H)CHCH2CO), 2.43-2.85 (2H, m, CH2CHCH2CO), 2.43-2.85 (1H, m, CH2CHCH2CO), 
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2.43-2.85 (2H, m, C=CCH2), 2.43-2.85 (1H, m, C=CCH2CH(H)), 4.63-4.66 (1H, m, 
NCHC=C), 4.90-5.05 (1H, m, C=CCH2CH(H)), 4.90-5.05 (2H, m, CHCH=CH2), 5.16 (1H, 
d, J 17.5, NCH(H)Ph), 5.25 (1H, d, J 17.5, NCH(H)Ph), 5.60-5.73 (1H, m, CHCH=CH2), 
6.90-6.93 (2H, m, ArH), 7.02-7.07 (3H, m, ArH), 7.16-7.25 (3H, m, ArH), 7.45-7.48 (1H, m, 
ArH). 
δC (300 MHz; CDCl3) 21.57 (CH2), 32.54 (CH), 34.42 (CH2), 35.88 (CH2), 40.55 (CH2), 
47.99 (CH2), 51.14 (CH), 109.77 (CH), 111.44 (C), 115.70 (CH2), 118.40 (CH), 119.90 
(CH), 122.23 (CH), 125.83 (2xCH), 126.60 (C), 127.60 (CH), 128.99 (2xCH), 134.53 (C), 
137.22 (C), 138.16 (C), 138.91 (CH), 169.33 (NC=O). 
MS (CI) m/z 357 [MH+, 100%]; (Found: MH+, 357.1962. C24H25N2O requires 357.1961). 
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tert-Butyl 4-oxo-2-vinyl-1,2,3,4,6,7-hexahydroindolo[2,3-a]quinolizine-12(12bH)-
carboxylate (102a, b) 
N
N O
H
Boc
 
 
A 1.0 M solution of vinyl magnesium bromide in tetrahydrofuran (12.10 ml, 12.10 mmol) 
was added to a suspension of copper cyanide (0.54 g, 6.06 mmol) in anhydrous 
tetrahydrofuran (20 ml) at -78 °C while stirring. The reaction was warmed to 0 °C for 
3 minutes then re-cooled to -78 °C. tert-butyl 4-oxo-1,6,7,12b-tetrahydroindolo[2,3-
a]quinolizine-12(4H)-carboxylate (74a, b) (0.41 g, 1.21 mmol) in anhydrous 
tetrahydrofuran (30 ml) was added via cannula at -78 °C. After 5 minutes trimethylsily 
chloride (0.77 ml, 6.06 mmol) was added and the reaction was left to warm to room 
temperature overnight.  
The reaction as quenched with the addition of saturated ammonium chloride solution 
(20 ml) and water (20 ml) and left stirring for 20 minutes.  A 1.0 M solution of 
tetrabutylammonium fluoride in tetrahydrofuran (6 ml) was added and the stirring 
continued for 15 minutes. The reaction was extracted into ethyl acetate (3 x 50 ml) and 
the combined organic extracts were dried over anhydrous magnesium sulphate. This was 
then removed by filtration and the solvents removed under reduced pressure. The crude 
product was absorbed onto silica and purified by flash column chromatography over silica 
with 2:1 ethyl acetate: petroleum ether as the eluent. This gave a yellow oil (0.20 g, 45%). 
νmax (cm-1) 1639 NC=O. 
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δH (300 MHz; CDCl3) 1.61-1.74 (2H, m, CH2CHCH2CO), 1.61 (9H, s, NCOOC(CH3)3), 
2.42-2.51 (1H, m, CH2CHCH2CO), 2.42-2.51 (1H, m, CH2CHCH(H)CO), 2.57-2.78 (1H, m, 
CH2CHCH(H)CO), 2.57-2.78 (1H, m, C=CCH2CH(H)), 2.57-2.78 (2H, m, C=CCH2), 4.98-
5.14 (1H, m, NCHC=C), 4.98-5.14 (1H, m, C=CCH2CH(H)), 4.98-5.14 (2H, m, 
CHCH=CH2), 5.88-5.99 (1H, m, CHCH=CH2), 7.14-7.25 (2H, m, ArH), 7.34-7.37 (1H, m, 
ArH), 7.91-7.94 (1H, m, ArH). 
δC (300 MHz; CDCl3) 21.67 (CH2), 28.22 (CH3)3, 32.88 (CH), 33.98 (CH2), 36.18 (CH2), 
39.26 (CH2),  52.43 (CH), 84.41 (C), 115.40 (CH), 115.49 (CH2), 118.26 (CH), 118.65 (C), 
122.98 (CH), 124.55 (CH), 128.71 (C), 135.55 (C), 136.75 (C), 139.25 (CH), 150.28 (C), 
169.33 (NC=O). 
MS (CI) m/z 367 [MH+, 100%]; (Found: MH+, 367.2021. C22H27N2O3 requires 367.2016). 
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2-Vinyl-1,2,3,6,7,12b-hexahydroindolo[2,3-a]quinolizin-4(12H)-one (103a, b) 
 
N
H
N O
H
 
 
tert-Butyl 4-oxo-2-vinyl-1,2,3,4,6,7-hexahydroindolo[2,3-a]quinolizine-12(12bH)-
carboxylate (102a, b) (0.12 g, 0.327 mmol) was dissolved in formic acid (4.80 ml, 
127.11 mmol) under a nitrogen atmosphere and stirred at room temperature for 24 hours.  
After this time the solvent was evaporated and shaken with 10 % aqueous sodium 
carbonate solution then extracted into dichloromethane, dried using magnesium sulphate, 
which was then removed by filtration and the solvent was removed under reduced 
pressure. The crude product was absorbed onto silica and purified by flash column 
chromatography over silica eluting with 1:1 ethyl acetate: petroleum ether as the eluent to 
give a brown oil (0.04 g, 46%). 
νmax (cm-1) 1615 NC=O, 3271 NH. 
δH (300 MHz; CDCl3) 2.09-2.18 (1H, m, CH(H)CHCH2CO), 2.26-2.35 (1H, m, 
CH(H)CHCH2CO), 2.55 (2H, t, J 6.9, CH2CHCH2CO), 2.70-2.83 (1H, m, CH2CHCH2CO), 
2.70-2.83 (1H, m, C=CCH2CH(H)), 2.86-2.99 (2H, m, C=CCH2), 4.84-4.89 (1H, m, 
NCHC=C), 5.09-5.18 (1H, m, C=CCH2CH(H)), 5.09-5.18 (2H, m, CHCH=CH2), 5.92 (1H, 
se, J 5.7, CHCH=CH2), 7.15 (2H, sd, J 18, 14.4, 7.2, 1.2, ArH), 7.34 (1H, d, J 7.5, ArH), 
7.50 (1H, d, J 7.5, ArH), 8.36 (1H, s br, NH). 
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δC (300 MHz; CDCl3) 21.05 (CH2), 32.86 (CH2), 32.96 (CH), 36.63 (CH2), 40.97 (CH2), 
51.77 (CH), 110.03 (C), 111.04 (CH), 115.75 (CH2), 118.30 (CH), 119.80 (CH), 122.10 
(CH), 127.03 (C), 133.18 (C), 136.13 (C), 138.93 (CH), 168.83 (NC=O). 
MS (CI) m/z 267 [MH+, 100%]; (Found: MH+, 267.1496. C17H19N2O requires 267.1492). 
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3.5 Towards a bis-indole compound 
 
Methyl 1,3-dithiolane-2-carboxylate (106) 3 
 
S
SO
MeO
 
 
Sodium hydroxide (0.08 g, 2.0 mmol), was dissolved in methanol (125 ml) and treated 
with ethyl-1,3-dithiolane carboxylate (105) (5 g, 28.2 mmol). The reaction was heated 
under reflux for 30 minutes with the exclusion of light. The solvent was removed under 
reduced pressure and the remaining liquid was dissolved in diethyl ether and washed with 
brine (30 ml). The ether layer was dried over anhydrous magnesium sulphate, which was 
then removed by filtration and the ether was removed under reduced pressure. This gave 
a yellow liquid (3.6 g, 78%). 
δH (300 MHz; CDCl3) 3.13-3.23 (2H, m, SCH2), 3.26-3.34 (2H, m, SCH2), 3.59 (3H, s, 
OCH3), 4.71 (1H, s, CH2SCH). 
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tert-Butyl 2-(2-(methoxycarbonyl)-1,3-dithiolan-2-yl)-4-oxo-1,2,3,4,6,7-
hexahydroindolo[2,3-a]quinolizine-12(12bH)-carboxylate (107a, b) 
 
N
N O
HBoc
S
S
OMe
O
 
 
Diisopropylamine (0.5 ml, 3.54 mmol) was dissolved in anhydrous tetrahydrofuran (20 ml) 
under a nitrogen atmosphere. After cooling to 0 °C, n-butyllithium (2.5 M in hexanes, 
1.42 ml, 3.54 mmol) was added and the reaction stirred at 0 °C for 15 minutes. It was then 
re-cooled to -78 °C and methyl, 1-2 dithiolane carboxylate (106) (0.21 g, 1.18 mmol) in 
20 ml of anhydrous tetrahydrofuran was added via cannula. The reaction was left stirring 
for a further 15 minutes and then tert-butyl 4-oxo-1,6,7,12b-tetrahydroindolo[2,3-
a]quinolizine-12(4H)-carboxylate (74a, b) (0.2g, 0.591 mmol) in anhydrous tetrahydrofuran 
(40 ml) was added also via cannula. The reaction was then left to warm slowly to room 
temperature overnight. 
The reaction was quenched with the addition of water (25 ml) and extracted into ethyl 
acetate (3 x 50 ml), dried over anhydrous magnesium sulphate, which was then removed 
by filtration and the solvents removed under reduced pressure. The crude product was 
absorbed onto silica and purified by flash column chromatography over silica using 3:1 
petroleum ether: ethyl acetate as the eluent. This yielded a brown oil (0.16 g, 54%). 
νmax (cm-1) 1635 NC=O. 
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δH (300 MHz; CDCl3) 1.34 (1H, qu, J 6.9, CH(H)CHCH2CO), 1.63 (9H, s, NCOOC(CH3)3), 
2.47 (1H, dd, J 17.4, 11.7, CH2CHCH(H)CO), 2.64-2.65 (1H, m, C=CCH(H)), 2.72-2.77 
(1H, m, C=CCH(H)), 2.80-2.84 (1H, m, CH(H)CHCH2CO), 2.80-2.84 (1H, m, 
C=CCH2CH(H)), 2.87-2.96 (1H, m, CH2CHCH(H)CO), 2.87-2.96 (1H, m, CH2CHCH2CO), 
3.18-3.26 (2H, m, SCH2), 3.28-3.36 (2H, m, SCH2), 3.74 (3H, s, COOCH3), 5.03-5.10 (1H, 
m, C=CCH2CH(H)), 5.03-5.10 (1H, m, NCHC=C), 7.15-7.27 (2H, m, ArH), 7.36-7.38 (1H, 
m, ArH), 7.96 (1H. d, J 7.8, ArH).  
δC (300 MHz; CDCl3) 21.67 (CH2), 28.13 (CH3)3, 33.77 (CH2), 35.73 (CH2), 38.39 (CH), 
39.05 (CH2), 40.03 (CH2), 40.32 (CH2), 53.57 (CH3), 55.44 (CH), 74.09 (C), 84.57 (C), 
115.52 (CH), 118.39 (CH), 118.68 (C), 123.08 (CH), 124.77 (CH) 128.55 (C), 135.66 (C), 
136.82 (C), 150.29 (C), 168.67 (C), 171.90 (NC=O). 
MS (CI) m/z 503 [MH+, 100%]; (Found: MH+, 503.1665. C25H31N2O5S2 requires 503.1669). 
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tert-Butyl 2-(2-methoxy-2-oxoethyl)-4-oxo-1,2,3,4,6,7-hexahydroindolo[2,3-a]quinolizine-
12(12bH)-carboxylate (108a, b) 
N
N O
HBoc
O
OMe
 
 
tert-Butyl2-(2-(methoxycarbonyl)-1,3-dithiolan-2-yl)-4-oxo-1,2,3,4,6,7-
hexahydroindolo[2,3-a]quinolizine-12(12bH)-carboxylate (107a, b) (0.06 g, 0.12 mmol) 
was dissolved in a 1:3 mixture of tetrahydrofuran: methanol (8 ml). The solution was 
cooled using an ice bath and nickel chloride hexahydrate (0.29 g, 1.20 mmol) was added. 
When this had completed dissolved, sodium borohydride (0.14 g, 3.60 mmol) was added 
cautiously. The reaction was then left to stir at room temperature for 4 hours.  
After this time it was filtered through celite, concentrated, extracted into ethyl acetate 
(3 x 20 ml) and washed with brine (40 ml). It was then dried over anhydrous magnesium 
sulphate, which was removed by filtration and the solvents were removed under reduced 
pressure. The crude product was absorbed onto silica and purified by flash column 
chromatography over silica using 1:1 ethyl acetate: petroleum ether as the eluent. This 
yielded a white oil (0.03g, 61%). 
νmax (cm-1) 1644 NC=O. 
δH (300 MHz; CDCl3) 1.17-1.29 (1H, m, CH(H)CHCH2CO), 1.69 (9H, s, NCOOC(CH3)3), 
2.08-2.18 (1H, m, CH2CHCH(H)CO), 2.24-2.40 (2H, m, CH2CO2CH3), 2.45-2.59 (1H, m, 
CH2CHCH2CO), 2.63-2.88 (1H, m, CH(H)CHCH2CO), 2.63-2.88 (1H, m, 
CH2CHCH(H)CO), 2.63-2.88 (2H, m, C=CCH2), 2.63-2.88 (1H, m, C=CCH2CH(H)), 3.69 
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(3H, s, OCH3), 5.11-5.17 (1H, m, C=CCH2CH(H)), 5.11-5.17 (1H, m, NCHC=C), 7.23-7.34 
(2H, m, ArH), 7.43-7.46 (1H, m, ArH), 8.05 (1H, d, J 7.8, ArH). 
δC (300 MHz; CDCl3) 21.70 (CH2), 28.12 (CH3)3, 28.45 (CH), 35.97 (CH2), 38.27 (CH2), 
39.00 (CH2), 40.40 (CH2), 51.77 (CH3), 55.59 (CH), 84.55 (C), 115.53 (CH), 118.34 (CH), 
118.57 (C), 123.07 (CH), 124.75 (CH), 128.58 (C), 134.78 (C), 136.92 (C), 150.21 (C) 
168.52 (C), 171.95 (NC=O). 
MS (CI) m/z 413 [MH+, 100%]; (Found: MH+, 413.2070. C23H29N2O5 requires 413.2071). 
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Methyl 2-(4-oxo-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl)acetate (109a, b) 
 
N
H
N O
H
O
OMe
 
 
tert-Butyl 2-(2-methoxy-2-oxoethyl)-4-oxo-1,2,3,4,6,7-hexahydroindolo[2,3-a]quinolizine-
12(12bH)-carboxylate (108a, b) (0.86 g, 2.08 mmol) was dissolved in formic acid 
(30.52 ml, 807.84 mmol) under a nitrogen atmosphere and stirred at room temperature for 
24 hours.  
After this time the solvent was evaporated and the remaining oil was shaken with 10% 
aqueous sodium carbonate solution, then extracted into dichloromethane, dried over 
anhydrous magnesium sulphate, which was then removed by filtration. The solvent was 
removed under reduced pressure to yield a brown oil (0.53g, 82%) which required no 
further purification. 
νmax (cm-1) 1619 NC=O, 3249 NH. 
δH (300 MHz; CDCl3) 1.34 (1H, q, J 12, CH(H)CHCH2CO), 2.00 (1H, q, J 12, 
CH2CHCH(H)CO), 2.14-2.30 (1H, m, CH2CHCH2CO), 2.14-2.30 (2H, m, CH2CO2Me), 
2.50-2.79 (1H, m, CH(H)CHCH2CO), 2.50-2.79 (1H, m, CH2CHCH(H)CO), 2.50-2.79 (2H, 
m, C=CCH2), 2.50-2.79 (1H, m, C=CCH2CH(H)), 3.59 (3H, s, OCH3), 4.67 (1H, d, J 8.4, 
NCHC=C), 5.04 (1H, d, J 7.8, C=CCH2CH(H)), 7.04 (2H, qu, J 6.9, ArH), 7.22 (1H, d, J 
7.8,  ArH), 7.39 (1H, d, J 7.5, ArH), 8.89 (1H, br s, NH). 
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δC (300 MHz; CDCl3) 21.05 (CH2), 28.20 (CH), 34.78 (CH2), 38.29 (CH2), 39.64 (CH2), 
40.08 (CH2), 51.87 (CH3), 53.96 (CH), 108.83 (C), 111.12 (CH), 118.35 (CH), 119.63 
(CH), 122.03 (CH), 126.65 (C), 133.08 (C), 136.42 (C), 168.43 (C), 172.27 (NC=O). 
MS (CI) m/z 312 [MH+, 100%]; (Found: MH+, 313.1551. C18H21N2O3 requires 313.1547). 
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 (+/-) -12b-Epidevinylantirhine (110a, b) 
 
N
H
N
HO
H
 
 
Lithium aluminium hydride (0.44 g, 11.59 mmol) was weighed into a dry, three necked 
flask under a nitrogen atmosphere. Anhydrous tetrahydrofuran (20 ml) was added and 
cooled to 0 °C. Methyl 2-(4-oxo-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-
yl)acetate (109a, b) (0.46 g, 1.47 mmol) dissolved in anhydrous tetrahydrofuran (10 ml) 
was added dropwise via syringe. The experiment was heated under reflux for 3 hours and 
then stirred at room temperature for a further 12 hours. 
The reaction was quenched with diethyl ether (20 ml) and the addition of a potassium 
tartrate solution (10 ml); it was then left stirring for one hour. The organic layer was 
separated and dried with anhydrous magnesium sulphate which was then removed by 
filtration and the solvents were removed under reduced pressure. The crude product was 
absorbed onto alumina and purified by flash column chromatography over alumina using 
1% methanol into chloroform. This yielded a yellow solid (0.30 g, 76%). 
Mp: 238-240 °C; νmax (cm-1) 3181 NH, OH. 
δH (300 MHz; MeOD) 1.17-1.29 (1H, m CH(H)CHCH2CH2N), 1.46 (1H, dd, J 12.3, 3.6, 
CHCH(H)CH2N), 1.53-1.63 (2H, m, CH2CH2OH), 1.73-1.90 (1H, m, CHCH(H)CH2N), 2.40-
2.53 (1H, m, CH(H)CHCH2CH2N), 2.40-2.53 (1H, m, CHCH2CH2N), 2.60-2.77 (2H, m, 
C=CCH2), 2.60-2.77 (1H, m, C=CCH2CH(H)), 2.95-3.15 (1H, m, C=CCH2CH(H)), 2.95-
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3.15 (1H, m, NCHC=C), 2.95-3.15 (2H, m, CHCH2CH2N), 3.71 (2H, t, J 6.6, CH2OH), 7.02 
(2H, si, J 7.2, ArH), 7.30 (1H, d, J 7.8, ArH), 7.39 (1H, d, J 7.5, ArH).  
NH and OH protons were not observed 
δC (300 MHz; MeOD) 22.38 (CH2), 32.88 (CH2), 33.76 (CH), 36.69 (CH2), 40.46 (CH2), 
54.43 (CH2), 56.54 (CH2), 60.36 (CH2), 61.67 (CH), 107.66 (C), 111.95 (CH), 118.57 (CH), 
119.74 (CH), 121.92 (CH), 128.35 (C), 135.81 (C), 138.05 (C). 
MS (CI) m/z 270 [MH+, 100%]; (Found: MH+, 271.1809. C17H23N2O requires 271.1805). 
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tert-Butyl 2-(1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl)ethyl carbonate 
(112a, b) 
 
N
H
N
BocO
H
 
 
(+/-) -12b-Epidevinylantirhine (110a, b) (0.05 g, 0.176 mmol) was dissolved in anhydrous 
tetrahydrofuran (20 ml), triethylamine (0.037 ml, 0.264 mmol), 4-dimethylaminopyridine 
(0.011 g, 0.088 mmol) and di-tert-butyl dicarbonate (0.06 g, 0.264 mmol) were 
subsequently added. The reaction was left stirring for one hour after which thin layer 
chromatography was used to determine the reaction was complete.  
The solvents were removed under reduced pressure and the crude oil was dissolved in 
ethyl acetate, and washed with saturated ammonium chloride solution (2 x 50 ml), 
saturated sodium carbonate solution (2 x 50 ml) and brine (100 ml). The organic layer was 
dried using anhydrous magnesium sulphate which was then removed by filtration and the 
solvents were removed under reduced pressure. The crude product was absorbed onto 
silica and purified using flash column chromatography over silica with 1:1 ethyl 
acetate: methanol as the eluent. This yielded a yellow oil (0.05 g, 77%). 
νmax (cm-1) 1639 NC=O. 
δH (300 MHz; MeOD) 1.07-1.17 (1H, m, CH(H)CHCH2CH2N), 1.07-1.17 (1H, m, 
CHCH(H)CH2N), 1.37 (9H, s, CH2OCOOC(CH3)3), 1.52-1.58 (2H, m, CH2CH2OH), 1.68 
(1H, d, J 13.2, CHCH(H)CH2N), 2.25-2.34 (1H, m, CH(H)CHCH2CH2N), 2.25-2.34 (1H, m, 
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CHCH2CH2N), 2.50 (1H, td, J 10.8, 4.02, C=CCH(H)), 2.60 (1H, d, J 15.3, C=CCH(H)), 
2.82-3.01 (2H, m, C=CCH2CH2), 2.82-3.01 (1H, m, CHCH2CH(H)N), 3.14 (1H, d, J 10.8, 
CHCH2CH(H)N), 3.14 (1H, d, J 10.8, NCHC=C), 4.05 (2H, t, J 6, CH2OH), 6.82-6.92 (2H, 
m, ArH), 7.19 (1H, d J 7.8, ArH), 7.27 (1H, d, J 7.5, ArH).  
NH proton not observed. 
δC (300 MHz; MeOD) 20.71 (CH2), 26.49 (CH3)3, 30.99 (CH2), 32.15 (CH), 34.76 (CH2), 
34.92 (CH2), 52.70 (CH2), 54.71 (CH2), 59.87 (CH), 64.09 (CH2), 81.12 (C), 106.06 (C), 
110.47 (CH), 117.06 (CH), 118.23 (CH), 120.44 (CH), 126.72 (C), 133.90 (C), 136.46 (C), 
153.67 (C). 
MS (CI) m/z 370 [MH+, 100%]; (Found: MH+, 371.2332. C22H31N2O3 requires 371.2332). 
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2-(1,2,3,4,6,7,12,12b-Octahydroindolo[2,3-a]quinolizin-2-yl)acetaldehyde (111a, b) 
 
N
H
N
H
O
 
 
Methyl 2-(4-oxo-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl)acetate (109a, b) 
(0.032 g, 0.102 mmol) was dissolved in anhydrous dichloromethane (6 ml) under a 
nitrogen atmosphere. The reaction was cooled to -100 °C using liquid nitrogen and 
methanol. Diisobutylaluminium hydride (1M in hexanes, 0.31 ml, 0.305 mmol) was added 
and the reaction stirred at -100 °C for 3 hours. Thin layer chromatography showed 
formation of new compounds, and no remaining starting material.  
The reaction was quenched by the slow addition of methanol (20 ml), and the solvents 
removed under reduced pressure. The crude product was absorbed onto silica and 
purified using flash column chromatography over silica with ethyl acetate as the eluent. 
This yielded a brown oil (0.0102 g, 35%). 
νmax (cm-1) 3215 NH, 2852 and 2923 CHO. 
δH (300 MHz; CDCl3) 1.26-1.47 (1H, m, CH(H)CHCH2CH2N), 2.03-2.11 (1H, m, 
CH2CHCH2CH2N), 2.34-2.58 (2H, m, CH2CHCH2CH2N), 2.34-2.58 (2H, m, CH2CHO), 
2.34-2.58 (1H, m, CH(H)CHCH2CH2N), 2.64-2.86 (2H, m, CH2CHCH2CH2N), 2.64-2.86 
(2H, m, C=CCH2CH2), 2.64-2.86 (1H, m, C=CCH2CH(H)), 4.76-4.80 (1H, m, NCHC=C), 
5.05-5.11 (1H, m, C=CCH2CH(H)), 7.02-7.15 (2H, m, ArH), 7.27 (1H, d, J 7.5, ArH), 7.44 
(1H, d, J 7.5, ArH), 7.97 (1H, br s, NH), 9.76 (1H, s, CHO). 
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δc (300 MHz; CDCl3) 20.98 (CH2), 30.30 (CH), 31.95 (CH2), 35.92 (CH2), 38.34 (CH2), 
53.03 (CH2), 55.15 (CH2), 59.56 (CH), 108.10 (C), 110.87 (CH), 118.16 (CH), 119.43 
(CH), 121.46 (CH), 127.26 (C), 134.19 (C), 136.03 (C), 201.80 (CHO). 
MS (CI) m/z 268 [MH+, 100%]; (Found: MH+, 269.1649. C17H21N2O requires 269.1648). 
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